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Functional characterization of ion channels 
All living cells are enveloped by a plasma membrane that functions as a barrier between the cell 
cytoplasm and the surrounding environment. Due to its hydrophobic composition, the plasma 
membrane is essentially impermeable to ions. Thus, specialized proteins facilitate the flow of 
ions across the membrane. These proteins can be most broadly categorized as being either 
transporters or channels. 
Transporters are proteins that aid movement of electrolytes across membranes without forming 
a pore (1) and are classically viewed as enzymes whose catalytic cycles involve a selective 
recognition/binding site of the transported ion(s), conformational changes in the transporter 
protein itself due to binding of the ion(s) and the coupling of these changes to physical 
movement of the ion(s) across the membrane. Most transporters, unlike channels, mediate the 
active transport of certain ions against their electrochemical gradient, ultimately through energy 
consumption (4-7). However, there are also transporters that transfer ions passively down their 
electrochemical gradient, e.g. the Na+/Ca2+ exchanger (NCX1), Na+/H+ exchanger. 
Ion channels are proteins that facilitate ion diffusion across a membrane by forming a 
hydrophilic pore (8). Spanning the plasma membrane, ion channels control its permeability to 
charged molecules. For this purpose, ion channels possess a set of essential properties such 
as the presence of a hydrophilic pore that connects the intracellular medium with the 
extracellular medium. This pore provides the route by which diffusion across the plasma 
membrane can take place. Mainly hydrophilic amino acid residues line the pore. Another 
important property of ion channels is the existence of a gating mechanism that can close the 
pore via a change in protein conformation. A range of factors depending on the channel species 
can initiate this conformational change. Classified by their gating factor, there are three main 
classes of ion channels: 
• Voltage-dependent channels open or close depending on the membrane potential. These 
channels contain charged amino acid residues that shift position within the protein in 
response to membrane potential changes, called voltage sensors. Based on structure 
homology and presumed evolutionary origin with the voltage-gated K+ channels, some 
members of the Transient Receptor Potential (TRP) superfamily could be included in this 
category of ion channels (8). 
• Ligand-gated channels open or close depending on the binding of an extracellular factor, 
such as a hormone or a neurotransmitter. Beside the acetylcholine receptor and other 
channels activated by neurotransmitters, this class could include some members of the TRP 
family such as TRPV1 (9), activated by capsaicin, and the menthol-activated TRPM8 (10). 
• Second messenger-operated channels open or close in response to intracellular factors, 
such as Ca2+ or activated G protein subunits. The members of the TRPC family could be 
included in this class. 
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The focus of the present thesis, the epithelial Ca2+ and Mg2+ channels, form a specific category. 
These channels open or close (gate) independently of any ligand binding or of voltage changes, 
since they are constitutively active in physiological states.  
These three types of channels species are sometimes referred to as VOCs (voltage-operated 
channels), ROCs (receptor-operated channels) and SMOCs (second messenger-operated 
channels), respectively. This classification of ion channels does not exclude inter-associations. 
For example, some Ca2+-activated K+ channels are also voltage-dependent. In addition, 
modulator mechanisms can influence channel functioning independent of the primary gating 
factor. Phosphorylation of the protein on the cytosolic side is a common mechanism for fine-
tuning the channel activity. Phosphorylation can enhance or reduce channel function, 
depending on the phosphorylation site and channel type. Another mechanism of controlling ion 
channels activity is their different expression levels according to the cellular stage. Since ion 
channels are proteins, they can be subject to varying levels of expression that can modulate 
channel function over longer time scales. 
Most ion channels present a more or less pronounced selective permeability. Ion channels 
possess selectivity in that their pores are more permeable to some ions than to others. The 
mechanism of selective permeability is based on a combination of ion size (in its hydrated form) 
and its charge. Residues in the channel pore lining interact with ions to form a thermodynamic 
energy barrier that favors the passage of certain ions. Based on their selective permeability, the 
ion channels could be subdivided in: Na+ selective, K+ selective, Ca2+ selective, Mg2+ or Cl- 
selective channels, and non-selective channels that do not discriminate between their 
permeants. 
The functional characteristics and the molecular mechanism of regulation for ion channels from 
the TRP superfamily, and in particular, the molecular regulation of the epithelial Ca2+ (TRPV5 
and TRPV6) and Mg2+ channels (TRPM6) are the focus of the present thesis. 
 
The patch-clamp technique – an ultimate tool in electrophysiology 
From all electrophysiological tools, the patch-clamp technique had the most important role in 
discovering and describing ion channels properties. In the beginning, ionic currents were 
recorded by the means of two microelectrodes introduced into large biological samples as the 
squid giant axons and imposing a certain voltage, with the voltage-clamp method (11). Although 
very useful for large biological samples, the technique of voltage-clamp (controlling the potential 
across the plasma membrane) could not be used for smaller samples as the usual mammalian 
cells. A profound advance in electrophysiology came with the development of the patch-clamp 
technique in 1976 and its improvement the following years. Erwin Neher and Bert Sakmann 
recorded ion currents from a tiny area of the plasma membrane (patch) by pressing against it a 
fire-polished glass pipette. In 1976, the first successful recording of a single-channel current 
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from the acetylcholine-activated receptor was reported. The main improvement of the technique 
came in 1981 with development of the “gigaseal” (sealing the pipette to the plasma membrane 
to resistance in extent of gigaohms) (12). 
suction
cell-attached
pull pull
inside-out
pull pull
outside-outwhole-cell
suction
 
For their discoveries concerning the single-channel recordings in living cells, Erwin Neher and 
Bert Sakmann received in 1991 the Nobel Prize in Physiology and Medicine. 
The gigaseal led to development of four new configurations for recording ion currents 
(Figure 1). After the pipette is sealed to the plasma membrane, single channel currents can be 
measured in the cell-attached mode (Figure 1A). From the cell-attached mode, the patch can 
be deliberately ruptured by suction with the pipette still sealed to the cell. The resulting 
configuration is called whole-cell (Figure 1B). In this configuration, the content of the pipette 
solution will diffuse into the cell cytoplasm and allow efficient control of its ionic concentration. 
The seal achieved in the cell-attached mode is so stable, that membrane patch can be pulled off 
the cell and dipped into a variety of test solutions; this maneuver leads to formation of the 
inside-out configuration (Figure 1C). Finally, pulling the pipette away from the cell, in whole-cell 
mode, results in an outside-out patch (Figure 1D). Over the last decades, patch-clamp became 
the primary technique in membrane biophysics and determined the further development of 
electrophysiology. Since the pipette solution exchanges molecules with the cytoplasm in the 
Figure 1. Configurations of the patch-clamp technique. (A) Pressing the pipette to the plasma membrane and 
by applying a slight suction the basic configuration of the patch-clamp technique, cell-attached is achieved. (B) By 
applying a suction pulse, the membrane enclosed by the pipette tip can be ruptured giving access to cell 
cytoplasm. (C) By pulling away the pipette from the cell in the cell-attached configuration the plasma membrane 
remains sealed to the pipette tip. This maneuver results in the formation of the inside-out configuration (the 
intracellular side of the membrane faces now the extracellular medium). (D) Pulling away the pipette from the cell 
in the whole-cell configuration results in the coupling of the loose membrane parts forming a vesicle at the pipette 
tip. In this way the outside-out configuration is achieved 
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whole-cell mode, this configuration developed into a valuable tool for biological and biochemical 
studies when is required to introduce ions, metabolites, inhibitors or fluorescent indicators into 
cells during the recordings. The whole-cell configuration enables the measurement of 
macroscopic currents from all ion channels present in the plasma membrane. Thus, measuring 
this macroscopic current can give an estimation of the functioning of all ion channels of one cell. 
The macroscopic currents (I) correspond to the formula: 
PNiI **=  
where i represents the single-channel current (in pA), N is the number of ion channels in the 
plasma membrane and P is the open probability of the channels. 
Furthermore, the patch-clamp technique development enabled the stable measurements of 
real-time activity of single ion channels. 
 
The Transient Receptor Potential superfamily  
TRP channels were identified in the late 60’s in the phototransduction cascade of the fruit fly 
Drosophila melanogaster (13). In wild-type flies, continuous illumination of the eye produced a 
long lasting depolarization of the photoreceptor cells (13,14). In the trp mutant, the initial onset 
of the response to prolonged illumination was identical to wild-type flies but the depolarization 
was transiently decaying towards baseline within seconds despite continuous illumination. This 
results in a functional loss in sensitivity to bright light (15). The trp gene was cloned in 1989 (16) 
and subsequently it was demonstrated that its product, the TRP protein, forms all, or part, of a 
Ca2+-permeable cation channel (17). Following the identification of TRP channels as Ca2+-
conducting channels in Drosophila melanogaster, 28 new genes encoding TRP channels have 
been cloned from different species and their functions are now beginning to be understood 
(Table 1). 
 
 
 
TRP 
Activators Inhibitors 
Putative 
Interacting 
Proteins 
Proposed 
Functions References 
TRPC1 Activation 
potentiated by 
PLC pathways 
Gd, La TRPC4, TRPC5, 
calmodulin, 
TRPC3, TRPP1, 
IP3Rs, caveolin-1, 
PMCA 
Homodimer is a 
supposed stretch-
sensitive ion 
channel; form 
heteromeric ion 
channels with 
TRPC4 or TRPC5 in 
neurons 
(18-20) 
Table 1. Functional properties of the mammalian TRP channels. The table is showing the functional 
characteristics as activators, blockers or interacting protein partners of the TRP ion channels. (adapted and 
updated from Clapham (2)). 
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TRPC2 Pheromone 
receptor 
mechanism? 
 Calmodulin, IP3R, 
enkurin, TRPC6 
TRPC2-/- mice 
respond abnormally 
to urine-based 
olfactory cues; 
pheromone sensing 
(21-24) 
TRPC3 Diacylglycerol, 
[Ca2+]i, activation 
potentiated by 
PLC pathways 
BTP2, 
flufenamate, 
Gd, La 
TRPC1, 
calmodulin, PLCβ, 
PLCγ, IP3R, 
RyR,SERCA,cave
olin-1, αSNAP, 
NCX1 
Potential role in 
vasoregulation and 
airway regulation 
(25-27) 
TRPC4 La (100 µM), 
calmidazolium, 
activation 
potentiated by 
PLC pathways 
[Ca2+]i, 2-APB, 
niflumic acid, 
DIDS, La (mM) 
TRPC1, TRPC5, 
calmodulin, PLCβ, 
NHERF1, IP3R 
TRPC4-/- mice have 
abnormalities in 
endothelial-based 
vessel permeability 
(28-31) 
TRPC5 La (100 µM), nitric 
oxide, activation 
potentiated by 
PLC pathways 
2-APB, 
flufenamate, 
La (mM) 
TRPC1, TRPC4, 
calmodulin, PLCβ, 
NHERF1/2, ZO-1, 
IP3R 
No phenotype yet 
reported in TRPC5-/- 
mice; potentially 
regulates growth 
cones and neurite 
extension 
(32-34) 
TRPC6 Diacylglycerol, 
[Ca2+]i, 20-HETE, 
activation 
potentiated by 
PLC pathways 
2-APB, 
amiloride, Cd, 
La, Gd 
Calmodulin, 
TRPC3, TRPC7, 
FKBP12 
Missense mutation in 
human focal 
segmental 
vasoregulation in 
TRPC6-/- mice, 
proposed role in 
ATII-induced cardiac 
hypertrophy 
(35-38) 
TRPC7 Diacylglycerol, 
activation 
potentiated by 
PLC pathways 
[Ca2+]i, 
flufenamate, 
La 
Calmodulin, 
TRPC3, TRPC6, 
FKBP12, MxA, 
TRPC1 
No phenotype yet 
reported in TRPC7-/- 
mice; potential role in 
myocardial apoptosis 
(39,40) 
TRPV1 T>~45oC, V-dep, 
H+, activation 
potentiated by 
PLC pathways, 
anandamide, 2-
AG, HETE, 
HPETE, 
capsaicin, olvanil, 
resiniferatoxin, 
arvanil, piperine, 
OEA, 2-APB, 
DPDBA, camphor 
Capsazepine, 
RR, acyl-
polyamines, 
camphor 
desensitizises 
Calmodulin, 
TRPV3, TRPV2, 
PI3K, snapin, 
synaptogamin IX, 
β-tubulin 
In TRPV1-/- mice 
decreased response 
to heat, acid pH; 
diminished stretch-
evoked responses in 
bladder; upregulated 
in inflammatory 
bowel disease, 
osteoarthritis 
(9,41-44) 
TRPV2 T>~53oC, 
neuropeptide 
head activator, 
DPBA, 2-APB 
RR, La, 
SKF96365 
TRPV1, RGA No phenotype yet 
reported in TRPV2-/- 
mice; role in thermal 
pain, osmosensing in 
myocites? 
(45-47) 
TRPV3 T>~30oC, 2-APB, 
DPBA, carvacrol, 
thymol, eugenol, 
camphor, vanillin, 
ethyl vanillin, 
menthol, 
cinnemaldehyde 
RR, La TRPV1 TRPV3-/- mice have 
decreased response 
to heat; potential role 
in warmth sensing in 
skin 
(46,48-50) 
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TRPV4 Anandamide, 
arachidonic acid, 
5’6’-
epoxyeicosatri-
enoic acids, 4α-
phorbol 12,13 
didecanoate, 
PMA 
RR, Gd, La Calmodulin, Src 
family kinases, 
aquaporin 5, 
pacsin 3 
TRPV4-/- mice have 
impaired pressure 
and acid sensation, 
dysregualted ADH; 
potential role in CNS 
osmosensing and 
temperature sensing 
in skin 
(51-56) 
TRPV5 Constitutively 
active, PIP2 
[Ca2+]i, RR, 
econazole, 
Cd>>Gd>La, 
Mg, Cu, Pb 
TRPV6, 
S100A/annexin, 
80K-H, NHERF4, 
BSPRY, Rab11a 
TRPV5-/- mice have 
bone abnormalities; 
possible role in Ca2+ 
uptake in the kidney, 
gut 
(3,57-60) 
TRPV6 Constitutively 
active 
[Ca2+]i, RR, 
Cd>>Gd>La, 
Mg 
TRPV5, 
S100A/annexin 
TRPV6-/- mice have 
alopecia, dermatitis 
and decreased 
intestinal Ca2+ 
absorption 
(59,61,62) 
TRPM1 Not determined  Not determined Potential role in 
melanoma 
progression 
(63) 
TRPM2 Constitutively 
active, ADP-
ribose, cADP-
ribose, βNAD, 
hypo-osmolarity 
enhances 
ADP, N-ACA, 
econazole, 
miconazole, 
clotrimazole, 
flufenamate 
Calmodulin, 
cADP-ribose 
hydrolase, Sir2 
Senses oxidant 
stress in immune 
cells and glia 
(64-67) 
TRPM3 Constitutively 
active, hypo-
osmolarity 
enhances, 
sphingolipids, 
steroids 
[Mg2+]i for 
TRPM3a1, a2 
(9mM); Gd, La 
Not determined Potential role in 
kidney Ca2+ 
reabsorption 
(68-70) 
TRPM4 [Ca2+]i, 
decavanadate, 
BTP2, PKC 
phosphorylation 
AMP, ATP, 
flufenamate, 
polyamines; 
La, Gd for 
TRPM4a; 
[ATP]i for 
TRPM4b 
Calmodulin, 
SUR1 
TRPM4-/- mice have 
enhanced 
anaphylactic 
responses; potential 
role in smooth 
muscle 
(71-74) 
TRPM5 T1R,T2R-Ggus-
PLCβ2, [Ca2+]i, 
PIP2, V-dep, heat 
sensitive 
<pH 7.0, 
spermine 
Not determined TRPM5-/- mice do not 
detect sweet, bitter 
or umami flavors 
(75-78) 
TRPM6 Acid pH, 2-APB [Mg2+]i, RR Integral kinase 
domain, TRPM7, 
RACK1 
Human TRPM6 
mutations cause 
hypomagnesemia 
with secondary 
hypocalcemia 
(79-84) 
TRPM7 Acid pH, PIP2, 
activation 
potentiated by 
PLC pathways 
[Mg2+]i, La, 
PIP2 hydrolysis 
Integral kinase 
domain, PLCβ1-3, 
PLCγ1, snapin, 
TRPM6, myosin 
IIA heavy chain 
Human TRPM7 
variant associated 
with Guamanian 
amyotrophic lateral 
sclerosis and 
Parkinson dementia; 
possible mediator of 
trace metal entry; 
role in excitotoxic 
neuron death 
(85-91) 
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TRPM8 T<~25oC; V-dep, 
PIP2, menthol, 
icilin, eucalyptol 
BCTC, 
capsazepine, 
2-APB 
Not determined Responds to cold 
and pain; proposed 
roles in prostate 
cancer, activation-
induced analgesia 
(10,92-94) 
TRPA1 T<~18oC, 
modification of 
intracellular 
cysteines by allil 
isothiocianate, 
allicin, acrolein, 
Δ9-THC, 
carvacrol, icilin, 
cinnamaldehyde, 
eugenol, gingerol 
RR, amiloride, 
camphor, 
menthol, 
gentamicin, 
Gd; carvacrol 
desensitizes 
Not determined TRPA1-/- mice have 
normal hearing; pain 
defects disputed; 
responds to pungent 
natural compounds, 
environmental 
irritants, 
inflammatory 
peptides 
(95-98) 
TRPP1 Also called PC2 
or PKD2; 
mechanical 
stress, [Ca2+]i? 
[Gd, La, Cd, 
SKF96365, 2-
APB]? 
PKD1/PKC1, 
Hax-1, cortactin, 
Id2, mDia, 
troponin, 
tropomyosin, 
actinin; cadherin 
via PKD1/PC1 
Mutations in human 
TRPP1 cause 
autosomal dominant 
polycystic kidney 
disease; proposed to 
localize to cilia and 
be activated by 
ciliary movement 
(99-102) 
TRPP2 Also called 
PKD2L1; acid, 
[Ca2+]i? 
[Flufenamate, 
Cd, La]? 
PKD1L3 TRPP2 is deleted 
(among other genes) 
in krd mice that have 
kidney and retinal 
abnormalities; mice 
with targeted 
deletion in taste cells 
do not respond to 
sour (acid) stimuli 
(101,103-
105) 
TRPP3 Also called 
PKD2L2, [Ca2+]i? 
[amiloride, Gd, 
La, Ni]? 
Not determined Probable function in 
testis 
(106) 
TRPML1 Also called 
MCOLN1; [Ca2+]i? 
[amiloride, Gd, 
La, Ni]? 
Not determined Mutations in 
TRPML1 cause 
mucolipidosis type 
IV, a recessive 
neurodegenerative 
lysosomal storage 
disorder 
(107,108) 
TRPML2 Also called 
MCOLN2, not 
determined 
 TRPML3 Not determined (108) 
TRPML3 Na+-free 
extracellular 
media 
Na+ TRPML1, 
TRPML2 
+/- Varitint-waddler 
mice are deaf with 
vestibular defects 
(109,110) 
 
TRP channels are universal biological sensors that detect changes in the environment. TRP 
channels gate in response to a multitude of stimuli including cold or hot temperatures, natural 
chemical compounds (menthol, camphor and “hot pepper”), mechanical stimuli, or changes in 
the composition of the lipid bilayer. TRP channels are crucially involved in physiological 
processes, such as photoreception, pheromone sensing, taste perception, thermosensation, 
pain perception, mechanosensation, perception of pungent compounds (mustard, garlic), renal 
Ca2+/Mg2+ handling, smooth muscle tone and blood pressure regulation (9,10,57,81,111-113). 
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Members of the TRP superfamily of channels share the common features of six transmembrane 
(TM) domains, with a pore-forming region between TM5 and TM6. Based on amino acid 
sequence homology, the TRP channel family can be grouped into 6 subfamilies: canonical 
(TRPC), vanilloid (TRPV), melastatin (TRPM), and the smaller subfamilies anchorin-repeat 
containing channels (TRPA), polycystins (TRPP) and mucolipins (TRPML). 
 
TRPC subfamily 
The TRPC subfamily consists of seven channels, named TRPC1-7. From all the TRP channels, 
this subfamily shares the highest homology with the TRP from Drosophila melanogaster. TRPC 
channels can be subdivided in three groups based on homology: TRPC1-4-5, TRPC3-6-7, and 
TRPC2 (114). All these channels share a structural feature, a so-called TRP box consisting of 
an invariant amino acid sequence “EWKFAR” located intracellular close to the TM6. 
Furthermore, these channels contain three to four amino-terminal ankyrin repeats (115). TRPC 
channels are Ca2+ permeable non-selective cation channels with permeability ratios PCa/PNa 
varying from ~1 for TRPC4 to ~9 for TRPC5 (28,29,116). In general, TRPC channels open in 
response to stimulation of receptors that activate different isoforms of phospholipase C (PLC). 
TRPC3, -6, and -7 are activated by diacylglycerol (DAG), independent of the stimulation of 
protein kinase C (PKC) (117-120), suggesting that DAG mediates their physiological activation. 
In contrast, TRPC1, -4, and -5 are completely unresponsive to DAG (19,27,117) and the 
mechanism via which PLC stimulation leads to channel activation remains controversial. 
Surprisingly, it was shown that TRPC1 is directly activated by membrane stretch, independent of 
PLC activity, and that it may be the molecular homologue of the vertebrate stretch-activated 
cation channel MscCa (19). The TRPC channels are broadly expressed, and a given cell type 
generally contains multiple TRPC channels (121,122). Further complexity in the functional 
characterization of TRPC channels arises from the fact that these proteins can form 
heterotetramers, beside homotetramers. TRPC1 can form heteromers with TRPC4 and TRPC5, 
and the TRPC subfamilies TRPC4/5, and TRPC3/6/7 can form heteromers among themselves, 
with current properties significantly different from those of the homotetramers (20,30,123,124). 
 
TRPV subfamily 
Based on structure and function, the TRPV family comprises four groups of channels: 
TRPV1/TRPV2, TRPV3, TRPV4 and TRPV5/6. The Caenorhabditis elegans Osm-9 (125) and 
the Drosophila melanogaster Nanchung (Nan) are also included in this family (126). The 
founding member, TRPV1 was identified by expression cloning based on the capacity of hot 
pepper-derived vanilloid compound capsaicin to induce Ca2+ influx within sensory neurons (9). 
Similar to the TRPC channels, members of the TRPV subfamily have a TRP box close to TM6 
and three to six ankyrin repeats in the amino-terminal tail (127-129). TRPV1-4 channels are 
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non-selective for cations, modestly permeable to Ca2+, with permeability ratios (PCa/PNa) 
between 1 and 10 and can be activated and regulated by temperature. TRPV1 is activated by 
temperatures above 43oC and in addition, by chemical compounds as 2-aminoethoxydiphenyl 
borate (2-APB) (46), capsaicin and endogenous cannabinoid receptor ligands like anandamide 
(41-43).  
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When heterologously expressed, TRPV1 channels display an outward rectifying current-voltage 
relation (I-V) (Figure 2C) and an anomalous mole fraction behavior (currents decrease with 
increasing in the extracellular Ca2+ concentration from zero to certain value and then increase) 
as apparent from linearization of I-V relation in divalent free medium (Figure 2A). TRPV1 
currents are activated by pH values in the acid range (below 5.9) (130) and inhibited by 
phosphatidylinositol-4,5-biphosphate (PIP2) (131). Furthermore, TRPV1 function is regulated by 
PKC and protein kinase A (PKA) activity via a so far unidentified mechanism. Considering its 
Figure 2. Typical current-voltage (I-V) relations for TRP channels. All the traces are obtained by applying a 
ramp protocol from -100mV to +100mV (inset). (A) The linear I-V relation corresponds to a channel that allows 
both ion influx (inwardly movement of ions) and efflux (outwardly movement of ions) in the same extent. (B) The 
inward rectifying I-V relation corresponds to a channel that allows better ion influx than ion efflux. (C) The outward 
rectifying I-V relations are obtained from channels that allow better efflux of ions compared to ion influx. 
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expression pattern, TRPV1 is demonstrated to be involved in nociception, hypothermic effects 
of vanilloid compounds (44), pancreatitis (132) and asthma (133). 
TRPV2 shares ~50% sequence homology with TRPV1 and is activated by noxious heat (above 
52oC) and by 2-APB, rather than capsaicin or acidic pH (46,47,134). TRPV2 channels display a 
moderately outward rectifying I-V relation upon activation (Figure 2C).  
TRPV3 and TRPV4 channels are also temperature-sensitive, but in a lower range: above 31oC 
for TRPV3 (135) and above 25oC for TRPV4 (136). TRPV3 channels display an outward 
rectifying I-V relation (Figure 2C) (49), while TRPV4 current show a linear I-V relation 
(Figure 2A) (53). Beside temperature, the activity of TRPV4 channels is enhanced upon 
hypotonicity (osmotic cell swelling) (137) and similar to TRPV1, their activation is sensitized by 
PKC (138). 
In contrast to the other members of the subfamily, TRPV5 and TRPV6 channels are not 
activated by temperature changes. These channels, also known as epithelial Ca2+ channels, 
were cloned using expression cloning strategies based on their capacity to mediate sustained 
Ca2+ influx from the renal and intestinal epithelia, respectively (57,61). Opposite to the other 
subfamily members, TRPV5 and TRPV6 are constitutively active at physiological membrane 
potentials and intracellular Ca2+ concentrations (139). TRPV5 and TRPV6 share 75% homology 
at the amino acid level with the main sequence differences located in the amino- and carboxyl-
terminal tails. Strikingly, several domains in TRPV5 and TRPV6 are conserved within different 
species including the core structure of the protein consisting of six TM segments and the pore 
region (Figure 3A). Detailed sequence analysis of TRPV5 and TRPV6 lead to the identification 
of several putative phosphorylation sites including PKC, PKA, and cGMP-dependent kinase. 
However, these predicted phosphorylation sites are not conserved in other species or in TRPV6. 
This is in contrast to the putative PKC phosphorylation sites of which three are conserved within 
the complete TRPV5 and TRPV6 subfamily (Figure 3B). Despite this, the physiological 
relevance of the conserved PKC sites is not clear so far. To date, no information is available 
about the phosphorylation of TRPV5 and TRPV6. In addition, TRPV5 and TRPV6 contain PDZ 
motifs and ankyrin repeat domains in the amino-terminal region, which are also present in a 
diverse range of receptors and ion channels including the TRP superfamily. PDZ motifs are 
recognized by PDZ domains that are modular protein interaction domains playing a role in 
protein targeting and protein complex assembly. Although binding to carboxyl-terminal motifs 
appears to be the typical mode of interaction, PDZ domains could also interact with internal 
motifs that are present in TRPV5 and TRPV6. In general, ankyrins link transporters and cell 
adhesion molecules to the spectrin-based cytoskeletal elements in specialized membrane 
domains. 
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When heterologously overexpressed, both channels display inward rectifying I-V relations with 
almost no outward currents at positive membrane potentials (Figure 2B), and they are highly 
selective for Ca2+ (PCa/PNa > 100) (140,141). TRPV5 and TRPV6 exhibit a similar ion permeation 
Figure 3. Structural organization of TRPV5 and TRPV6. (A) Potential regulatory sites in the amino- and 
carboxyl-tail of TRPV5 and TRPV6 including ankyrin repeats, PDZ motifs and conserved PKC phosphorylation 
sites. (modified and updated from Hoenderop et al (3)) (B) The epithelial Ca2+ channels are 730 amino acids long 
with a predicted molecular mass of ~83 kDa. TRPV5 contains a core domain consisting of six transmembrane 
(TM) segments. The region between TM1 and TM2 contains an N-glycosylation site. In addition, large cytosolic 
amino- and carboxyl-terminal domains are present. The amino-terminal domain contains six ankyrin repeats, 
while conserved PKC phosphorylation sites are present at both termini. Between TM5 and TM6 there is a short 
hydrophobic stretch predicted to be the pore-forming region of the channel. Inner and outer sides of the plasma 
membrane are indicated.
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sequence for divalent cations (Ca2+>Sr2+~Ba2+>Mn2+) (141). Both channels are blocked by 
extracellular Mg2+ and show an anomalous mole fraction behavior (in case of TRPV5 and 
TRPV6 currents decrease with increasing in the extracellular Ca2+ concentration from 0 to 
100 µM and then increase) described for L-type voltage-gated Ca2+ channels. Similar to the 
voltage-gated Ca2+ channels, the epithelial Ca2+ channels allow monovalent cation permeation 
in the absence of divalent cations, with the permeation sequence of Na+>Li+>K+>Cs+>>NMDG+ 
(140,141). Single-channel measurements of TRPV5 Na+ currents revealed the same inward 
rectifying I-V relation as the macroscopic currents. So far, no reliable TRPV5 single-channel 
measurements could be performed in the presence of extracellular Ca2+, since the currents 
inactivates quickly in the presence of Ca2+. Another typical feature of TRPV5 and TRPV6 
currents is the inactivation at negative potentials. This inactivation is nearly complete with Ca2+ 
as charge carrier and is delayed when Ba2+ substitutes Ca2+. Currents of monovalent cations 
through TRPV5 and TRPV6 do not inactivate. 
Although most of the basic electrophysiological properties of TRPV5 and TRPV6 are rather 
similar, the channels differ in kinetics of Ca2+-dependent inactivation, the recovery from 
inactivation and some pharmacological characteristics. Interestingly, these typical differences 
could be explained by sequence differences between TRPV5 and TRPV6. While TRPV6 clearly 
shows a fast component of inactivation, TRPV5 is lacking this: time to 10% inactivation recorded 
from hyperpolarizing steps to -100 mV is ~125 ms for TRPV5 and just ~40 ms for TRPV6. Fast 
inactivation is about two fold prolonged when Ca2+ is substituted by Ba2+ for TRPV5, but ~20 
times for TRPV6. Surprisingly, the structural determinants of these differences are not located in 
either the amino or carboxyl termini, but in the TM2-TM3 intracellular linker. Swapping of the 
TM2-TM3 linker of TRPV6 to TRPV5 confers the kinetic and permeation phenotype of TRPV6 to 
TRPV5, whereas swapping of the amino- or carboxyl-terminal is ineffective (142). Some 
pharmacological properties also discriminate between the epithelial Ca2+ channels. Ruthenium 
red is 100-fold more potent blocker for TRPV5 than for TRPV6 (IC50 ~9 µM for TRPV6 but ~90 
nM for TRPV5, respectively). TRPV5 is about four times more sensitive to Cd2+ block than 
TRPV6 (IC50 ~70 nM for TRPV5 compared to IC50 ~260 nM for TRPV6) (143). Significant 
progress in identification of the molecular determinants of TRP channel pores and 
understanding of the high selectivity for Ca2+ has been particularly achieved for TRPV5 and 
TRPV6 channels. Structural differences in the channel pore explain the striking permeation 
differences in the TRPV subfamily.  
Figure 4A shows an amino acid sequence alignment of the putative pore regions of three 
mammalian TRPV channels. Based on structural similarity with the selectivity filter of the 
potassium channel KcsA (signature sequence “TXXTXGYGD”) (144), the structural determinant 
of the pore of TRPV1 to TRPV4 channels is the GM(L/M)GD motif (145). Importantly, this motif 
is missing in TRPV5 and TRPV6. Instead, the molecular determinants of Ca2+ selectivity and 
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permeation of TRPV5 and TRPV6 reside at a single aspartate residue (D542 for TRPV5 and 
D541 for TRPV6) present in the pore-forming region (Figure 4A) (146,147). Neutralization of 
these residues not only affects the high Ca2+ selectivity of TRPV5 and TRPV6, but also 
abolishes Mg2+- and voltage-dependent gating of these channels (147,148). It appears that high 
Ca2+ selectivity of TRPV5 and TRPV6 depends on a ring of four aspartate residues in the 
channel pore, similar to the ring of four negative residues (aspartate and/or glutamate) in the 
pore of voltage-gated Ca2+ channels (Figure 4A). A detailed analysis of the structure of the 
TRPV5 and TRPV6 pores has now been published (149,150). To obtain insight in the pore 
architecture of TRPV6, permeation studies were performed and a pore diameter of ~5.4 Å was 
estimated. Mutating D541, a residue involved in high-affinity Ca2+ binding, altered the apparent 
pore diameter, indicating that this residue lines the narrowest part of the pore and is part of the 
selectivity filter (150). Pore lining amino acids were determined by substituted cysteine 
accessibility method (SCAM). Cysteine residues introduced in a region preceding D542 for 
TRPV5 and D541 for TRPV6 displayed a cyclic pattern of reactivity to cysteine reacting agents 
indicative of a pore helix.  
C-term pore helix selectivity filter
pore 
helix
front view top view
 
 
Figure 4. Structure of the TRPV5 and TRPV6 pores. (A) Alignment of the pore regions of TRPV4, TRPV5, and 
TRPV6 with the K+ channel KcsA. The boxed sequences represent the putative selectivity filter of all channels. 
The amino-terminal part of this pore structure likely represents a putative pore helix. (B) Model for the TRPV6 
pore region, based on the KcsA structure. Views of the structure are shown, looking sideways at two opposite 
subunits (left) or looking down from the external solution to the complete homotetrameric channel (right). At the 
narrowest point, formed by the acidic side chain of D541, the pore has a diameter of 5.4 Å. Blue residues 
correspond to the residues in TM5 and TM6 (TM1 and TM2 in KcsA), whose accessibility was not tested. Amino 
acids that were subjected to SCAM analysis (residues P526 to D547) are colored in green, yellow, red, or gray. 
Residues where cysteine substitution resulted in inactive channels are marked in gray. (figure updated from 
Hoenderop et al (3)) 
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The location of the cation-selective filter was identified at the outer part of the pore helix 
(Figure 4B). The pattern of covalent modification of cysteines supports a KcsA homology-based 
three-dimensional model (144). The external vestibule in TRPV5 and TRPV6 may build up the 
three structural domains consisting of a coiled structure that is connected to a 15-amino acid 
pore helix followed by the selectivity filter (probably a coiled structure with D542 and D541 as 
the narrowest part) and another coiled structure before the beginning of TM6 (Figure 4B).  
 
TRPM subfamily 
TRPM channels show a large variety in cell biological and biophysical properties. The members 
of this subfamily can be subdivided into three subgroups: TRPM4 and TRPM5 that share 
significant similarities in both functional and biophysical characteristics; TRPM2, TRPM6 and 
TRPM7 that are remarkable combinations of ion channels and enzymes; and the remaining 
channels TRPM1, TRPM3 and TRPM8. In contrast to TRPC and TRPV, TRPM channels do not 
contain ankyrin repeats within their amino-terminal domain. Alternatively, the amino-terminal 
part of TRPM proteins, which is considerably longer (by 300–400 amino acids) than the 
corresponding regions in TRPC and TRPV members, contains a large TRPM homology region. 
The carboxyl-terminal sequences of TRPM channels are highly variable, thus determining 
differences in total protein length. 
TRPM channels exhibit highly variable permeabilities to Ca2+ and Mg2+, ranging from Ca2+ 
impermeable (the monovalent cations selective TRPM4 and TRPM5) to Ca2+ and Mg2+ 
permeable (TRPM6, TRPM7 and specific splice variants of TRPM3). The gating mechanisms of 
the TRPM subfamily members are equally varied. TRPM2 is activated by intracellular ADP-
ribose, hydrogen peroxide (64,151), and heat (152), whereas reported activation mechanisms 
for TRPM3 include cell swelling and sphingosine (69). TRPM4 and TRPM5 gate upon an 
increase in intracellular Ca2+ (75,153) and are strongly activated by raising in temperature (154). 
Finally, TRPM8 is activated upon cooling and by cooling agents such as menthol or icilin (93). 
So far, functional characterization of TRPM1 has not been reported. 
Within the TRPM subfamily, two members, TRPM6 (Chak2) and TRPM7 (ChaK1, TRP-PLIK, 
LTRPC7), share the unique feature of a kinase domain belonging to the atypical family of α-
kinases fused to the ion channel domain (Figure 5). Complete sequence analysis of TRPM6 
lead to the identification of several putative phosphorylation sites including PKC and PKA 
(Figure 5). Additionally, TRPM6 contains PDZ motifs and in the amino- and carboxyl-terminal 
regions (Figure 5). These putative phosphorylation and protein-protein interaction sites could 
prove to be important for regulating TRPM6 activity. 
The TRPM6 channel conducts mono and divalent cations currents, but at physiological ion 
concentration and membrane potential, it is an Mg2+-selective channel (81). When 
heterologously expressed, TRPM6 channels display an outward rectifying I-V relation 
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(Figure 2C) with currents reversing ~0 mV (81). TRPM6 currents are activated by a decrease in 
intracellular Mg2+. The analysis of inward and outward currents revealed one interesting feature 
of TRPM6. Whereas outward currents are mainly carried by monovalent cations, TRPM6 
channels preferentially conduct divalent cations in the inward direction, resulting in a high Ca2+ 
and Mg2+ (inward) permeability. In the absence of extracellular divalent cations, however, 
inward currents (carried by monovalent cations) are strongly increased. The resulting linear I-V 
relation (Figure 2A) supports the argument against a voltage-dependent activation of TRPM6. 
Monovalent cation inward currents were inhibited by 10 µM ruthenium red at negative 
membrane potentials.  
TRPM6 expression pattern is predominantly restricted to intestinal and renal epithelia 
supporting its proposed role in body Mg2+ homeostasis. Recently, it was postulated that TRPM6 
requires assembly with TRPM7 to form functional channel complexes in the plasma membrane 
and that disruption of multimer formation by a mutated TRPM6 variant, TRPM6S141L, results in 
hypomagnesemia with secondary hypocalcemia (HSH) (82). In this study, TRPM6S141L was 
not directed to the cell surface by TRPM7 and failed to interact with the co-expressed TRPM7. 
Remarkably, in contrast to TRPM7, Gudermann and co-workers (82) found that TRPM6 
expression in Xenopus leavis oocytes and HEK293 cells did not entail significant ion currents. In 
contrast, we measured significantly larger currents in TRPM6-transfected HEK293 cells 
compared to control cells (81). An explanation for this discrepancy might be the existence of 
specific TRPM6 splice variants with different functional properties. Chubanov et al (82) 
demonstrated that 5' rapid amplification of cDNA ends revealed three short alternative 5' exons, 
called 1A, 1B, and 1C, that were found to be individually spliced onto exon 2, suggesting that 
the TRPM6 gene harbors a promoter with alternative transcription start sites. These cDNAs 
have been named accordingly TRPM6a, TRPM6b, and TRPM6c, and additional functional 
measurements are needed to explain possible biophysical differences. 
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Besides showing 50% sequence homology, TRPM7 share many properties with TRPM6. As for 
TRPM6, the TRPM7 currents are carried by divalent cations and display an outward rectifying I-
V relation (Figure 2C) (85,86). TRPM7 monovalent cations currents are inhibited by intracellular 
Mg2+ and therefore the I-V relation linearizes in divalent free solutions (Figure 2A). In addition, 
depletion of intracellular Mg2+ (155,156) or Mg-nucleotides (85,157) fully activates TRPM7 by a 
Figure 5. Structural organization of TRPM6. (A) Potential regulatory sites in the amino- and carboxyl-tails of 
TRPM6 including PDZ motifs and conserved PKC and PKA phosphorylation sites. (B) TRPM6 is 2022 amino 
acids long with a predicted molecular mass of ~234 kDa. TRPM6 contains a core domain consisting of six 
transmembrane (TM) segments. In addition, large cytosolic amino and carboxyl-terminal domains are present. 
Putative PKC and PKA phosphorylation sites are present at both TRPM6 extremities. Between TM5 and TM6 
there is a short hydrophobic stretch predicted to be the pore-forming region of the channel. Inner and outer sides 
of the plasma membrane are indicated. 
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mechanism independent of Mg2+ permeation block. Besides Ca2+ and Mg2+, TRPM7 provides a 
mechanism for entry of trace metal ions as Ni2+, Co2+, Mn2+, and Zn2+ (89). Since the cloning of 
TRPM6 and TRPM7, it has been debated whether the α-kinase domain is involved in the 
regulation of the channel gating. Initially, it was suggested that TRPM7 gating requires a 
functional α-kinase domain (86). However, subsequent studies demonstrated that channel 
gating could be dissociated from the α-kinase activity and TRPM7 autophosphorylation. 
Furthermore, it has been reported that the α-kinase domain is neither required for the TRPM7 
channel activity nor that it contains the internal Mg2+ sensing domain (158-160). 
 
TRPA 
The TRPA family currently comprises one mammalian member, TRPA1, which is expressed in 
dorsal root ganglion (DRG), trigeminal ganglion (TG) neurons, and in hair cells (95,161,162). 
TRPA1 exhibits 14 amino-terminal ankyrin repeats (95), an unusual structural feature that may 
be relevant to the proposed role of the channel as a mechanosensor (162). 
 
TRPP subfamily 
The TRPP subfamily is heterogeneous and can be divided, based on structures, into PKD1-like 
(TRPP1-like) and PKD2-like (TRPP2-like) proteins. PKD1-like members comprise TRPP1 
(previously termed PKD1), PKDREJ, PKD1L1, PKD1L2, and PKD1L3. TRPP1 consists of 11 
transmembrane domains, a very long and complex ~3000 amino acid extracellular domain, and 
an intracellular carboxyl-terminal domain that interacts with the carboxyl-terminal domain of 
TRPP2 through a coiled-coil domain. The PKD2-like members structurally resemble other TRP 
channels in that they are predicted to have intracellular amino- and carboxyl-terminal domains, 
six TM-spanning domains, and a pore region. The members of this group comprise PKD2 
(TRPP2), PKD2L1 (TRPP3), and PKD2L2 (TRPP5). All PKD2-like proteins posses a coiled-coil 
structure in their carboxyl-terminal domain and form multiprotein/ion channel complexes. 
Mutations in human TRPP1 cause autosomal dominant polycystic kidney disease (102). 
 
TRPML subfamily 
The TRPML family consists of three mammalian members (TRPML1–3) that are relatively small 
proteins consisting of ~600 amino acid residues. TRPML1 is widely expressed and it appears 
that resides in late endosomes/lysosomes (163,164). The loop between TM1 and TM2 contains 
a lipase domain of unknown function, although it may be speculated that this region is 
enzymatically active, or represents a binding site for lipids that could exert a regulatory influence 
on TRPML1. Recently, TRPML1 has been described to function as H+ channel determining an 
H+ leak in lysosomes to prevent excessive acidification in these organelles (165,166). The 
cellular functions of TRPML2 are presently unknown. TRPML3 is involved in vesicular and 
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intracellular ion homeostasis in inner ear hair cells and melanocytes (167,168). Gain-of-function 
mutation in TRPML3 cause cytotoxicity and finally results in the development of the varitint-
waddler phenotype in mice (109,110,168). 
 
Calcium homeostasis 
The maintenance of the extracellular Ca2+ concentration is of vital importance for many 
physiological processes including intracellular signaling, neuronal excitability, muscle 
contraction and bone formation (3). Disturbed blood Ca2+ levels can be associated with serious 
clinical symptoms ranging from neuromuscular irritability, neuropsychiatric to renal dysfunction 
and cardiovascular diseases. Therefore, the extracellular Ca2+ concentration is regulated by a 
homeostatic mechanism tightly controlling the concerted actions of intestinal Ca2+ absorption, 
exchange of Ca2+ to and from the bone and renal Ca2+ reabsorption (3). The main determinants 
of Ca2+ homeostasis are the active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 
the parathyroid hormone (PTH) and calcitonin (169-173). The parathyroid glands play a key role 
in controlling the Ca2+ balance through their capacity to sense small changes in the extracellular 
Ca2+ concentration (174). When the extracellular Ca2+ levels drop, PTH is secreted into the 
blood and acts primarily on kidney and bone. Additionally, PTH stimulates 25-hydroxyvitamin-
D3-1α-hydroxylase, the crucial enzyme in the biosynthesis of 1,25(OH)2D3 which controls Ca2+ 
(re)absorption in kidney and intestine. In both organs, Ca2+ can cross the epithelial barrier to 
reach the extracellular fluid via two pathways: paracellular (passive) and transcellular (active) 
(3). Intestinal Ca2+ absorption is a crucial control system in the regulation of Ca2+ balance, 
because it facilitates the entry of dietary Ca2+ into the extracellular compartment. Here, Ca2+ is 
absorbed via two distinct passive and active mechanisms, with their relative magnitude of 
importance being set by the dietary Ca2+ content. Active transcellular Ca2+ absorption is located 
largely in the duodenum, whereas paracellular Ca2+ absorption occurs throughout the entire 
length of the intestine (175,176). In the kidney, the bulk of filtered Ca2+ is reabsorbed through 
paracellular reabsorption in the proximal tubule, and to a lower degree in the thick ascending 
loop of Henle (TAL), where it is functionally coupled to Na+ reabsorption (3). The Na+ and water 
reabsorption in the proximal tubules increases luminal Ca2+ concentration, creating a favorable 
Ca2+ concentration gradient resulting in passive diffusion of ~60% of filtered Ca2+ through the 
tight junctions towards the renal interstitium. In TAL, parallel reabsorption of Na+, K+ and Cl- by 
the Na+,K+,2Cl--co-transporter (NKCC2), in combination with K+ recycling through the renal outer 
medullary K+ channel (ROMK), generates a lumen positive electrochemical gradient to drive the 
paracellular Ca2+ reabsorption in this nephron segment (3). Furthermore, renal active Ca2+ 
reabsorption is limited to the distal convoluted tubules (DCT) and the connecting tubules (CNT) 
(177). Active renal Ca2+ reabsorption is considered to determine the net urinary Ca2+ excretion 
(3). 
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Roles of TRPV5 and TRPV5 in active Ca2+ transport  
Renal DCT and CNT as well as duodenal epithelial cells are unique in their ability to mediate 
transcellular Ca2+ transport from the luminal to the basolateral compartments, while maintaining 
their cytosolic Ca2+ concentration at low values (3). This transport is a three steps process: (i) 
Ca2+ entry through the apical membrane via the specialized epithelial Ca2+ channels, TRPV5 
and TRPV6, (ii) intracellular buffering and facilitated diffusion of Ca2+ bound to Ca2+-binding 
proteins (calbindins). (iii) Subsequently, Ca2+ extrusion across the basolateral membranes by 
the Na+/Ca2+ exchanger subtype 1 (NCX1) and/or by the plasma membrane Ca2+ ATPase 
(PMCA1b) (3). Regulation of Ca2+ entry at the apical membranes via TRPV5 and TRPV6 is 
essential for the active Ca2+ process. Therefore, the epithelial Ca2+ channels are generally 
regarded as the gatekeepers of transcellular Ca2+ transport (3). 
A tight control of the epithelial Ca2+ channels activity is important for their function in body Ca2+ 
homeostasis. The regulation of the epithelial Ca2+ channels occurs at different levels and 
involves: 
• The long-term transcriptional and translational effects of hormones. TRPV5 and TRPV6 
gene expression is regulated by PTH (178) and 1,25(OH)2D3 (179,180).  
• The role of regulatory proteins affecting the trafficking of the channels towards and from the 
plasma membrane. The Na+/H+ exchanger regulatory factor 4 (NHERF4) (181), Rab11a 
(182) and “with no lysine” kinase 4 (WNK4) (183) affect trafficking of TRPV5 and TRPV6 
proteins to regulate channel activity.  
• The contribution of accessory proteins to the regulation of the biophysical properties of the 
channels directly altering their conformation at the plasma membrane. Modulation of TRPV5 
channel activity at the plasma membrane is facilitated by the B-box and SPRY-domain 
containing protein (BSPRY) (184) and the Ca2+-binding protein (calbindin-D28K), (185), 80 K-
H (186) calmodulin (187,188) . 
Whereas the long-term transcriptional and translational regulation of epithelial Ca2+ channels by 
hormones could be systematically studied in mice models, the role of accessory proteins and 
their molecular mechanisms to regulate channels activity was studied using comprehensive 
electrophysiological (patch-clamp measurements) and biochemical approaches (binding 
studies, cell surface biotinylation, etc.). Accessory proteins can regulate channel activity either 
by changing the open probability (gating) of the channel or by modifying channel expression at 
the plasma membrane (trafficking). The advantage of using the patch-clamp technique was that 
it enabled us to measure changes in channel gating determined by the action of accessory 
proteins, while by cell surface biotinylation or by Total Internal Reflection Fluorescence (TIRF) 
the amount of channels at the plasma membrane could be determined. 
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Magnesium homeostasis 
Being the second most abundant intracellular cation, Mg2+ plays an important role as co-factor 
in many enzymatic reactions (189,190). Mg2+ homeostasis depends on the balance between 
intestinal absorption, renal excretion and Mg2+ deposit in bone (191). Regulation of body Mg2+ 
balance principally occurs in the kidney where Mg2+ excretion tightly matches intestinal Mg2+ 
absorption (192). Around 80% of the total blood Mg2+ is filtered in the glomeruli, of which 
approximately 85% is reabsorbed via passive (paracellular) mechanisms in the proximal tubules 
and TAL, in a similar manner as Ca2+. However, the relative contribution of these nephron 
segments differs significantly with only ~20% of Mg2+ reabsorption taking place in the proximal 
tubules and the bulk ~70% of filtered Mg2+ being reabsorbed in TAL. 
 
Roles of TRPM6 and TRPM7 in active Mg2+ transport  
Active (transcellular) Mg2+ transport takes place in DCT, where ~10% of the filtered Mg2+ is 
reabsorbed (190,193). The reabsorption rate in this nephron segment determines the final 
urinary Mg2+ concentration. However, the molecular mechanisms and regulation of Mg2+ 
reabsorption remain largely unknown. Previously, mutations in the γ subunit of the basolateral 
Na+,K+-ATPase were discovered in patients suffering from autosomal dominant 
hypomagnesemia (194,195) demonstrating a role of this protein in Mg2+ transport. Recently, two 
groups independently demonstrated that mutations in the gene encoding TRPM6 cause 
autosomal recessive hypomagnesemia, characterized by disturbed intestinal Mg2+ absorption 
and renal Mg2+ wasting (79,80). Subsequently, detailed studies demonstrated that TRPM6 
forms Mg2+-permeable channels predominantly expressed along the apical membrane of 
epithelial cells from duodenum and DCT of the kidney (81). Current studies generally 
acknowledge TRPM6 as the gatekeeper of epithelial Mg2+ transport, suggesting a key role in 
body Mg2+ homeostasis, while its closest homologue, TRPM7 plays critical roles in cellular Mg2+ 
homeostasis (159). Dietary Mg2+ restriction in mice resulted in hypomagnesemia and renal Mg2+ 
and Ca2+ conservation, whereas a Mg2+-enriched diet led to increased urinary Mg2+ and Ca2+ 
excretion (196). Conversely, Mg2+ restriction significantly up-regulated renal TRPM6 mRNA 
levels, whereas an Mg2+ enriched diet increased TRPM6 mRNA expression in colon (196). 
Dietary Mg2+ did not alter TRPM7 mRNA expression in mouse kidney and colon (196), 
consistent with its role in cellular Mg2+ homeostasis. 
 
Aims and outline of this thesis 
As described in previous paragraphs, the members of the TRPV family of cation channels, 
TRPV5 and TRPV6, are key players in transepithelial Ca2+ transport and thus important factors 
to modulate body Ca2+ balance. Similarly, TRPM6 proteins function as epithelial Mg2+ channels 
contributing to body Mg2+ homeostasis. Therefore, the general goal of this thesis was to get 
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further insight into the physiological and molecular regulation of epithelial Ca2+ and Mg2+ 
channels in order to ultimately understand mechanisms of active transport of these divalent 
cations. To this end, the above-described electrophysiological technique, patch-clamp analysis, 
was used for functional characterization of different accessory proteins that regulate epithelial 
Ca2+ channels, and to identify the molecular determinants of cation permeation through the 
epithelial Mg2+ channel TRPM6. 
In the study described in chapter 2, the molecular basis of hypercalciuria observed in tissue 
kallikrein knockout (TK-/-) mice was investigated. The study combined functional and 
biochemical assays to determine the effect of TK on active Ca2+ reabsorption.  
The Ca2+-sensing receptor (CaSR) is mainly expressed in the chief cell of the parathyroid 
glands and throughout the whole length of the nephron. CaSR functions as a G-protein coupled 
receptor and is activated by increased Ca2+ concentrations in the blood or extracellular fluids. In 
the proximal nephron segments, CaSR inhibits passive Ca2+ reabsorption. CaSR is also present 
in the apical membrane of DCT and CNT of the kidney, the primary sites of TRPV5 expression. 
By the study described in chapter 3, a potential role of the CaSR in the DCT and CNT of the 
kidney was determined using functional assays as patch-clamp recordings and measurements 
of the intracellular Ca2+ concentrations. 
FKBP52 is a widely expressed cytosolic enzyme that belongs to the FK506-binding proteins 
(FKBPs) subfamily of immunophillin proteins. FKBP52 was identified as a candidate to regulate 
TRPV5 using a microarray to screen for genes that code for proteins involved in Ca2+ 
reabsorption. In the study presented in chapter 4, this novel TRPV5 accessory protein, 
FKBP52, was functionally characterized. 
RGS2 is member of the family of proteins that regulate the G protein signaling by enhancing the 
GTP-ase activity of active Gα subunits. In the study described in chapter 5, RGS2 was 
identified as a novel binding partner of TRPV6 by yeast-two-hybrid screening. The role of the 
RGS2 protein as putative TRPV6 regulator was further examined using functional and 
biochemical assays. 
Further, the pore permeation properties of the epithelial Mg2+ channel TRPM6 were investigate 
in the study described in chapter 6. A combined approach consisting in site-directed 
mutagenesis and electrophysiological measurements was used to investigate the role of amino 
acid residues from the putative selectivity filter in the permeation properties of TRPM6.  
Finally, the outcome of this thesis and the implications of the described studies in ion channel 
physiology were discussed and summarized in chapter 7. 
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ABSTRACT 
The Transient Receptor Potential Vanilloid 5 (TRPV5) channel determines urinary Ca2+ 
excretion and is therefore critical for Ca2+ homeostasis. Interestingly, mice lacking the serine 
protease tissue kallikrein (TK) exhibit robust hypercalciuria comparable to the Ca2+ leak in 
TRPV5 knockout mice. Here, we delineated the molecular mechanism through which TK 
stimulates Ca2+ reabsorption. Using TRPV5-expressing primary cultures of renal Ca2+-
transporting epithelial cells, we showed that TK activates Ca2+ reabsorption. The stimulatory 
effect of TK was mimicked by bradykinin (BK) and could be reversed by application of JE049, a 
BK receptor type 2 antagonist. A cell permeable analog of DAG increased TRPV5 activity within 
30 minutes via protein kinase C activation of the channel since mutation of TRPV5 at the 
putative PKC phosphorylation sites S299 and S654 prevented the stimulatory effect of TK. Cell 
surface labeling revealed that TK enhances the amount of TRPV5 channels at the plasma 
membrane by delaying its retrieval. In conclusion, TK stimulates Ca2+ reabsorption via the BK-
activated PLC/DAG/PKC pathway and the subsequent stabilization of the TRPV5 channel at the 
plasma membrane. 
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INTRODUCTION 
The overall Ca2+ balance is regulated by a homeostatic mechanism tightly controlling the 
concerted actions of intestinal Ca2+ absorption, exchange of Ca2+ from bone and renal Ca2+ 
reabsorption. In kidney, Ca2+ can cross the epithelial cells and reach the blood compartment via 
two pathways: passive (paracellular) and active (transcellular) Ca2+ reabsorption. Active Ca2+ 
reabsorption takes place in the distal convoluted (DCT) and the connecting (CNT) tubules (1). 
Although it accounts only for ~15% of total renal Ca2+ reabsorption, it is generally considered 
the site for fine-tuning of urinary Ca2+ excretion. Furthermore, active Ca2+ reabsorption is the 
primary target for regulation by calciotropic hormones, including 1,25-dihydroxyvitamin D3 and 
parathyroid hormone (PTH), enabling the organism to regulate Ca2+ reabsorption to the body’s 
demand. 
The Transient Receptor Potential Vanilloid 5 (TRPV5) channel is expressed along the apical 
membrane of DCT and CNT and represents the rate-limiting step in renal transcellular Ca2+ 
reabsorption (1). Inactivation of TRPV5 in mice (TRPV5-/-) abolishes active Ca2+ reabsorption in 
kidney resulting in severe hypercalciuria (2). To compensate this renal Ca2+ leak, TRPV5-/- mice 
exhibit intestinal Ca2+ hyperabsorption. In addition, the bone structure of these mice was 
significantly disturbed as illustrated by a reduced trabecular and cortical bone thickness (2). 
Hence, these data demonstrate the key function of TRPV5 in active Ca2+ reabsorption and its 
essential role in the body Ca2+ homeostasis. 
Interestingly, hypercalciuria was recently observed in tissue kallikrein-deficient (TK-/-) mice (3). 
TK is a serine protease produced in CNT (4), where it co-localizes with TRPV5 (2). Proteolytic 
enzymes such as TK are synthesized as inactive precursors or zymogens, to prevent protein 
degradation and to enable spatial and temporal regulation of enzymatic activity. The precursor 
of TK is converted to the mature active form before entering the luminal tubular compartment. 
Trypsin, plasma kallikrein, plasmin and thermolysin can cleave in vitro the TK precursor, but the 
endogenous activator is still unknown (5). Once activated, TK is excreted and can process low 
molecular weight kininogen to release kinin which acts through kinin receptors such as the 
bradykinin (BK) 2 receptor (B2R) (6). Remarkably, recent studies show that TK can directly 
activate the B2R independently of BK release (7). However, the molecular events that link TK to 
Ca2+ balance are at present unknown.  
The aim of this study was, therefore, to elucidate the molecular mechanism of hypercalciuria 
observed in TK-/- mice. To this end, the relation between TK expression and hypercalciuria was 
investigated in vivo using TK-/- and TRPV5-/- mice. Subsequently, the effect of TK on 
transcellular Ca2+ transport was examined in primary cultures of renal CNT/CCD cells. Finally, 
the signaling pathway through which TK acts on Ca2+ reabsorption and its effect on TRPV5 
surface expression was delineated in TRPV5-expressing cells. 
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EXPERIMENTAL PROCEDURES 
Animal experiments 
TK-/- mice were produced as previously described (3,8) and fed ad libitum two Na+ diets 
containing 0.3% (w/w) or 3% (w/w) for 14 days. Subsequently, 24 hour urine was collected from 
TK-/- mice and from their wild-type littermates (TK+/+) housed in metabolic cages and blood was 
obtained by orbital puncture. Measurements of biological parameters in the animals plasma and 
urine were performed as previously described (3). Urinary Na+, Ca2+ and Mg2+ excretion was 
expressed as ratios to urinary creatinine excretion to take into account the variations in urine 
collection. TRPV5-/- mice were generated as described previously (2). At the age of 4 weeks, 
mice were fed ad libitum two diets containing 0.02% (w/w) or 2% (w/w) Ca2+ for 5 weeks and 
were subsequently placed in metabolic cages. 24 hour urine samples were collected and 
subjected to TCA precipitation. The animal ethics board of the Radboud University Nijmegen 
approved all animal experimental procedures. 
 
Urine protein precipitation by TCA 
10% of the 24 hours urine volume collected of TRPV5-/- mice was centrifuged at 200 g for 10 
minutes at 4°C to remove cell debris. Proteins in the urine were precipitated using ice-cold TCA 
(Acros organics, New Jersey, USA). The TCA mixture was centrifuged at 13,000 g for 10 
minutes at 4°C, and the pellet was subsequently washed with 300 μl acetone. Next, the pellet 
was air-dried for approximately 3 minutes, dissolved in Laemmli buffer containing 0.1 M DTT 
and 150 mM Tris (pH 8.8) and analyzed by immunoblot analysis for the expression of TK using 
a rabbit anti-TK antibody (Calbiochem, San Diego, CA, USA). Immunopositive bands were 
scanned using an imaging densitometer to determine pixel density (Molecular Analyst Software, 
BioRad Laboratories, Hercules, CA). 
 
DNA constructs and cell culture 
The TRPV5 pCINeo/IRES-GFP constructs were generated as described previously (9). Single 
and combined PKC mutants were generated by alanine substitution of the six putative 
phosphorylation sites of TRPV5 (S144A, S299A, S316A, S654A, S664A, S698A) using in vitro 
mutagenesis (QuickChange Site-Directed Mutagenesis kit, Stratagene, La Jolla, CA, USA). The 
B2R pcDNA3 was a kind gift from Prof G. Erdös, MD (Department of Pharmacology, University 
of Illinois, Chicago, USA). HEK293 cells were transfected at 70% of confluency using 
polyethylenimine (Polysciences, Inc., Warrington, USA) or Lipofectamin 2000 (Invitrogen Life 
Technologies, Breda, The Netherlands). After 48-60 hours, cells were used for 45Ca2+ uptake 
assays, patch-clamp and/or biotinylation experiments. Prior to the assays, cells were incubated 
for 1 hour in serum-free medium containing the particular compound.  
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Transcellular Ca2+ transport in renal primary cultures 
CNT/CCD tubules were immunodissected from kidney cortex of New Zeeland White rabbits 
(~0.5 kg) using antibody R2G9 and then placed in primary culture on permeable filters (0.33 
cm2; Costar, Cambridge, MA, USA) as described before (10). At confluence, monolayers were 
used for the transepithelial Ca2+ transport assay as previously described (10). Transepithelial 
potential difference and resistance were checked before and after transport measurement to 
confirm the integrity of the monolayer. 
 
45Ca2+ uptake assay 
HEK293 cells were transfected with TRPV5 pCINeo/IRES-GFP or pCINeo/IRES-GFP cDNA. 
Ca2+ uptake was determined in uptake medium (110 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.1 
mM CaCl2, 10 mM Na-acetate, 2 mM NaH2PO4, 20 mM HEPES-Tris, pH 7.4 supplemented with 
10 µM felodipine, 10 µM methoxy-verapamil, 1 mM BaCl2 and 1 µCi/ml 45CaCl2) for 10 minutes 
at room temperature (20–25°C). Each well was washed extensively with stop buffer (110 mM 
NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.5 mM CaCl2, 1.5 mM LaCl3, 10 mM Na-acetate, 20 mM 
HEPES-Tris, pH 7.4) at 4 °C, incubated with 0.05% (w/v) SDS and the lysates were counted for 
radioactivity using liquid scintillation. 
 
Electrophysiology and solutions 
Patch-clamp experiments were performed as described previously (11) in the tight seal whole-
cell configuration at room temperature using an EPC-9 patch-clamp amplifier computer 
controlled by the Pulse software (HEKA Elektronik, Lambrecht, Germany). Two voltage 
protocols were used: a ramp, to establish the I-V relation in nominally DVF or in 10 mM Ca2+-
containing extracellular solutions and a hyperpolarizing step protocol to measure the Ca2+-
dependent inactivation. Na+ current densities were calculated from the current at -80 mV during 
the ramp protocols, while the and Ca2+ currents were calculated from the current at -80 mV 
during the ramp protocols or from Ca2+ peak values were extracted from the current at -100 mV 
during the step protocol. The analysis and display of patch-clamp data were performed using 
Igor Pro software (WaveMetrics, Lake Oswego, USA). 
 
Cell surface labeling with biotin 
HEK293 cells were transfected with 15 µg HA-TRPV5, TRPV5-S299A or TRPV5- S654A 
pCINeo/IRES-GFP or pCINeo/IRES-GFP in poly-L-lysine (Sigma, St Louis, MO, USA) coated 
10 cm dishes. 48 hours after transfection, cells were incubated for 1 hour with 100 nM TK and 1 
µM JE049. The biotinylation assay was performed, cells were homogenized in 1 ml lysis buffer 
as described previously (12) using the NHS-LC-LC-biotin (Pierce, Etten-Leur, The Netherlands). 
Finally, biotinylated proteins were precipitated using neutravidin-agarose beads (Pierce, Etten-
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Leur, The Netherlands). TRPV5 expression was analyzed by immunoblot for the precipitates 
(plasma membrane fraction) and for the total cell lysates using the guinea pig anti-TRPV5 
antibody (13). For the half-life assay, the biotinylation assay was pursued as described above. 
For time point 0 hours, cells were collected from plates and lysed, immediately after 
biotinylation. Other plates of cells were further cultured after biotinylation for 1, 3, 6 or 12 hours, 
then washed once with ice-cold PBS (pH 7.4), and subsequently homogenized in lysis buffer. 
All samples were processed as described above. 
 
Compounds 
TK, BK, PMA and OAG were purchased from Sigma (St Louis, MO, USA). U73122 and U73343 
were purchased from Upjohn Laboratories (Kalamazoo, MI, USA). JE049, formerly known as 
icatibant or HOE140, was a kind gift of Dr. J. Pünter (Aventis Pharma Deutschland GmbH, 
Frankfurt, Germany). 
 
Statistical analysis 
In all experiments, the data is expressed as mean ± SEM. Overall statistical significance was 
determined by analysis of variance (ANOVA). In case of significance, differences between the 
means of two groups were analyzed by unpaired t-test, while multiple comparisons between 
groups were performed by Bonferroni post-hoc tests. P < 0.05 were considered significant. The 
statistical analyses were performed using the SPSS software (SPSS Inc, Chicago, Il, USA). 
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RESULTS 
TK expression levels inversely correlate with urinary Ca2+ excretion 
The relation between urinary TK expression and urinary Ca2+ excretion was investigated by 
using wild-type (TK+/+) and TK-/- mice fed a 0.3% (w/w) (normal) and 3% (w/w) (high) Na+ diet. 
Urinary Ca2+ excretion was significantly increased in TK+/+ mice on high Na+ diet compared to 
mice on normal diet (P < 0.05, n = 12 mice) (Figure 1A).  
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Conversely, Ca2+ excretion in TK-/- mice on normal Na+ diet was significantly higher (140 ± 13%) 
than in TK+/+ mice (P < 0.05, n = 12 mice), but remained constant on a high Na+ diet (P > 0.2, n 
= 12 mice) (Figure 1A). On the high Na+ diet there was no significant difference in urinary Ca2+ 
excretion between TK+/+ and TK-/- mice. Body weight, food intake, urinary creatinine as well as 
plasma values of Ca2+, creatinine and protein concentrations did not differ between mice 
genotypes on either diet (Table 1). 
Figure 1. TK expression in relation to Ca2+ excretion. (A) 24 hour Ca2+ excretion normalized for creatinine 
excretion (UCa2+/UCr) in wild-type (TK+/+, closed bars) and knockout (TK-/-, open bars) mice fed a 0.3% (w/w) or 
3% (w/w) Na+ diet. Data are expressed as means ± SEM (n = 12 mice). *P < 0.05 versus TK+/+ mice on 0.3% 
(w/w) diet. (B) Immunoblotting of urinary TK in wild-type (TRPV5+/+) and knockout (TRPV5-/-) mice fed a 0.02 % or 
a 2% (w/w) Ca2+ diet. Each lane represents the protein TCA-precipitate of 24 hours urine from one individual 
mouse. (C) The intensity of the immunopositive bands was quantified by densitometry and TK expression was 
depicted as a percent ratio to TRPV5+/+ mice (closed bars) fed with 0.02% (w/w) Ca2+ diet. Data are expressed as 
means ± SEM (n = 4 mice). *P < 0.05 versus TRPV5+/+ mice on the same diet. 
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 0.3% (w/w) Na+ 3% (w/w) Na+ 
 TK+/+ TK-/- TK+/+ TK-/- 
Weight (g) 23.8 ± 1.0 24.5 ± 0.8 24.6 ± 1.0 23.8 ± 0.4 
Food intake (g/24 h) 2.68 ± 0.64 2.09 ± 0.5 1.91 ± 0.32 2.18 ± 0.34 
Plasma values     
Total Ca2+ (mM) 2.05 ± 0.06 1.96 ± 0.07 2.01 ± 0.08 2.07 ± 0.08 
Creatinine (µM) 10.5 ± 1.0 9.3 ± 0.9 9.5 ± 2.1 9.0 ± 2.2 
Protein (g/L) 46.3 ± 0.9 44.9 ± 0.9 49.3 ± 1.0 44.8 ± 1.0 
Urine values     
Volume (ml/24 h) 1.47 ± 0.20 1.36 ± 0.26 3.47 ± 0.89* 2.18 ± 0.34 
Creatinine excretion 
(µmol/24 h) 
4.94 ± 0.42 4.56 ± 0.37 4.79 ± 0.39 4.71 ± 0.38 
UNa+/UCr 
(mmol/mmol) 
39.6 ± 2.5 33.9 ± 2.4 292.5 ± 38.3* 223.2 ± 23.8* 
 
 
 
TK is up-regulated in TRPV5-/- mice 
The amount of TK excreted in the urine was determined by trichloroacetic acid (TCA) protein 
precipitation of 24 hours urine collected from wild-type (TRPV5+/+) and TRPV5-/- mice fed either 
a 0.02% (w/w) (low) or a 2% (w/w) (high) Ca2+ diet. Immunoblot analysis of the TCA-precipitate 
showed the specific TK band migrating at ~40 kDa (Figure 1B). Semi-quantitative densitometry 
of the TK corresponding protein band demonstrated that urinary TK excretion increased in 
TRPV5-/- mice compared to TRPV5+/+ littermates on low Ca2+ diet, whereas the high Ca2+ diet 
did not affect TK excretion between TRPV5-/- and TRPV5+/+ genotypes (Figure 1C). 
 
TK stimulates Ca 2+ transport in renal primary cell cultures 
The effect of TK on transcellular Ca2+ transport was evaluated in primary cultures of renal 
CNT/CCD cells. Application of 100 nM TK to the apical side of the monolayer significantly 
stimulated Ca2+ transport compared to non-treated monolayers, while no effect was observed 
when TK was added to the basolateral side only (Figure 2A). Importantly, apical addition of 
TRPV5 channel blocker ruthenium red (10 µM) completely inhibited baseline Ca2+ transport and 
Table 1. Phenotypic characterization of TK+/+ and TK-/- mice on 0.3% (w/w) and 3% (w/w) Na+ diets. 
*P < 0.05 versus same genotype on 0.3% (w/w) Na diet (n = 12 mice). 
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abrogated the stimulatory effect of TK on transepithelial Ca2+ transport (Figure 2A). TK action 
was mimicked by apical addition of 100 nM trypsin, which like TK displays serine protease 
activity, (Figure 2B) as well as 1 µM BK (Figure 2C). Interestingly, the stimulatory effect on 
Ca2+ reabsorption of both BK and TK was inhibited by apical application of 1 µM JE049, a B2R 
antagonist (Figure 2C). Basolateral treatment of trypsin, BK or JE049 did not affect transcellular 
Ca2+ transport across the monolayer (data not shown). 
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TK enhances TRPV5 channel activity 
The stimulatory effect of TK on Ca2+ transport was further examined in TRPV5-transfected 
Human Embryonic Kidney (HEK) 293 cells. Incubation of these cells with TK concentrations 
ranging from 0.05 to 5,000 nM enhanced 45Ca2+ influx in a dose-dependent manner with a 
maximal stimulation at 500 nM and an EC50 of 6.00 ± 0.04 nM (Figure 3A) whereas no effect 
was observed in mock-transfected cells (data not shown). Further, TK action on TRPV5 channel 
activity was investigated by the whole-cell patch-clamp technique in TRPV5-expressing HEK293 
cells. Pre-incubation with 100 nM TK increased the inward Ca2+ current in response to the step 
protocol, but the Ca2+-dependent inactivation of the TRPV5 currents remained unchanged 
(Figure 3B).  
Figure 2. Stimulatory effect of TK on active Ca2+ reabsorption. (A) Monolayers of rabbit primary cultures of 
CNT/CCD cells were incubated with 100 nM TK for 90 minutes at the apical, basolateral or both sides. Some 
monolayers were incubated for 90 minutes in the presence of the TRPV5 blocker ruthenium red (RR, 10 µM, 
apical side) in the presence or absence of TK (100 nM, apical side). Vehicle-treated cells were used as control 
(CTRL) and net apical to basolateral Ca2+ transport was measured. Data are expressed as means ± SEM. (n = 6 
wells). *P < 0.05 versus CTRL, #P < 0.05 versus TK-treated. (B) Primary cells were treated apically with 100 nM 
trypsin or 100 nM TK. (C) 1 µM BK and 100 nM TK were applied at the apical side of the monolayers in the 
presence (open bars) or absence (closed bars) of 1 µM JE049, a B2R antagonist. In all experiments vehicle-
treated cells were used as control (CTRL) and net apical to basolateral Ca2+ transport was measured. Data are 
expressed as means ± SEM (n = 4 wells). *P < 0.05 versus CTRL. 
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The current-voltage (I-V) relation of the currents in response to a voltage ramp did not change 
after pre-incubation with 100 nM TK (Figure 3C), but the inward Ca2+ current at -80 mV 
increased by 167 ± 14% compared to non-treated, control (CTRL) cells (P < 0.05, n = 15 cells) 
as depicted in Figure 3D. 
Likewise, in divalent free (DVF) solution a significant increase of 149 ± 17% in Na+ inward 
currents at -80 mV (P < 0.05, n = 15 cells) was observed, while the I-V relation remained 
unchanged (Figure 3E,F). 
 
Figure 3. Effect of TK on TRPV5-transfected HEK293 cells. (A) HEK293 cells were transfected with TRPV5 
and treated for 1 hour with TK in concentrations ranging from 0.05 to 5,000 nM and finally 45Ca2+ uptake was 
measured. Values are expressed as means ± SEM (n = 6 wells). (B) Averaged Ca2+ currents measured with 10 
mM Ca2+ in the extracellular solution during a 3 seconds step to -100 mV from a holding potential of +70 mV in 
TRPV5-transfected HEK293 cells treated (dotted trace) or non-treated (solid trace) with 100 nM TK. (C) Current-
voltage relations measured from 450 milliseconds voltage ramps in 10 mM Ca2+-containing extracellular solution 
from non-treated CTRL (solid trace) or TK treated (dotted trace) TRPV5-expressing HEK293 cells. (D) Average 
density of the Ca2+ current measured as in (C), was 400 ± 56 pA/pF (n = 15 cells) for TK treated cells compared 
to 240 ± 33 pA/pF (n = 15 cells) for CTRL cells. (E) Current-voltage relations measured from 450 milliseconds 
voltage ramps in nominally DVF solution in TRPV5-transfected HEK293 cells treated (dotted trace) or non-treated 
(solid trace) with TK. (F) Average Na+ current density at -80 mV in nominally DVF solution were 745 ± 85 pA/pF (n 
= 15 cells) for TK treated cells compared to 500 ± 55 pA/pF for CTRL cells (n = 15 cells). *P < 0.05 versus CTRL. 
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TK increases TRPV5-mediated currents via the B2R 
Since BK mimicked the TK action on Ca2+ transport in primary cultures of CNT/CCD cells, the 
effect of BK on TRPV5-expressing HEK293 cells was further studied. First, the expression of 
B2R in HEK293 cells was confirmed by immunoblot analysis. B2R-transfected HEK293 cells 
were used as a positive control. In both mock and B2R-transfected HEK293 cells, B2R was 
detected as a single immunopositive band of ~69 kDa (Figure 4A), confirming the presence of 
endogenous B2R in this cell line. Subsequently, TRPV5-transfected HEK293 cells were 
incubated for 1 hour with 1 µM BK and functionally characterized by patch-clamp 
measurements in comparison to non-treated (CTRL) cells. Interestingly, BK treatment resulted 
in a significant increase of 150 ± 18% in both Ca2+ (Figure 4D) and Na+ (Figure 4F) currents 
(P < 0.05, n = 12 cells) compared to CTRL cells, without affecting the Ca2+-dependent 
inactivation (Figure 4B) or the I-V relations of the currents (Figure 4C,E). Because the different 
treatments of TRPV5-expressing HEK293 cells affected both Ca2+ and Na+ current amplitudes 
leaving unaffected the other current properties, only the Ca2+ currents are now depicted to 
demonstrate the effect of particular compounds. Incubation of TRPV5-transfected cells with 1 
μM JE049 reversed the stimulatory effect of TK on TRPV5-mediated currents. The Ca2+-
dependent inactivation of Ca2+ currents remained unchanged for cells treated with TK or TK and 
JE049 (Figure 4G). Ca2+ current amplitudes measured from the step protocol were significantly 
lower, 285 ± 50 pA/pF, for the JE049-treated cells (P < 0.05, n = 11 cells) compared to TK-
treated cells (Figure 4H). 
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TK stimulates TRPV5-mediated currents via the PLC-dependent PKC pathway  
To elucidate in detail the mechanism through which TK enhances TRPV5 activity, the following 
strategies were followed. First, pre-treatment with 10 µM of the PLC inhibitor U73122 for 10 
minutes abolished the TK stimulatory effect on TRPV5-mediated Ca2+ currents, whereas 10 µM 
of its inactive analogue U73343 had no effect (P < 0.05, n = 10 cells) (Figure 5A). Then, 
TRPV5-transfected cells were incubated for 1 hour with 10 µM 1-oleoyl-acetyl-sn-glycerol 
(OAG), a synthetic DAG analogue. OAG mimicked the stimulatory effect of TK on TRPV5-
Figure 4. TK stimulation of TRPV5 activity is mediated by B2R. (A) B2R transfected and mock cells were 
lysed and calibrated for equally protein loading on gel. Immunoblot analysis of the samples shows the B2R 
expression. (B) Inward Ca2+ currents in TRPV5-transfected HEK293 cells treated (dotted trace) or non-treated 
(solid trace) with 1 µM BK for 1 hour measured with the step protocol as in Figure 3B. (C) Current-voltage 
relations measured from 450 milliseconds voltage ramps in 10 mM Ca2+-containing extracellular solution from 
non-treated CTRL (solid trace) or BK (dotted trace) treated TRPV5-expressing HEK293 cells. (D) Amplitude of 
Ca2+ current for BK treated cells was 363 ± 45 pA/pF and for control cells 240 ± 30 pA/pF (n = 12 cells for each 
condition). (E) Current-voltage relations measured from voltage ramps in nominally DVF extracellular solution 
from non-treated CTRL (solid trace) and BK (dotted trace) treated TRPV5-expressing HEK293 cells. (F) Average 
Na+ current for cells treated with BK was 615 ± 49 pA/pF and for CTRL cells 460 ± 46 pA/pF. (G) Inward Ca2+ 
currents measured with 10 mM Ca2+ in the extracellular solution during the voltage step to -100 mV of control 
non-treated cells (solid trace), cells treated with TK (dotted trace), and cells treated with both TK and 1 µM of the 
B2R antagonist JE049 (dashed trace). Inactivation of currents remained unchanged. (H) Average peak Ca2+ 
current of cells treated with TK and JE049 was 285 ± 45 pA/pF and for CTRL cells 300 ± 50 pA/pF compared to 
500 ± 55 pA/pF measured from TK treated cells. *P < 0.05 versus CTRL. #P < 0.05 versus TK treated cells. 
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mediated Ca2+ currents (P < 0.05, n = 10 cells) (Figure 5B). The stimulatory effect of OAG was 
observed within 30 minutes after addition (Figure 5C). Next, the effect of TK on the sextuple 
PKC phosphorylation-deficient mutant was tested. In HEK293 cells expressing this mutant, the 
stimulatory effect of TK was abolished (Figure 5D).  
Subsequently, the PKC phosphorylation sites were individually mutated into an alanine residue. 
TK increased Ca2+ currents of all single PKC mutants, except of S299A and S654A (P < 0.05, 
n = 12 cells) (Figure 5E). Furthermore, to determine which PKC isoforms are involved in this 
process, cells were incubated for 24 hours with 1 µM of phorbol ester (phorbol 12-myristate 13-
acetate-PMA) to down-regulate the PMA-sensitive PKC isoforms expressed in HEK293 cells as 
previously described (14). Then, these PMA-pretreated cells were treated as aforementioned 
with 100 nM TK for 1 hour. TK was still able to significantly increase (164 ± 14% of control, 
P < 0.05, n = 14 cells) the TRPV5-mediated Ca2+ currents (Figure 5F). Vehicle-incubated (NT) 
cells were used as control for the effect of PMA on TRPV5 currents and PMA incubation left 
TRPV5-mediated currents unaffected.  
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Subsequently, the possible involvement of other G-protein coupled receptors in addition to B2R 
was investigated. To this end, purinergic receptors were activated by the addition of 
extracellular ATP (1 mM for 1 hour) to TRPV5-expressing HEK293 cells. Indeed, as shown in 
the Figure 6, ATP treatment enhanced the inward Ca2+ currents in these cells, while leaving the 
I-V relation and Ca2+-dependent inactivation unchanged. Moreover, after pre-treatment with the 
Figure 5. TK action is mediated by the DAG/PKC-dependent PLC signaling pathway. TRPV5 expressing 
cells were incubated for 1 hour with 100 nM TK and subsequently treated as described below. (A) 10 minutes 
incubation with 10 µM of the PLC inhibitor U73122 reverted the average Ca2+ currents amplitude of the TK treated 
cells to values similar to CTRL cells, contrary to its inactive form U73343 which let the TK effect unaltered (n = 10 
cells). (B) Ca2+ current of cells pre-treated for 1 hour with 10 µM OAG Ca2+ currents was 355 ± 30 pA/pF and for 
CTRL cells 191 ± 25 pA/pF. (C) Time-course of TRPV5 currents stimulation by OAG. Points represent Ca2+ peak 
current measured at -100 mV using the step protocol from cells pre-treated with 10 µM OAG for 15, 30 and 60 
minutes or non-treated cells. *P < 0.05 versus non-treated cells at 0 min. (D) Average Ca2+ currents for cells 
expressing TRPV5 mutated for all its six PKC phosphorylation sites were 123 ± 36 pA/pF and TK treated cells 
were 113 ± 25 pA/pF (n = 10 cells for each condition). (E) Point mutation of the PKC phosphorylation sites S299 
and S654 did not affect Ca2+ currents in comparison with the other four PKC mutants upon TK treatment. Data 
are expressed as percentage of Ca2+ currents measured of cells expressing PKC-TRPV5 point mutants treated 
with 100 nM TK normalized to non-treated CTRL cells (n = 12 cells for each mutant). (F) 24 hours incubation with 
1 µM PMA was used to down-regulate the PMA-sensitive PKC isoforms in TRPV5-transfected cells. In both 
cases, non-treated (NT), or 24 hours incubation with PMA, TK (black bars) was still able to significantly increase 
TRPV5-mediated Ca2+ currents compared to control cells (white bars) (n = 14 cells for each condition) *P < 0.05 
versus CTRL cells. 
 52 
B2R antagonist JE049, ATP was still able to stimulate the TRPV5 currents, indirectly 
demonstrating the specificity of TK stimulation via the B2R. 
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TK increases cell surface expression of TRPV5 by delaying channel retrieval  
The effect of TK on the amount of TRPV5 channel expressed at the plasma membrane was 
investigated in HEK293 cells. TRPV5-transfected cells were incubated with 100 nM TK alone or 
in combination with 1 µM JE049 for 1 hour and then subjected to cell surface biotinylation. 
Biotinylated cell lysates were precipitated with neutravidin-agarose beads and immunoblotted 
for TRPV5. Mock-transfected and non-biotin-treated cells were used as negative controls. TK 
treatment enhanced TRPV5 expression in the biotinylated fraction, whereas JE049 abolished 
this effect (Figure 7A, left panel). Importantly, TRPV5 was equally expressed in total cell 
lysates of all tested conditions (Figure 7A, right panel). The observed increase in cell surface 
expression of TRPV5 by TK could be due to either an enhanced trafficking from the Golgi 
apparatus to the cell surface or a reduction in channel retrieval from the plasma membrane. The 
kinetics of cell-surface retrieval was measured in HEK293 cells using half-life cell-surface 
biotinylation. After a 2 hours TK treatment, the retrieval of TRPV5 channel from the plasma 
membrane was decreased by 71, 46, and 17% (P < 0.05, n = 3 blots) at the time points of 1, 3 
and 6 hours, respectively (Figure 7B). TRPV5 expression in total cell lysates was identical in all 
tested conditions (Figure 7C). These results suggested that TK increases cell surface 
expression of TRPV5 by delaying channel retrieval from the plasma membrane.  
Figure 6. B2R confers specificity to TK-dependent stimulation of TRPV5 activity. (A) Averaged Ca2+ 
currents measured with 10 mM Ca2+ in the extracellular solution during a 3 seconds step to -100 mV from a 
holding potential of +70 mV in TRPV5-transfected HEK293 cells treated with 1 mM ATP (dotted trace), treated 
with 1 mM ATP and 1 µM of the B2R antagonist JE049 (dashed line) or non-treated CTRL (solid trace). (B) 
Current-voltage relationships measured from 450 milliseconds voltage ramps in 10 mM Ca2+-containing solution 
in TRPV5-transfected HEK293 cells treated with ATP (dotted trace), treated with ATP and JE049 (dashed trace) 
or non-treated (solid trace) with ATP. (C) Average density of the Ca2+ peak current measured as in (B), was 
300 ± 54 pA/pF for ATP treated cells and 322 ± 65 pA/pF for ATP and JE049, compared to 190 ± 23 pA/pF 
(n = 15 cells) for CTRL cells. *P < 0.05 versus CTRL. 
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TRPV5 PKC mutants S299A and S654A are insensitive to TK treatment 
The effect of TK on the TRPV5 PKC mutants S299A and S654A was investigated in HEK293 
cells by half-life analysis. TRPV5+/+, S299A and S654A transfected cells were incubated with or 
without 100 nM TK for 1 hour and then the kinetics of cell-surface retrieval was measured in 
HEK293 cells using half-life cell-surface biotinylation. Without an hour TK treatment 
(Figure 8A), the plasma membrane expression of TRPV5+/+, S299A and S654A was decreased 
at the similar extent at the time points of 1, 3, 6 and 12 hours. Interestingly, with an hour TK 
treatment (Figure 8B), the retrieval of TRPV5 channel from the plasma membrane was 
decreased, but S299A and S654A were not. TRPV5+/+, S299A and S654A expression in total 
cell lysates was identical in all tested conditions. These results suggested that the TK effect of 
delaying channel retrieval from the plasma membrane is abolished in TRPV5 PKC mutants 
S299A and S654A. 
Figure 7. TK affects the plasma membrane expression of TRPV5. (A) TRPV5-transfected HEK293 cells were 
treated with 100 nM TK with or without 1 µM JE049. Cells were subjected to cell surface biotinylation and after 
lysis precipitated with neutravidin-agarose beads. TRPV5 expression was analyzed by immunoblot for the plasma 
membrane fraction (left panel) and for the total cell lysates (right panel). As negative controls, mock cells were 
used and biotin was omitted in the procedure. (B) and (C) TK treated or non-treated TRPV5-transfected cells 
were subjected to biotinylation. Cells were immediately homogenized (time point 0), or further cultured for 1, 3, 6, 
12 hours. Subsequently, the cells were lysed, following immunoprecipitation with neutravidin-agarose beads and 
TRPV5 expression of plasma membrane (B) and total lysates (C) was visualized by immunoblot analysis. 
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Figure 8. TK does not affect the plasma membrane expression of TRPV5 PKC mutants S299A and S654A. 
TRPV5+/+, S299A and S654A-transfected HEK293 cells were treated for 1 hour without (A) or with (B) 100 nM 
TK. Subsequently, cells were subjected to cell-surface biotinylation and then homogenized at 0, 1, 3, 6, 12 hours 
after biotinylation. Subsequently, Cells were immediately homogenized (time point 0), or further cultured for 1, 3, 
6, 12 hours. Subsequently, the cells were lysed, following immunoprecipitation with neutravidin-agarose beads 
and TRPV5 expression of plasma membrane was visualized by immunoblot analysis. The expression of TRPV5 
in the cell lysates was similar in the various conditions (data not shown). 
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DISCUSSION 
The present study showed that extracellular TK stimulates TRPV5-mediated Ca2+ reabsorption 
by activating the B2R and subsequently the DAG/PKC pathway resulting in the stabilization of 
TRPV5 channels at the cell surface. This conclusion is based on the following experimental 
observations: (i) Urinary Ca2+ excretion in mice is inversely related to the expression of TK; (ii) 
TK stimulates Ca2+ reabsorption in primary cultures of renal CNT/CCD cells, which can be 
blocked by the B2R antagonist JE049; (iii) the stimulatory effect of TK is mediated by the 
PLC/DAG-pathway and requires the two conserved PKC sites S299 and S654 in TRPV5; (iv) 
TK enhances Ca2+ transport by increasing TRPV5 abundance at the plasma membrane.  
TK stimulated TRPV5-mediated Ca2+ transport via the B2R receptor. The physiological 
relevance of this latter finding is substantiated by the co-localization of B2R with TK (15) and 
TRPV5 (2) in DCT and CNT. B2R belongs to the seven-transmembrane domain G protein-
coupled receptor superfamily (16) and signals via Gαq protein with consequent activation of 
PLC. PLC catalyzes the hydrolysis of phosphatidylinositol-4,5-biphosphate (PIP2) in inositol 
trisphosphate (IP3) and DAG (17). Commonly, IP3 releases Ca2+ from the endoplasmic reticulum 
stores, while DAG activates PKC (17). Certainly, our results show that TRPV5 activation 
requires PIP2 breakdown following B2R stimulation and relies on DAG as a down-stream 
effector. Subsequently, DAG increases TRPV5 activity via PKC phosphorylation of the channel 
since potential PKC phosphorylation deficient mutants of TRPV5 at positions S299 and S654 
lack the TK effect. This is the first study demonstrating that TRPV5 is activated through its PKC 
phosphorylation sites. Among the six predicted phosphorylation sites in the TRPV5 sequence, 
two serines, S299 and S654 are critical for TRPV5 activation by TK. Importantly, TRPV5 closest 
homologue, TRPV6, did not respond to TK (data not shown). Since the second serine (S654) is 
not conserved in TRPV6, both serines are apparently critical for stimulation of TRPV5 by TK. In 
addition, 24 hours pre-incubation with PMA down-regulates α, β, and ε isoforms of PKC, but not 
PKC ζ (18). This latter PKC isoform is presumably involved in TK increase of TRPV5 currents 
since the stimulatory effect of PKC was similar in PMA-pretreated and control cells. 
Interestingly, stimulation of active Ca2+ transport in primary cultures of renal CNT/CCD also 
involves PMA-insensitive PKC isotypes (19) among which the isotype PKC ζ can be activated 
by B2R (20). However, B2R knockout mice (B2R-/-) mice showed no change in urine Ca2+ 
excretion (3), in contrast with TK-/- mice, suggesting that compensation mechanisms could mask 
the TK effect on Ca2+ balance in these knockout mice. For instance, it has been shown that in 
these knockout mice a compensatory induction of the B1 receptor occurs which could 
theoretically be a new target for TK. Alternatively, TK exerts its in vivo effect via a mechanism 
independent of B2R.  
Previous studies showed that different signaling molecules of the PLC pathway activate TRP 
channels. For example, the three canonical TRP members TRPC3, 6 and 7 are characterized 
 56 
by their sensitivity to DAG (21). Alternatively, the vanilloid and melastatine members of TRP 
family, TRPV1 (22), TRPV5 (23), TRPM4 (24), TRPM5 (25), TRPM7 (26) and TRPM8 (27) can 
be directly regulated by PIP2. Thus, in vivo TRPV5 activation by PIP2 (23) or DAG/PKC could 
adjust TRPV5 activity in response to physiological fluctuations. In addition, Ca2+ entering the cell 
through TRPV5 could prevent the electrostatic interaction between the negatively charged PIP2 
and the channel by screening the negative charge on the lipid head group, as proposed for Mg2+ 
and TRPM7 (28).  
Stimulation of Ca2+ transport through TRPV5 upon TK action could be the result of an increase 
in either open probability of the channel or in expression of TRPV5 at the plasma membrane. 
Surface biotinylation analysis showed that TK increases the amount of TRPV5 channels at the 
plasma membrane. Thus, PKC activation of TRPV5 following the TK application would regulate 
the balance between constitutive exocytosis and endocytosis in favor of the former leading to 
the accumulation of TRPV5 at the cell surface. Similarly, the epidermal growth factor prevents 
the internalization of plasma membrane TRPC3 (29). The role of the cytoskeleton in this 
translocation process is at present unknown. It is possible that PKC-dependent phosphorylation 
of TRPV5 leads to activation of motor proteins that transport the channels towards the plasma 
membrane. This process could involve the FKBP52 protein, characterized previously as a 
TRPV5 regulatory protein (30), since FKBP52 is known to interact with the motor protein dynein 
(31,32). Interestingly, TRPM7 associates to the actomyosin cytoskeleton upon BK stimulation 
regulating cell adhesion (33). Interestingly, the protein synaptotagmin has been proposed to 
regulate the exocytosis of TRPC5, in part because of their co-localization (34). However, the 
cytoskeletal elements and the motor proteins participating in the incorporation of TRPV5 in the 
plasma membrane remain to be determined. Furthermore, accumulation of channels at the cell 
surface can also occur by increased incorporation into the plasma membrane. Indeed, PKC 
potentiation of TRPV1 promotes the recruitment of a channel vesicular pool to the cell surface 
(35). This exocytosis process of TRPV1 is dependent on the soluble N-ethylmaleimide-
sensitive-factor attachment proteins receptor (SNARE) (35), known to act as membrane 
recognition molecules and acceptors for vesicle trafficking, docking and fusion (36). It would be 
interesting to investigate the role of similar scaffold proteins in the assembly of TRPV5 and PKC 
upon TK treatment, considering that such signaling pathways are currently indicated to function 
in spatially distinct microdomains (37). For instance, the A-kinase-anchoring protein, AKAP, has 
been described to coordinate the subcellular localization of second messenger-regulated 
enzymes, such as PKC in order to modulate the activity of K+ channel, KCNQ/M, upon agonist 
stimulation via Gq-coupled pathway (38). 
The aforementioned data are in support of plasma membrane recycling of TRPV5 protein as 
mechanism of channel regulation. A tight control of TRPV5 activity is of primordial importance 
for body Ca2+ homeostasis, since TRPV5 constitutes the fine-tuned Ca2+ entry step in active 
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Ca2+ reabsorption (1). Besides the hormonal regulation of TRPV5, accessory proteins play a 
role in modulating channel trafficking and activity (9,39). Together with a recent report on the β-
glucuronidase klotho (12), our study introduces a new mechanism of TRPV5 regulation which is 
based on extracellular enzymatic activation. TK and klotho co-localize with TRPV5 in the distal 
part of the nephron where they activate the channel from the luminal side. A comparable 
enzymatic regulation is described for the epithelial Na+ channel, ENaC, present in CNT, by the 
channel activating proteases, CAP-1, CAP-2 and CAP-3 (40). Unlike the protease CAP and the 
β-glucuronidase klotho, TK stimulates TRPV5 indirectly via activation of B2R that then induces 
a redistribution of TRPV5 channels towards the plasma membrane. On the contrary, CAPs 
which are membrane-bound serine proteases, act directly on the channel gating by enhancing 
the open probability of ENaC (41) to stimulate epithelial Na+ absorption. Likewise, klotho directly 
activates TRPV5 by enzymatic modification of the N-glycan to stabilize TRPV5 channels in the 
plasma membrane (12).  
Interestingly, we showed that an increase in Na+ supply induced a Ca2+ wasting in wild-type 
mice. It is well know that a high Na+ diet increases the plasma volume that triggers the renin-
angiotensin-aldosterone system (42). These hormones will act as a negative feedback response 
lower the reabsorption of Na+ and consequently Ca2+ in the proximal tubules. Ultimately, this will 
increase the urinary excretion of Ca2+. The anticipated calciuria was not observed in TK-/- mice, 
possibly these mice cannot further increase their urinary Ca2+ excretion. In addition, the rates of 
urinary Ca2+ excretion in wild-type and TK-null mice were similar on a high Na+ diet, whereas 
they markedly differed on a normal Na+ diet. This strongly supports the fact that TK participates 
in the renal response to a high Na+ diet and to the attendant decrease in urinary Ca2+ 
reabsorption. 
Here, we demonstrated that TK displays autocrine or paracrine stimulation of active Ca2+ 
reabsorption in a dose-dependent manner. As shown in the mice models, reduction in TK 
expression increases urinary Ca2+ excretion as reflecting of impaired tubular Ca2+ reabsorption. 
Conversely, genetic ablation of TRPV5 doubled the renal expression of TK possibly to 
counterbalance the Ca2+ wasting observed in the TRPV5-/- mice by maximally stimulating the 
process of Ca2+ reabsorption. Indeed, an increase in dietary Ca2+ intake as an alternative 
maneuver to offset the renal Ca2+ loss in TRPV5-/- mice prevented the compensatory increase in 
TK expression. These results underline the role of TK during Ca2+ restriction. It is, therefore, 
interesting to study the Ca2+ excretion in humans with a genetically reduced TK activity. In this 
respect, a loss-of-function polymorphism of the TK gene in which the active-site arginine at 
position 53 is changed into a histidine (R53H), reduces by 50-60% TK activity is interesting (43). 
Partial genetic deficiency in TK activity of the R53H subjects is associated with a form of arterial 
dysfunction (44). TK is well known as a vasodilator factor of renal cortical blood vessels through 
BK production, while abnormalities of TK levels has long been documented in the pathogenesis 
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of hypertension (45). It is therefore tempting to speculate that TK stimulation of TRPV5-
mediated Ca2+ reabsorption plays a role in TK hypotensive action, since urinary Ca2+ leak has 
been correlated with higher baseline systolic and diastolic blood pressures (46). 
 
In conclusion, our data demonstrated that TK reduces urinary Ca2+ excretion by an autocrine 
and paracrine stimulation of TRPV5-mediated Ca2+ reabsorption explaining the hypercalciuria in 
TK-/- mice. Figure 9 illustrates the molecular pathway linking TK to stimulation of TRPV5, as 
elucidated in the present study. TK activates B2R and through the PLC derived-messenger 
DAG initiates the phosphorylation of the TRPV5 PKC sites S299 and S654. Subsequently, Ca2+ 
influx through TRPV5 is enhanced by the accumulation and stabilization of the channel at the 
plasma membrane. Thus, TK-directed translocation of TRPV5 channels constitutes a 
mechanism by which renal cells can fine-tune Ca2+ reabsorption. 
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Figure 9. Schematic diagram of TK stimulatory effect on TRPV5. TK activates the B2R and subsequently 
PLC, leading to the hydrolysis of PIP2 in IP3 and DAG. DAG induces subsequently the phosphorylation of TRPV5 
through PKC-dependent mechanism with consequent stabilization of TRPV5 channel in the plasma membrane. 
The increased number of channels at the plasma membrane is the result of delayed channel retrieval ensuing 
enhanced Ca2+ transport through TRPV5. 
 59
REFERENCES 
1. Hoenderop, J. G., Nilius, B., and Bindels, R. J. Physiol Rev. 85: 373-422, 2005 
2. Hoenderop, J. G., van Leeuwen, J. P., van der Eerden, B. C., et al. J Clin Invest. 112: 
1906-1914, 2003 
3. Picard, N., Van Abel, M., Campone, C., et al. J Am Soc Nephrol. 16: 3602-3610, 2005 
4. Figueroa, C. D., MacIver, A. G., Mackenzie, J. C., and Bhoola, K. D. Histochemistry. 89: 
437-442, 1988 
5. Margolius, H. S. Hypertension. 26: 221-229, 1995 
6. Bhoola, K. D., Figueroa, C. D., and Worthy, K. Pharmacol Rev. 44: 1-80, 1992 
7. Hecquet, C., Tan, F., Marcic, B. M., and Erdos, E. G. Mol Pharmacol. 58: 828-836, 2000 
8. Meneton, P., Bloch-Faure, M., Hagege, A. A., et al. Proc Natl Acad Sci U S A. 98: 2634-
2639, 2001 
9. van de Graaf, S. F., Hoenderop, J. G., Gkika, D., et al. Embo J. 22: 1478-1487, 2003 
10. Bindels, R. J., Hartog, A., Timmermans, J., and Van Os, C. H. Am J Physiol. 261: F799-
807, 1991 
11. Vennekens, R., Hoenderop, J. G., Prenen, J., et al. J Biol Chem. 275: 3963-3969, 2000 
12. Chang, Q., Hoefs, S., van der Kemp, A. W., Topala, C. N., Bindels, R. J., and 
Hoenderop, J. G. Science. 310: 490-493, 2005 
13. Hoenderop, J. G., Hartog, A., Stuiver, M., Doucet, A., Willems, P. H., and Bindels, R. J. J 
Am Soc Nephrol. 11: 1171-1178, 2000 
14. Camden, J. M., Schrader, A. M., Camden, R. E., et al. J. Biol. Chem. 280: 18696-18702, 
2005 
15. Figueroa, C. D., Gonzalez, C. B., Grigoriev, S., et al. J Histochem Cytochem. 43: 137-
148, 1995 
16. Hess, J. F., Borkowski, J. A., Young, G. S., Strader, C. D., and Ransom, R. W. Biochem 
Biophys Res Commun. 184: 260-268, 1992 
17. Blaukat, A. Andrologia. 35: 17-23, 2003 
18. Frecker, H., Munk, S., Wang, H., and Whiteside, C. Am J Physiol Renal Physiol. 289: 
F1078-1087, 2005 
19. Hoenderop, J. G., De Pont, J. J., Bindels, R. J., and Willems, P. H. Kidney Int. 55: 225-
233, 1999 
20. Christopher, J., Velarde, V., Zhang, D., Mayfield, D., Mayfield, R. K., and Jaffa, A. A. Am 
J Physiol Heart Circ Physiol. 280: H1537-1546, 2001 
21. Hofmann, T., Obukhov, A. G., Schaefer, M., Harteneck, C., Gudermann, T., and Schultz, 
G. Nature. 397: 259-263, 1999 
22. Chuang, H. H., Prescott, E. D., Kong, H., et al. Nature. 411: 957-962, 2001 
23. Lee, J., Cha, S. K., Sun, T. J., and Huang, C. L. J Gen Physiol. 126: 439-451, 2005 
24. Nilius, B., Mahieu, F., Prenen, J., et al. Embo J. 25: 467-478, 2006 
25. Liu, D., and Liman, E. R. Proc Natl Acad Sci U S A. 100: 15160-15165, 2003 
26. Runnels, L. W., Yue, L., and Clapham, D. E. Nat Cell Biol. 4: 329-336, 2002 
27. Liu, B., and Qin, F. J Neurosci. 25: 1674-1681, 2005 
28. Kozak, J. A., and Cahalan, M. D. Biophys J. 84: 922-927, 2003 
29. Smyth, J. T., Lemonnier, L., Vazquez, G., Bird, G. S., and Putney, J. W., Jr. J Biol 
Chem. 281: 11712-11720, 2006 
30. Gkika, D., Topala, C. N., Hoenderop, J. G., and Bindels, R. J. Am J Physiol Renal 
Physiol. 290: F1253-1259, 2006 
31. Czar, M. J., Lyons, R. H., Welsh, M. J., Renoir, J. M., and Pratt, W. B. Mol Endocrinol. 9: 
1549-1560, 1995 
32. Silverstein, A. M., Galigniana, M. D., Kanelakis, K. C., Radanyi, C., Renoir, J. M., and 
Pratt, W. B. J Biol Chem. 274: 36980-36986, 1999 
33. Clark, K., Langeslag, M., van Leeuwen, B., et al. Embo J. 25: 290-301, 2006 
34. Strubing, C., Krapivinsky, G., Krapivinsky, L., and Clapham, D. E. Neuron. 29: 645-655, 
2001 
 60 
35. Morenilla-Palao, C., Planells-Cases, R., Garcia-Sanz, N., and Ferrer-Montiel, A. J Biol 
Chem. 279: 25665-25672, 2004 
36. Duman, J. G., and Forte, J. G. Am J Physiol Cell Physiol. 285: C237-249, 2003 
37. Ambudkar, I. S. Trends Pharmacol Sci. 27: 25-32, 2006 
38. Hoshi, N., Langeberg, L. K., and Scott, J. D. Nat Cell Biol. 7: 1066-1073, 2005 
39. Gkika, D., Mahieu, F., Nilius, B., Hoenderop, J. G., and Bindels, R. J. J Biol Chem. 279: 
26351-26357, 2004 
40. Rossier, B. C. Proc Am Thorac Soc. 1: 4-9, 2004 
41. Vuagniaux, G., Vallet, V., Jaeger, N. F., Hummler, E., and Rossier, B. C. J Gen Physiol. 
120: 191-201, 2002 
42. Nijenhuis, T., Vallon, V., van der Kemp, A. W., Loffing, J., Hoenderop, J. G., and 
Bindels, R. J. J Clin Invest. 115: 1651-1658, 2005 
43. Slim, R., Torremocha, F., Moreau, T., et al. J Am Soc Nephrol. 13: 968-976, 2002 
44. Azizi, M., Boutouyrie, P., Bissery, A., et al. J Clin Invest. 115: 780-787, 2005 
45. Chao, J., and Chao, L. Exp Physiol. 90: 291-298, 2005 
46. McCarron, D. A., and Reusser, M. E. J Am Coll Nutr. 18: 398S-405S, 1999 
 
 
 
Chapter 3 
 
 
 
 
The Ca2+-sensing receptor stimulates TRPV5 activity 
 
 
 
 
 
 
 
 
 
 
Catalin N. Topala1, Joost P. Schoeber1, Daniela Riccardi2,  
Joost G. Hoenderop1 and René J. Bindels1 
 
 
 
 
1Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud 
University Nijmegen Medical Centre, The Netherlands, 2Cardiff School of Biosciences, 
University of Cardiff, United Kingdom 
 
 
 
 
 
 
Manuscript in preparation 
 62 
 63
ABSTRACT 
The role of the Ca2+-sensing receptor (CaSR) in the parathyroid glands has been thoroughly 
studied in recent years and its central function in Ca2+ homeostasis is now well established. 
Moreover, the CaSR is expressed in kidney, where it modulates divalent mineral excretion and 
urinary concentrating ability particularly in the proximal nephron segments. However, in distal 
convoluted tubules (DCT) and connecting tubules (CNT) of the kidney, the role of CaSR is not 
yet understood. Here, the Ca2+-selective Transient Receptor Potential Vanilloid subtype 5 
channel (TRPV5) is a key player in renal active Ca2+ reabsorption, forming the apical entry gate 
in the Ca2+-transporting cells. Using patch-clamp measurements, determinations of the relative 
intracellular Ca2+ concentrations and cell surface biotinylation, we demonstrated that CaSR 
activation leads to elevated TRPV5-mediated currents when co-expressed in Human Embryonic 
Kidney (HEK293) cells. CaSR stimulation by neomycin (200 µM) initiated a down-stream 
signaling cascade that activated phorbol 12-myristate 13-acetate (PMA)-insensitive protein 
kinase C (PKC) isoforms which in turn increased the TRPV5 channel activity. Detailed analysis 
of TRPV5 amino acid sequence revealed the existence of six putative PKC phosphorylation 
sites. Only inactivation of the putative PKC phosphorylation sites at positions S299 and S654 in 
TRPV5 prevented the effect of CaSR activation, proving that these two amino acid residues are 
essential for the observed effect. Preliminary results from cell surface biotinylation assays 
suggested that CaSR activation increases the plasma membrane localization of TRPV5 
channels. Interestingly, the activity of the TRPV5 closest homologue, TRPV6, was not affected 
upon CaSR activation. In conclusion, activation of the CaSR stimulated TRPV5-mediated Ca2+ 
transport via the PMA-insensitive PKC isoforms pathway possibly due to a subsequent increase 
in cell surface availability of the TRPV5 protein. 
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INTRODUCTION 
The cloning of an extracellular Ca2+-sensing receptor (CaSR) from parathyroid (1), kidney (2) 
and other cell types (3-5) has clarified the mechanisms through which Ca2+ exerts its direct 
actions on various cells and tissues. In the parathyroid glands, the CaSR mediates the inhibitory 
effect of elevated blood ionized Ca2+ concentrations on parathyroid hormone (PTH) secretion. 
As a G protein-coupled receptor (GPCR), CaSR determines intracellular signaling cascades, 
which result in low-frequency oscillations in cytosolic Ca2+ concentration. Oscillations in 
cytosolic Ca2+ concentration determine reductions in the secretion of PTH. In addition to its 
primary effect of reducing PTH secretion, CaSR activation could influence the expression of the 
PTH gene (6) and parathyroid cell proliferation (7). CaSR expressed in the parathyroid glands 
plays a central role in overall body Ca2+ homeostasis, directly controlling the blood release of 
PTH, body’s main calciotropic hormone. 
Beside its main expression site in the chief cells of the parathyroid glands, the CaSR is also 
expressed in the kidney. Here, the CaSR protein expression is prominently observed in proximal 
tubules, thick ascending limbs (TAL) of the Henle’s loop, and cortical collecting tubules (8). 
Notably, the membrane domain at which the CaSR is detected differs between different 
segments of the nephron. In proximal tubules, the CaSR is expressed in apical brush-border 
membranes. In contrast, in TAL the CaSR is found on the basolateral site (8,9). In cortical and 
inner medullar collecting ducts the CaSR is localized on the apical plasma membrane (8,10,11). 
Together with the expression pattern, the function of CaSR in the respective nephron segments 
was thoroughly investigated. In TAL, where it is expressed at the basolateral membrane, CaSR 
inhibits Ca2+ reabsorption that is driven by the lumen-positive, transepithelial potential gradient. 
This electrical gradient is generated by the apical Na+-K+-2Cl- co-transporter (NKCC2) combined 
with the recycling of K+ into the tubular lumen via the renal outer medulla K+ channel (ROMK1). 
CaSR activation reduces NKCC2 activity by lowering the cAMP levels (12) and inhibits ROMK1 
by stimulating the production of arachidonic acid (13,14). Although the role of the CaSR in TAL 
was clearly demonstrated, the functional importance of the apical localization of CaSR in distal 
convoluted tubules (DCT) and connecting tubules (CNT), where active Ca2+ reabsorption takes 
place (15), remains elusive. DCT and CNT (15) account for ~15% of total renal Ca2+ 
reabsorption and are generally considered the fine-tuning sites of urinary Ca2+ excretion. Here, 
the Transient Receptor Potential Vanilloid subtype 5 (TRPV5) channel is the gatekeeper for 
active Ca2+ reabsorption (16,17). TRPV5 proteins form tetrameric channel complexes (18), 
remarkable selective for Ca2+ (PCa/PNa ~100) (19). TRPV5-mediated currents exhibit an inward-
rectifying signature of their current-voltage (I-V) relations (19).  
Until now, the physiological relevance of the co-localization of TRPV5 with CaSR in DCT and 
CNT is unclear. The aim of the present study was, therefore, to investigate the functional link 
between the CaSR and TRPV5 in the kidney. To this end, the putative role of the CaSR in 
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regulating TRPV5 function was assessed using a combined approach including intracellular 
Ca2+ measurements, patch-clamp measurements and TRPV5 cell surface protein labeling. 
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EXPERIMENTAL PROCEDURES 
DNA constructs and cell culture 
The rabbit TRPV5pCINeo/IRES-GFP and mouse TRPV6pCINeo/IRES-GFP vectors were 
generated as described previously (20,21). Single and combined protein kinase C (PKC) 
TRPV5 mutants were generated by alanine substitution of the six putative phosphorylation sites 
(S144A, S299A, S316A, S654A, S664A, S698A) using in vitro mutagenesis (Quick-Change 
Site-Directed Mutagenesis kit, Stratagene, La Jolla, CA, USA). The amino-terminally GFP-
tagged human CaSR in the pcDNA3.1 vector was generated as described previously (22). 
Human embryonic kidney (HEK293) cells were grown in DMEM (BioWhittaker, Walkersville, 
MD, USA) containing 10% (v/v) fetal calf serum, 2 mM L-glutamine, and 10 μg/ml Ciproxin at 
37°C in a humidity-controlled incubator with 5% (v/v) CO2. Cells were transiently transfected at 
70% of confluence using polyethylenimine (Polysciences, Inc., Warrington, PA, USA) and 
Lipofectamin 2000 (Invitrogen Life Technologies, Breda, The Netherlands) according to 
manufacturer’s protocols (23). After 24-48 hours, cells were used for patch-clamp and/or 
biotinylation experiments. Prior to the assays, cells were incubated for 1 hour in serum-free 
DMEM containing neomycin, or L-phenylalanine (L-Phe) (Sigma, St Louis, MO, USA). To down-
regulate the phorbol 12-myristate 13-acetate (PMA)-sensitive PKC isoforms (24) cells were 
incubated overnight with PMA. 
 
Fura-2 measurements 
Intracellular Ca2+ concentration measurements were performed as described previously (25,26). 
Shortly, HEK293 cells co-transfected with CaSR and TRPV5 or empty vector were loaded for 20 
minutes with 3 µM Fura-2 AM (Invitrogen, Leiden, The Netherlands) in the presence of 100 nM 
pluronic (Invitrogen, Leiden, The Netherlands) and 500 µM probenecid (Sigma, St Louis, MO, 
USA) in DMEM and incubated at 37°C before starting the measurements. Since the phenol red 
in DMEM interferes with the Fura-2 measurements, the experiments were performed in 
HEPES/Tris buffer (in mM: 132.6 NaCl, 5.8 glucose, 10 HEPES, 4.2 KCl, and 1 MgCl2, 1.2 
CaCl2 pH = 7.4 with TRIS) supplemented with 500 µM probenecid. At the specified time-points, 
neomycin was added from a stock solution to reach a concentration of 200 µM in the recording 
chamber. The Fura-2 dye was excited alternatively 340 at 380 nm using a monochromator 
(Polychrome IV; TILL Photonics, Gräfelfing, Germany). Fluorescence emission light was 
directed by a 560DRLP dichroic mirror (Omega Optical, Brattleboro, VT, USA) through a 
565ALP emission filter (Omega) on a CoolSNAP HQ monochrome charge coupled device 
(CCD) camera (Roper Scientific, Vianen, The Netherlands). All hardware was controlled by 
Metafluor 6.0 software (Universal Imaging, Downingtown, PA, USA). 
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Electrophysiology and solutions 
Patch-clamp experiments were performed as described previously (19) in the tight seal whole-
cell configuration at room temperature using an EPC-9 patch-clamp amplifier computer 
controlled by the Pulse software (HEKA Elektronik, Lambrecht, Germany). Two voltage 
protocols were used: a ramp from -100 to +100 mV with a holding potential of +20 mV, to 
establish the current-voltage (I-V) relation in nominally DVF or in 10 mM Ca2+-containing 
extracellular solutions, and a hyperpolarizing step protocol to -100 mV to measure the Ca2+-
dependent inactivation. Na+ current densities were calculated from the current at -80 mV during 
the ramp protocols while the Ca2+ currents values were extracted from the peak current at –100 
mV during the step protocol. The analysis and display of patch-clamp data were performed 
using Igor Pro software (WaveMetrics, Lake Oswego, OR, USA). 
 
Cell surface labeling with biotin 
HEK293 cells seeded on poly-L-lysine (Sigma, St Louis, MO, USA) coated 10 cm dishes were 
co-transfected with an empty vector or with CaSR-eGFP pcDNA3.1 and TRPV5pCINeo/IRES-
GFP. At 48 hours after transfection, cells were incubated for 1 hour with 200 µM neomycin. The 
biotinylation assay was performed using NHS-LC-LC-biotin (Pierce, Etten-Leur, The 
Netherlands) and cells were homogenized in 1 ml lysis buffer as described previously (27). 
Finally, biotinylated proteins were precipitated using neutravidin-agarose beads (Pierce, Etten-
Leur, The Netherlands) and TRPV5 expression was analyzed by immunoblotting using the 
guinea-pig anti-TRPV5 antibody (16).  
 
Statistical analysis 
In all experiments, the data are expressed as mean ± SEM. Overall statistical significance was 
determined by analysis of variance (ANOVA). In case of significance, differences between the 
means of two groups were analyzed by unpaired Student’s t-test, while multiple comparisons 
between groups were performed by Bonferroni post hoc tests. P < 0.05 was considered as 
significant. 
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RESULTS 
CaSR activation stimulates TRPV5 activity 
The potential role of CaSR co-localization with TRPV5 at the apical membrane of the DCT and 
CNT cells (8,10) was first investigated by measurements of the intracellular Ca2+ concentration 
performed using the Ca2+-sensing dye Fura-2. Neomycin (200 µM) was used to activate the 
CaSR co-transfected in HEK293 cells with TRPV5 or with an empty vector. CaSR stimulation by 
neomycin increased significantly (P < 0.05) intracellular Ca2+ concentrations of the cells co-
transfected with CaSR and the empty vector (140 ± 4%) and of the cells co-transfected with 
CaSR and TRPV5 (138 ± 3%), as shown in Figure 1A. The non-transfected control cells did not 
show an increase in the intracellular Ca2+ concentration upon neomycin application (Figure 1A). 
To address the effect of CaSR stimulation on TRPV5-mediated currents, HEK293 cells co-
transfected with CaSR and TRPV5 were incubated for 1 hour with neomycin (200 µM) or L-
phenylalanine (L-Phe) (3.5 mM) to activate CaSR and functionally characterized by patch-clamp 
measurements in comparison to non-treated control cells. Interestingly, the amplitude of the 
inward-rectifying Na+ currents measured at -80 mV from the treated cells (Figure 1B,C) was 
significantly increased (P < 0.05) compared to non-treated control cells, as depicted in 
Figure 1C, while the current-voltage relation (I-V) of the currents remained unaffected. Pre-
incubation with both neomycin and L-Phe increased the inward Ca2+ currents elicited by the 
step protocol, without affecting the Ca2+-dependent inactivation of the TRPV5 currents 
(Figure 1D,E). 
 69
0.9
0.8
0.7
0.6
0.5
200150100500
700
600
500
400
300
200
100
0
300
200
100
0
-600
-500
-400
-300
-200
-100-100 -50 50 100
-250
-200
-150
-100
-50
0
4321
Time (sec)
Fu
ra
-2
 ra
tio
 (A
.U
)
Neo
A
B
V (mV)
I (
pA
/p
F)
I (
pA
/p
F)
C
TR
L
N
eo
   
Time (sec)
I (
pA
/p
F)
I (
pA
/p
F)
C
TR
L
N
eo
   
D
*
*
C
E
P
he
*
P
he
*
 
 
The specificity of the effect of CaSR activation on TRPV5-mediated currents was investigated 
using HEK293 cells transfected with TRPV5 alone. When the cells were incubated with 200 µM 
neomycin for 1 hour, the I-V relation (Figure 2A) and the amplitude at -80 mV (Figure 2B) of 
TRPV5-mediated Na+ currents remained identical to those of non-treated control cells. 
Moreover, Ca2+-dependent inactivation and the peak value of the TRPV5-mediated inward Ca2+ 
currents recorded from the neomycin-stimulated cells were similar to Ca2+ currents measured in 
control cells (Figure 2C,D). 
 
Figure 1. Functional correlation between CaSR and TRPV5 co-expressed in HEK293 cells. (A) Ratiometric 
Fura-2 measurements from cells co-transfected with CaSR and TRPV5 (filled circles) or CaSR and an empty 
vector (empty circles) or not-transfected cells (squares) stimulated with neomycin at the time point indicated by 
the arrow. (B) I-V relations measured using voltage ramps in divalent-free (DVF) extracellular solution from 
HEK293 cells co-transfected with CaSR and TRPV5, incubated (dotted trace) with neomycin, with L-Phe (dashed 
trace) or non-treated (solid trace). (C) Average Na+ currents density at -80mV in DVF solution were 
575 ± 80 pA/pF (n = 12 cells) and 580 ± 95 pA/pF (n = 8 cells) for cells treated with neomycin, respective with L-
Phe, compared to 405 ± 40 pA/pF for control (CTRL) non-treated cells (n = 10 cells) (D) Average Ca2+ currents 
measured with 10 mM Ca2+ in the extracellular solution using the step protocol from CaSR and TRPV5 co-
transfected HEK293 cells treated (dotted trace), treated with L-Phe (dashed trace) or non-treated (solid trace) with 
neomycin (E) Average density of the Ca2+ peak current measured as in (D), was 220 ± 25 pA/pF (n = 12 cells) for 
neomycin treated cells and 239 ± 40 pA/pF (n = 8 cells) compared to 118 ± 10 pA/pF (n = 10 cells) for CTRL cells. 
*P < 0.05 versus CTRL cells. 
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The role of CaSR activation in the subsequent increased TRPV5 activity, was studied using a 
dominant-negative mutant of the CaSR, CaSR-R185Q (28,29) co-transfected with TRPV5 in 
HEK293 cells. The I-V relation (Figure 2E,F) and the amplitude at -80 mV of TRPV5-mediated 
Na+ currents measured from the neomycin-incubated cells were not different compared to 
currents measured from non-treated control cells. The Ca2+-dependent inactivation (Figure 2G) 
as well as the peak value (Figure 2H) of the inward Ca2+ currents also remained unaffected 
after neomycin stimulation compared to non-treated control cells. 
Figure 2. CaSR activation is required to increase TRPV5-mediated currents. (A) I-V relations measured 
using voltage ramps in DVF extracellular solution from TRPV5-transfected HEK293 cells treated (dotted trace) or 
non-treated (solid trace) with neomycin. (B) Average Na+ currents density at -80 mV in DVF solution were 
1185 ± 125 pA/pF (n = 8 cells) for neomycin treated cells compared to 1200 ± 125 pA/pF for CTRL cells (n = 6 
cells). (C) Average Ca2+ currents measured with 10 mM Ca2+ in the extracellular solution using the step protocol 
from TRPV5-transfected HEK293 cells treated (dotted trace) or non-treated (solid trace) with neomycin (D) 
Average density of the Ca2+ peak current measured as in (C) was 305 ± 40 pA/pF (n = 8 cells) for neomycin 
treated cells compared to 280 ± 38 pA/pF (n=6 cells) for CTRL cells. (E) I-V relations measured using voltage 
ramps in DVF extracellular solution from HEK293 cells co-transfected with the dominant negative mutant of CaSR 
(R185Q) together with TRPV5 treated (dotted trace) or non-treated (solid trace) with neomycin. (F) Average Na+ 
currents densities at -80 mV in DVF solution were 1000 ± 130 pA/pF (n = 8 cells) for neomycin treated cells 
compared to 840 ± 215 pA/pF for CTRL cells (n = 5 cells). (G) Average Ca2+ currents measured with 10 mM Ca2+ 
in the extracellular solution using the step protocol from HEK293 cells co-transfected with CaSR-R185Q and 
TRPV5 treated (dotted trace) or non-treated (solid trace) with neomycin. (H) Average density of the Ca2+ peak 
current measured as in (G), was 290 ± 40 pA/pF (n = 8 cells) for neomycin treated cells compared to 330 ± 90 
pA/pF (n = 5 cells) for CTRL cells. 
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To determine the specificity of the effect of CaSR on TRPV5-mediated currents, TRPV6, the 
closest relative of TRPV5, was co-transfected with CaSR in HEK293 cells.  
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After stimulation of CaSR with neomycin, the TRPV6-mediated inward Na+ currents recorded 
with the ramp protocol showed no difference in I-V relation (Figure 3A) or amplitude at -80 mV 
(Figure 3B) compared to non-treated control cells. Ca2+-dependent inactivation of the TRPV6 
currents (Figure 3C) and the peak Ca2+ current recorded with the step protocol from neomycin-
treated were comparable to non-treated control cells (Figure 3D). 
 
The role of PKC in the effect of CaSR activation on TRPV5 currents 
To elucidate the molecular mechanism down stream of CaSR activation in enhanced TRPV5 
activity consequent to CaSR activation, a sextuple PKC phosphorylation deficient mutant with 
all the six computer-predicted PKC phosphorylation sites in TRPV5 changed to alanines (23), 
was co-transfected with the CaSR in HEK293 cells. Subsequent to neomycin incubation, the 
inward rectification of the I-V relation (Figure 4A) as well as the amplitude at -80 mV of the Na+ 
currents were similar to non-treated control cells (Figure 4B). The peak value and the Ca2+-
dependent inactivation of the inward Ca2+ currents were unaffected by neomycin incubation 
compared to non-treated control cells (Figure 4C,D). Subsequently, the putative PKC 
phosphorylation sites were individually mutated into an alanine residue. Neomycin increased 
Figure 3. TRPV6 activity is unaffected upon CaSR activation. (A) I-V relations measured using voltage ramps 
in DVF extracellular solution from HEK293 cells co-transfected with CaSR and TRPV6, treated (dotted trace) or 
non-treated (solid trace) with neomycin. (B) Average Na+ currents density at -80 mV in DVF solution were 
423 ± 115 pA/pF (n = 8 cells) for neomycin treated cells compared to 391 ± 42 pA/pF for CTRL cells (n = 13 
cells). (C) Average Ca2+ currents measured with 10 mM Ca2+ in the extracellular solution using the step protocol 
from HEK293 cells co-transfected with CaSR and TRPV6, treated (dotted trace) or non-treated (solid trace) with 
neomycin. (D) Average density of the Ca2+ peak current measured as in (C) was 102 ± 29 pA/pF (n = 8 cells) for 
neomycin treated cells compared to 80 ± 10 pA/pF (n = 6 cells) for CTRL cells.
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Ca2+ currents of all single PKC mutants except of S299A and S654A (P < 0.05, n = 12 cells for 
each condition, Figure 4E).  
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Furthermore, to determine which of the PKC isoforms was involved in the increased TRPV5-
mediated currents consequent to CaSR activation, HEK293 cells were incubated overnight with 
1 µM of phorbol ester (phorbol 12-myristate 13-acetate (PMA) to down-regulate the PMA-
sensitive PKC isoforms) (24). Then, the PMA-pretreated cells were incubated with 200 µM 
neomycin for 1 hour. CaSR activation increased (P < 0.05, n = 10-17 cells for each condition) 
the TRPV5-mediated Na+ (Figure 5B) and Ca2+ currents (Figure 5D) versus non-treated control 
Figure 4. The effect of CaSR activation on TRPV5-mediated currents involves the PKC signaling pathway. 
(A) I-V relations measured using voltage ramps in DVF extracellular solution from HEK293 cells co-transfected 
with CaSR and TRPV5 mutated for all its six PKC phosphorylation sites and treated (dotted trace) or non-treated 
(solid trace) with neomycin. (B) Average Na+ currents densities at -80 mV in DVF solution were 806 ± 90 pA/pF 
(n = 10 cells) for neomycin treated cells compared to 846 ± 90 pA/pF for CTRL cells (n = 5 cells). (C) Average 
Ca2+ currents measured with 10 mM Ca2+ in the extracellular solution using the step protocol from HEK293 cells 
co-transfected with CaSR and TRPV5, treated (dotted trace) or non-treated (solid trace) with neomycin. (D) 
Average density of the Ca2+ peak current measured as in (C), was 335 ± 35 pA/pF (n = 10 cells) for neomycin 
treated cells compared to 319 ± 40 pA/pF (n = 5 cells) for CTRL cells. (E) Point mutation of the PKC 
phosphorylation sites S299 and S654 did not affect Ca2+ currents in comparison with the other four PKC mutants 
upon CaSR stimulation with neomycin. Data are expressed as percentage of Ca2+ currents measured from 
neomycin treated cells transfected with the indicated point mutants of TRPV5, normalized to non-treated CTRL 
cells (n = 12 cells for each mutant). *P < 0.05 versus CTRL cells. 
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cells. The I-V relations (Figure 5A) and the Ca2+-dependent inactivation (Figure 5C) remained 
identical to control cells. Overnight incubation with PMA (1 µM) had no effect on control TRPV5-
mediated currents (as previously shown (23)). 
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CaSR activation increases cell surface expression of TRPV5  
To address the effect of CaSR activation on the amount of TRPV5 channels expressed at the 
plasma membrane, cell surface biotinylation assays were performed using HEK293 cells. Cells 
co-transfected with CaSR and TRPV5, and the cells transfected with the empty vector (mock) 
were incubated with 200 µM neomycin for 1 hour and then subjected to cell surface 
biotinylation. Biotinylated cell lysates were precipitated with neutravidin-agarose beads and 
immunoblotted for TRPV5. Mock cells and the cells not treated with biotin were used as 
negative controls. Importantly, TRPV5 was equally expressed in total cell lysates of all tested 
conditions (Figure 6, upper panel). Preliminary results indicated that stimulation of CaSR by 
neomycin enhances TRPV5 expression in the biotinylated fraction (Figure 6, lower panel). 
Figure 5. TRPV5 activity is stimulated by a PMA-sensitive PKC isoforms downstream of CaSR activation. 
24 hours incubation with 1 µM PMA was used to down-regulate the PMA-sensitive PKC isoforms in cells co-
transfected with CaSR and TRPV5. (A) I-V relations measured using voltage ramps in DVF extracellular solution 
from cells co-transfected with CaSR and TRPV6, treated (dotted trace) or non-treated (solid trace) with neomycin. 
(B) Stimulation of CaSR with neomycin significantly increased TRPV5-mediated Na+ currents (881 ± 56 pA/pF) 
compared to CTRL cells (1477 ± 180 pA/pF) (n = 10-17 cells for each condition) (C) Averaged Ca2+ currents 
measured with 10 mM Ca2+ in the extracellular solution using the step protocol from HEK293 cells co-transfected 
with CaSR and TRPV5, treated (dotted trace) or non-treated (solid trace) with neomycin. (D) Stimulation of CaSR 
with neomycin significantly increased TRPV5-mediated Ca2+ currents (186 ± 14 pA/pF) measured as in (C) 
compared to CTRL cells (294 ± 40 pA/pF) (n = 10-17 cells for each condition). *P < 0.05 versus CTRL cells. 
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Figure 6. CaSR activation likely increases the plasma membrane localization of TRPV5. HEK293 cells co-
transfected with CaSR and TRPV5 were treated with 200 µM neomycin for 1 hour, or left untreated. Cells were 
subjected to cell surface biotinylation and after lysis precipitated with neutravidin-agarose beads. TRPV5 
expression was analyzed by immunoblotting for the total cell lysates (upper panel) and for the plasma membrane 
fraction (lower panel). As negative controls, cells transfected with the empty vector (mock) were used and biotin 
was omitted in the procedure. 
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DISCUSSION 
The present study demonstrated that activation of CaSR stimulates TRPV5 activity. This 
conclusion is based on the following experimental data: First, both Ca2+ and Na+ TRPV5-
mediated currents were stimulated after CaSR activation by neomycin or L-Phe. Second, CaSR 
stimulation influences specifically TRPV5, since the currents of its closest relative, TRPV6, were 
unaffected after CaSR activation. Moreover, obstruction of the CaSR signaling pathway using a 
dominant negative mutant of CaSR normalized the amplitudes of TRPV5-mediated currents to 
their standard values. Third, the stimulatory effect of CaSR activation on TRPV5-mediated 
currents was mediated via the PKC pathway and requires two conserved PKC phosphorylation 
sites, S299 and S654, in TRPV5. Fourth, CaSR activation likely increases TRPV5 channel 
abundance at the plasma membrane. 
To date, the expression pattern of the CaSR in the kidney is under extended investigation. 
CaSR was shown to be expressed essentially throughout the whole nephron with highest levels 
in the proximal segments. In TAL, where it is expressed at the basolateral membrane, CaSR 
inhibits the passive Ca2+ reabsorption by reducing the negative potential that drives this process 
(9,30). In contrast to TAL, where the role of CaSR was thoroughly studied, the role of CaSR in 
DCT and CNT remained elusive. Here, Ca2+ reabsorption occurs against a concentration 
gradient via an active mechanism in which TRPV5 plays a crucial role. We demonstrated by in 
vitro functional analysis that stimulation of the CaSR enhances TRPV5 activity. This effect can 
account for a distinct role of CaSR in DCT and CNT, compared to the TAL, stimulating active 
Ca2+ reabsorption while it inhibits passive Ca2+ reabsorption. The site of CaSR expression in the 
nephron segments, apical or basolateral can be determined by its physiological functions in the 
respective segments. In the proximal segments CaSR senses Ca2+ concentrations in the blood 
controlling Ca2+ passive reabsorption, while in the DCT and CNT, CaSR is activated by 
increased Ca2+ levels in the pro-urine. Elevated levels of Ca2+ in the pro-urine may stimulate the 
apical CaSR in DCT and CNT and increase here the active Ca2+ reabsorption. This process 
suggests novel local feedback regulatory mechanisms in DCT and CNT activated by Ca2+ levels 
in the pro-urine, beside the hormonal regulation that responds to Ca2+ concentration in the 
blood. This mechanism could minimize the Ca2+ loss via the urine by stimulating active Ca2+ 
reabsorption. We have previously shown that activation of another GPCR, the bradykinin 
receptor subtype 2, by tissue kallikrein (TK) increases TRPV5-mediated Ca2+ reabsorption (23). 
TK acts from the tubular compartment to regulate active Ca2+ reabsorption, supporting our 
hypothesis on the existence of local regulatory mechanisms in DCT and CNT for efficient control 
of Ca2+ balance. 
CaSR is functionally linked to a multitude of G-proteins isoforms and signal transduction 
pathways from Gi to Gs and Gq expressed in the parathyroid chief cells (31). In overexpression 
systems it was demonstrated that CaSR functionally couples to Gi isoforms inhibiting the 
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adenylate cyclase to reduce cAMP production (32), and with Gq isoforms to stimulate the 
phospholipase C pathway (33). The present study, demonstrated that CaSR activation initiates 
signaling pathways that activate PKC isoforms, which in turn determine the increase in TRPV5 
activity. In addition, by using an overnight incubation with PMA to down-regulate α, β and ε 
isoforms of PKC, but not PKC ζ (24), we imply that a PMA-insensitive isoform of PKC is 
responsible for the enhanced TRPV5 currents upon CaSR activation. This latter PKC isoform is 
presumably involved in the increase of TRPV5 currents since this stimulatory effect was similar 
in PMA-incubated and control cells. Interestingly, in primary cultures of rabbit kidney connecting 
and cortical collecting tubules, stimulation of active Ca2+ transport also involves PMA-insensitive 
PKC isoforms (34). Moreover, our study delineated the conserved residues S299 and S654 as 
the PKC phosphorylation sites involved in this effect. Importantly, the activity of TRPV6, the 
closest homologue of TRPV5, was not affected subsequent to CaSR activation. Since the 
serine residue S654 is not conserved in TRPV6, it appears that both serines are apparently 
critical for the increase in TRPV5 activity upon CaSR activation. The absence of this serine 
residue in TRPV6 may explain its insensitivity to neomycin activation of CaSR. Interestingly, 
TRPV6 activity was also unaffected by TK (23) that activates another GPCR. Beside this, both 
CaSR activation and TK manifest their effect on the same PKC phosphorylation sites and both 
increase TRPV5 plasma membrane localization suggesting a common mechanism down-
stream of GPCR regulating TRPV5 functioning. 
Stimulation of TRPV5-mediated currents upon CaSR activation could be the result of an 
increase in either open probability of the channel or in expression of TRPV5 proteins at the 
plasma membrane. Preliminary data from surface biotinylation analysis suggested that 
activation of the CaSR might increase the amount of TRPV5 channels at the plasma membrane 
Thus, PKC phosphorylation of TRPV5, following the stimulation of CaSR could regulate the 
balance between constitutive exocytosis and endocytosis in favor of the first leading to the 
accumulation of TRPV5 at the cell surface. Interestingly, Colley and colleagues (35) 
demonstrated that a member of the Shaker family of K+ channels, the voltage-gated K+ channel 
Kv1.3, is regulated upon phosphorylation by the neurotrophin B receptor kinase. Pulse-chase 
experiments showed an increased half-life residence time of these channels at the cell surface. 
The plasma membrane abundance of Kv1.3 was enhanced after phosphorylation, as a 
consequence of their retention at the plasma membrane. The mechanism for the increase of 
TRPV5 activity upon CaSR stimulation involves the activation of a signaling pathway that 
initiates the PKC-dependent phosphorylation of two serine residues in its sequence. PKC 
phosphorylation of these amino acid residues, S299 and S654, following the CaSR activation 
could increase the accumulation of TRPV5 at the cell surface. Still, the exact molecular 
mechanism of this process is presently unknown. It is possible that PKC-dependent 
phosphorylation of TRPV5 leads to activation of motor proteins that transport the channels to 
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the plasma membrane. Interestingly, depolymerization of filamentous actin increased functional 
expression of Ca2+-activated K+ channels in neurons (36). Nevertheless, the motor proteins 
participating in the incorporation of TRPV5 in the plasma membrane remain to be identified. 
Moreover, presumably accumulation of channels at the cell surface can occur by increased 
incorporation into the plasma membrane of newly synthesized channels. Supporting this 
hypothesis, PKC activation delivers newly formed N-methyl-D-aspartate channels to the plasma 
membrane through increased exocytosis (37). On the other hand, the suggested increase in the 
number of channels present at the cell surface could be the consequence of diminished retrieval 
of the proteins from the plasma membrane. In accordance with this premise, we demonstrated 
that TK enhances the amount of TRPV5 channels at the plasma membrane by delaying their 
retrieval (23). Supporting this finding, a recent study by Cha and colleagues (38) showed that 
TRPV5 accumulation at the plasma membrane is determined by a decrease in the caveolin-
dependent endocytosis of the channels, consecutive to PKC activation. However, exactly which 
of these events determines the suggested increase of TRPV5 expression at the plasma 
membrane upon CaSR activation, explaining its enhanced channel activity, remains to be 
investigated. 
In conclusion, we postulate a role for the CaSR apical expressed in DCT and CNT of the kidney, 
the main expression sites of TRPV5. These results attest the existence of local feedback 
mechanisms that could rapidly adapt renal Ca2+ reabsorption to increased Ca2+ levels in the pro-
urine independently from hormonal regulation. 
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ABSTRACT 
In kidney, the epithelial Ca2+ channel TRPV5 constitutes the apical entry pathway in the process 
of active Ca2+ reabsorption. The regulation of Ca2+ influx through TRPV5 is of crucial 
importance, since it determines the final amount of Ca2+ excreted in the urine. The present 
study identifies FKBP52 as an auxiliary protein of TRPV5, inhibiting the channel activity. 
FKBP52 shows specific interaction with TRPV5 and both proteins co-localize in the distal part of 
the nephron. On the functional level, FKBP52 decreases Ca2+ influx through TRPV5 as 
demonstrated in radioactive 45Ca2+ uptake measurements and electrophysiological studies on 
TRPV5-overexpressing human embryonic kidney 293 cells. On the other hand, gene-silencing 
of FKBP52 or administration of the FKBP52 blocker, FK506, enhances Ca2+ influx through 
TRPV5. The inhibitory action of FKBP52 on TRPV5 activity is blunted by mutation of its peptidyl-
propyl cis-trans isomerase domain, showing that the FKBP52 catalytic property is critical for 
channel activity. In conclusion, these results suggest that FKBP52 plays an important role in the 
regulation of TRPV5 and thus in the process of Ca2+ reabsorption. 
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INTRODUCTION 
FKBP52 (also designed as FKBP59, p59 or Hsp56) is a widely expressed cytosolic enzyme that 
belongs to the FK506-binding proteins (FKBPs) subfamily of immunophillin proteins (1-3). 
FKBPs are characterized by their ability to catalyze the cis-trans isomerization of cis-peptidyl-
propyl bonds, as well as by their strong affinity to the immunosuppressive drug FK506 (2). The 
peptidyl-propyl cis-trans isomerase (PPIase) activity of FKBP52 plays an important role in 
diverse cellular processes and in particular in the translocation of steroid receptors to the 
nucleus through dynein association (4,5). Besides its function as a chaperone, FKBP52 is 
involved in ion regulation such as Cu2+ efflux (6), while its Drosophila melanogaster homologue 
inhibits Ca2+ influx through association with the transient receptor potential (TRP) channel, 
TRPL (7,8). Concerning the mammalian TRP channels, it was recently demonstrated that 
FKBP52 associates with TRPC1, -C4, -C5 orthologues (7,8), while there is no functional data 
addressing the effect of FKBP52 on these channels. 
In kidney, the TRP channel TRPV5 mediates Ca2+ reabsorption in the distal part of the nephron 
and determines the final amount of Ca2+ excreted in the urine (9,10). Therefore, a tight control of 
TRPV5 expression, trafficking to the plasma membrane and/or gating of the channel is 
important for the amount of reabsorbed Ca2+ in the kidney (11). There is growing interest in the 
identification of accessory proteins regulating TRPV5 activity. The S100A10-annexin 2 complex 
modulates TRPV5 trafficking towards the plasma membrane by direct association to the 
carboxyl-terminal tail of the channel (12). On the other hand, the 80K-H protein binds to the 
channel and acts as a Ca2+ sensor that facilitates Ca2+ influx through the TRPV5 channel (13). 
The aim of the present study was to assess whether FKBP52 is a regulator of TRPV5. To this 
end, we demonstrated by immunohistochemical, biochemical and functional analysis that 
FKBP52 inhibits TRPV5-mediated Ca2+ influx via its PPIase activity. 
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EXPERIMENTAL PROCEDURES 
DNA constructs and cRNA synthesis 
TRPV5 constructs were generated as described previously (12). FKBP52 was cloned in a 
pCMV-Sport6 vector (clone IRAKp961i125Q2) by the RZPD (Deutsches Ressourcenzentrum 
fuer Genomforschung, Berlin, Germany) and then subcloned into the pCINeo/IRES-GFP (14), 
pGEX6p-2 (Amersham Pharmacia Biotech AB, Uppsala, Sweden) and the pT7Ts (15) vectors. 
The FD67DV mutant of FKBP52 was generated by in vitro mutagenesis (QuickChange site-
directed Mutagenesis kit, Stratagene, La Jolla, California) with the primer set 5’- 
CTAGATGGCACAAAGGATGTCTCCAGTCTGGACCGC-3’, 5’-
GCGGTCCAGACTGGAGACATCCTTTGTGCCATCTAG-3’ (the underlined sequence shows 
the mutated codons). All constructs were verified by sequence analysis. pT7Ts constructs were 
linearized and cRNA was synthesized in vitro using T7 RNA polymerase as described 
previously (16). 
 
Experimental animals 
Young adult male Wistar rats were randomly assigned to either the control group animals 
receiving vehicle only (n = 5), or FK506 (n = 5) (17). TRPV5 knockout (TRPV5-/-) mice were 
generated as described previously (10). Kidney cortex was sampled and immediately frozen in 
liquid nitrogen. Subsequently, samples were stored at -80°C until further processing. The 
animals were kept in a light- and temperature-controlled room with ad libitum access to standard 
pelleted diet and water. The animal ethics board of the Radboud University Nijmegen approved 
all experimental procedures. 
 
Real-time quantitative PCR 
FKBP52 mRNA expression level was quantified by real-time quantitative PCR in a mouse cDNA 
panel including kidney, brain, heart, muscle, duodenum, jejunum, ileum, cecum, colon, bone 
and in renal tissue from control and FK506 treated rats. Total RNA was isolated using TRIzol 
(GIBCO, Life Technologies, Breda, The Netherlands) from which 2 μg were subjected to 
reverse transcription using Moloney murine leukemia virus reverse transcriptase. The following 
primers were used: the forward 5’-GAGTGGACATCAGCCCCAA-3’ and the reverse 5’-
TGTGCCTGTACCCTCTCTCTTG-3’. The probe (5’-CAGGACGAGGGCGTGCTCAAGGT-3’) 
was labeled with the reporter dye 6-carboxyfluorescein (5'-end) and the quencher dye 6-
carboxytetramethylrhodamine (3'-end) (Biolegio, Malden, The Netherlands). The mRNA 
expression level of hypoxanthine-guanine phosphoribosyl transferase (HPRT) was used as an 
internal control. 
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Immunohistochemistry 
Immunohistochemistry was performed as previously described (18). Briefly, rabbit kidney PLP-
treated sections were incubated for 16 hours at 4 ºC with guinea pig anti-TRPV5 (18) and 
mouse anti-FKBP52 antibodies (Stressgen, Victoria, Canada). To visualize the proteins 
corresponding secondary Alexa 488/594-conjugated antibodies (Molecular Probes, Eugene, 
USA) were used. 
 
Trypan-blue exclusion assay 
Cell suspension was mixed with an equal volume of 0.4% (w/v) isotonic trypan-blue solution. 
Total number of non-viable cells was counted after 2 minutes in a Fuchs-Rosenthal 
haemocytometer using a light microscope. 
 
Co-immunoprecipitation 
HEK293 cells were transfected with pCINeo/TRPV5-IRES-GFP and lysed after 48 hours in 
sucrose buffer containing 20 mM Hepes/Tris pH 7.4, 5 mM EDTA, 135 mM NaCl, 0.3% (v/v) 
NP-40, and 10% (w/v) sucrose. Lysates were centrifuged at 13,000 g for 1 hour and the protein 
concentration of the supernatants was determined with the BioRad protein assay (BioRad 
laboratories GmbH, München). Equal amounts of the lysates were incubated with guinea pig 
anti-TRPV5 antibody immobilized on protein A-agarose beads (Kem-En-Tec A/S, Kopenhagen, 
Denmark) for 16 hours at 4 °C. After three washing steps with sucrose buffer, 
immunoprecipitated proteins were eluted with SDS-PAGE loading buffer, separated on 12% 
(w/v) SDS-PAGE gels. TRPV5 and FKBP52 protein expression was detected by immunoblotting 
using guinea pig anti-TRPV5 (18) and mouse anti-FKBP52 (Stressgen, Victoria, Canada) 
respectively. 
 
Immunoblot analysis 
Cells were lysed in sucrose buffer containing 20 mM Hepes/Tris pH 7.4, 5 mM EDTA, 135 mM 
NaCl, 0.3% (v/v) NP-40, and 10% (w/v) sucrose and were centrifuged at 13,000 g for 1 hour. 
After the determination of the supernatants protein concentration, equal amounts of the lysates 
were subjected to SDS-PAGE electrophoresis (10-12% w/v). Immunoblots were incubated 
overnight at 4°C with primary antibodies including mouse anti-FKBP52 (Stressgen, Victoria, 
Canada), goat anti-FKBP52 (Santa Cruz Biotechnology, California, USA) and guinea pig anti-
TRPV5 in 1% (w/v) non-fat dry milk. After washing, immunoblots were incubated at room 
temperature with the corresponding secondary antibody IgG peroxidase sheep anti-mouse 
(Jackson ImmunoResearch Laboratories, West Grove, USA), rabbit anti-goat (DakoCytomation, 
Denmark) or anti-guinea pig (Sigma, St Louis, MO, USA) respectively. The specificity of the two 
commercial FKBP52 antibodies was confirmed by immunoblot analysis (data not shown). Both 
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antibodies recognized an abundant band of ~60 kDa, while the polyclonal antibody (Santa Cruz 
Biotechnology, California, USA) displayed an additional but weak band (lower than 25 kDa) that 
could be FKBP12 as suggested previously (7). Importantly, monoclonal antibody (Stressgen, 
Victoria, Canada), that only recognized the single band, was used in immunohistochemistry, 
immunoprecipitation and siRNA assays. 
 
GST-fusion proteins and pull-down assay 
pGEX6p-2 constructs were transformed in Escherichia coli BL21 and GST-fusion proteins were 
expressed and purified according to the manufacturer’s protocol (Amersham Pharmacia Biotech 
AB, Uppsala, Sweden). GST-fused TRPV5 N- and C-terminal tails constructs were generated 
as described previously (12). [35S]methionine-labeled TRPV5 or FKBP52, was prepared using 
the reticulocyte lysate system in the presence of canine microsomal membranes (Promega) and 
added to GST, GST-fused FKBP52 or GST-fused TRPV5 N- and C-terminal tails fusion proteins 
immobilized on glutathion-Sepharose 4B beads (Amersham Pharmacia Biotech AB, Uppsala, 
Sweden) in PBS containing 0.3% (v/v) Triton X-100. After 2 hours incubation at room 
temperature, the beads were washed extensively and bound proteins were eluted with SDS-
PAGE loading buffer, separated on 10% (w/v) SDS-PAGE gels and visualized by 
autoradiography. 
 
Small interference (si) RNA 
The mammalian expression vector, pSUPER (19) was used for expression of siRNA in Human 
Embryonic Kidney (HEK) 293 cells. The gene-specific insert specifies a 19-nucleotide sequence 
5’-GAGAGAGGGCACAGGTACA-3’ corresponding to nucleotides 114-133 downstream of the 
transcription start site of human FKBP52, which was separated by a 9-nucleotide non-
complementary spacer (5’-TTCAAAGA-3’) from the reverse complement of the 19-nucleotide 
sequence. HEK293 cells were co-transfected with pSUPER-FKBP52 and pCINeo/IRES GFP-
TRPV5 or empty pCINeo/IRES-GFP while the pSUPER-luciferase construct was used as a 
control. The gene-specific insert for luciferase specifies the 19-nucleotide sequence 5’-
CTTACGCTGAGTACTTCGA-3’. Three days after transfection cells were sorted for GFP 
expression by flow cytometry (FACS) using an Epics Elite flow cytometer (Coulter, Miami, FL, 
USA). The GFP-positive cells were used for the functional analysis. One day later measured for 
their functional activity using the 45Ca2+ uptake assay. FKBP52 protein expression was detected 
by immunoblotting using the mouse anti-FKBP52 (Stressgen, Victoria, Canada). 
 
45Ca2+ uptake assay 
HEK293 cells were transfected with pCINeo/TRPV5-IRES-GFP or co-transfected with 
pCINeo/TRPV5-IRES-GFP and wild-type or mutated FKBP52 constructs. Ca2+ uptake was 
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determined two days after transfection whereas co-transfected cells were first sorted for GFP by 
FACS. For the assays where FK506 was used, TRPV5-transfected cells were incubated 
overnight with 10, 100, and 1000 nM of FK506 (Fujisawa Pharmaceutical Co., Osaka, Japan). 
Ca2+ uptake was determined by incubation in uptake medium (110 mM NaCl, 5 mM KCl, 1.2 mM 
MgCl2, 0.1 mM CaCl2, 10 mM Na-acetate, 2 mM NaH2PO4, 20 mM HEPES/Tris, pH 7.4 
supplemented with 10 μM felodipine, 10 μM methoxy-verapamil and 1 mM BaCl2) for 10 
minutes at room temperature. Radioactive Ca2+ (1 μCi/ml 45CaCl2) was applied to the cells. Each 
well was washed extensively in stop buffer (110 mM NaCl, 5 mM KCl, 1.2 mM MgCl2, 0.5 mM 
CaCl2, 1.5 mM LaCl3, 10 mM Na-acetate, 20 mM HEPES/Tris, pH 7.4) at 4°C, incubated with 
0.05% (w/v) SDS, and counted for radioactivity using liquid scintillation. 
 
Electrophysiology and solutions 
Patch-clamp experiments were performed in the tight-seal whole-cell configuration at room 
temperature (20–25°C) using an EPC-9 patch-clamp amplifier controlled by the Pulse software 
(HEKA Electronics, Lambrecht, Germany). Patch pipettes had resistances between 3 and 5 MΩ 
after filling with the standard intracellular solution. Cells were held at +20 mV, and voltage 
ramps of 450 milliseconds duration ranging from -100 to +100 mV were applied every 5 
seconds. Cell capacitance and access resistance were monitored continuously using the 
automatic capacitance compensation of the Pulse software. Current densities were obtained by 
dividing the current amplitude measured at -80 mV by the cell capacitance. Ca2+-dependent 
inactivation was studied using a 3 seconds voltage step to –100 mV from a holding potential of 
+70 mV. The inactivation rate was assessed by the time for 10% decay of the current. The 
standard extracellular solution (Krebs) contained 150 mM NaCl, 6 mM CsCl, 1 mM MgCl2, 10 
mM HEPES/NaOH, pH 7.4 and 10 mM glucose. The concentration of Ca2+ ranged between 1 
and 10 mM. Divalent free (DVF) solutions did not contain added divalent cations, whereas trace 
amounts of divalent cations were removed with 100 μM EDTA. The standard internal (pipette) 
solution contained 20 mM CsCl, 100 mM Cs-aspartate, 1 mM MgCl2, 4 mM Na2ATP, 10 mM 
BAPTA, 10 mM HEPES/CsOH, pH 7.2. Cells were kept in a nominal Ca2+-free medium to 
prevent Ca2+ overload and exposed for a maximum of 5 minutes to a Krebs solution containing 
1.5 mM Ca2+ before sealing the patch pipette to the cell. 
 
Transcellular Ca2+ transport in primary culture of rabbit kidney connecting tubule and cortical 
collecting duct 
Rabbit kidney connecting tubules (CNT) and cortical collecting ducts (CCD) were 
immunodissected from kidney cortex of New Zeeland White rabbits (~0.5 kg) using antibody 
R2G9 and then placed in primary culture on permeable filters (0.33 cm2; Costar, Cambridge, 
MA, USA) as described previously in detail (20). At confluence, monolayers of rabbit CNT/CCD 
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cells growing on permeable filters were incubated overnight with 10, 100 and 1000 nM of FK506 
at the apical and the basolateral side. The next day filters were washed twice and preincubated 
in PSS buffer containing 140 mM NaCl, 2 mM KCl, 1 mM K2HPO4, 1 mM MgCl2, 1 mM CaCl2, 5 
mM glucose, 5 mM L-alanine, 5 μM indomethacin, 10 mM Hepes/Tris, pH 7.4, for 15 minutes at 
37°C. Subsequently, the filters were incubated in PSS (100 μl to apical and 600 μl to basolateral 
compartment). After 90 minutes transepithelial Ca2+ transport was measured by using a 
colorimetric assay kit as described (20). Transepithelial potential difference and resistance were 
checked before and after transport measurement to confirm cell confluence and integrity of the 
monolayer. 
 
Statistical analysis 
Values are expressed as mean ± SEM. Overall statistical significance was determined by 
analysis of variance (ANOVA). In case of significance, differences between the means of two 
groups were analyzed by unpaired t-test, while multiple comparisons between groups were 
performed by Bonferroni posthoc tests. P values < 0.05 were considered significant. The 
statistical analyses were performed using the SPSS software (SPSS Inc, Chicago, Illinois, 
USA). 
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RESULTS 
FKBP52 tissue distribution and localization 
FKBP52 expression was investigated at the mRNA level by quantitative real time PCR analysis, 
showing a higher abundance in kidney and heart in comparison to other tissues (Figure 1A).  
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Subsequently, the localization of FKBP52 was analyzed in kidney. Immunohistochemical 
staining of rabbit kidney sections showed partial co-localization of FKBP52 with TRPV5 in DCT 
and CNT, nephron segments known to be responsible for active transepithelial Ca2+ transport 
(Figure 1B). 
 
Interaction of FKBP52 with TRPV5  
In order to assess the FKBP52 interaction with TRPV5, HEK293 cells were transfected with 
TRPV5 or the empty vector and cell lysates were subsequently subjected to 
immunoprecipitation using the TRPV5 antibody. The endogenous FKBP52 was co-
immunoprecipitated with TRPV5 from these cells lysates, as represented by the immunopositive 
band of ~59 kDa (Figure 2A). The expression of both proteins in the cell lysates was also 
verified as shown in the two upper panels. 
Figure 1. Expression profile and localization of FKBP52. (A) RNA was extracted from mouse tissues and after 
reverse transcription, the relative FKBP52 expression was determined by real time PCR analysis. FKBP52 mRNA 
expression was normalized for the respective HPRT values. (B) Immunohistochemical localization of FKBP52 
(green) and TRPV5 (red) in rabbit kidney sections. In the merged picture the partial co-localization of the two 
proteins is depicted in yellow. 
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The interaction between FKBP52 and TRPV5 was further substantiated using GST pull-down 
assays. FKBP52 was expressed as a GST-fusion protein and analyzed for its interaction with 
the in vitro translated full-length 35S-methionine-TRPV5 in the presence (1 mM CaCl2) or 
absence of Ca2+ (10 mM EGTA) and with different concentrations of FK506. FKBP52 bound to 
TRPV5 in a Ca2+ (Figure 2B) and FK506 (Figure 2C) independent manner. No interaction was 
observed with GST alone indicating the specificity of the interaction. To determine the role of 
TRPV5 tails in the binding with FKBP52, the GST-fused N- and C-terminal tails of TRPV5 were 
analyzed for their interaction with the in vitro translated FKBP52. Both tails did not interact with 
FKBP52 (Figure 2D). 
 
Effect of FKBP52 knock-down on Ca2+ influx 
The role of FKBP52 in Ca2+ influx through TRPV5 was investigated using the pSUPER siRNA 
system. HEK293 cells were co-transfected with the pSUPER-FKBP52 (siFKBP52) and TRPV5. 
The pSUPER-luciferase (siLuc) construct was used as a negative control for the suppression of 
FKBP52, and the empty vector (mock) as a control for TRPV5 transfection.  
Figure 2. FKBP52 binds the TRPV5 channel. (A) Interaction of FKBP52 with TRPV5 as demonstrated by co-
immunoprecipitation in HEK293 cells transfected with TRPV5 or mock. Equal amount of cell lysates were 
subjected to immunoprecipitation using the TRPV5 antibody and co-immunoprecipitation of the endogenous 
FKBP52 was detected by immunoblot analysis using the FKBP52 antibody (IP). Total lysates were analyzed for 
TRPV5 and FKBP52 protein expression (lysates). (B) Direct interaction of FKBP52 and TRPV5 was confirmed by 
GST-pull down assay. In vitro translated [35S]methionine-TRPV5 associated with the GST-fused FKBP52 in the 
presence (1 mM CaCl2) and the absence (10 mM EGTA/ no CaCl2 added) of Ca2+. (C) Binding of GST-fused 
FKBP52 was not altered by the addition of FK506. (D) GST-fused TRPV5 N- and C-terminal tails were incubated 
with in vitro translated [35S]methionine-FKBP52 demonstrating no binding of FKBP52. 
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Application of FKBP52 siRNA significantly reduced FKBP52 protein expression, whereas no 
effect was observed in the siLuc-transfected cells demonstrating the specificity of the FKBP52 
gene-silencing (Figure 3A). 45Ca2+ uptake assay was performed to determine the effect of 
FKBP52 suppression on TRPV5 activity. Expression of siFKBP52 (closed bars) enhanced 
45Ca2+ influx through TRPV5, whereas no effect was observed for the siRNA control, siLuc 
(open bars), or the mock-transfected cells (Figure 3B). 
 
Modulation of TRPV5 currents by FKBP52 
To study whether FKBP52 affects TRPV5 channel kinetics, HEK293 cells were co-transfected 
with TRPV5 and FKBP52 and analyzed by the whole-cell patch-clamp technique. Both the Ca2+ 
and Na+ currents were significantly inhibited by FKBP52 over-expression (Figure 4). 
Measurements in nominally DVF solution (100 μM EDTA) revealed that the current-voltage 
Figure 3. Enhancement of TRPV5 activity by siRNA-mediated gene-silencing of FKBP52. HEK293 cells 
were co-transfected with the pSUPER-FKBP52 (siFKBP52) construct together with TRPV5 or the empty vector 
(mock). The pSUPER-Luciferase (siLuc) construct was used as a control for the specificity of FKBP52 gene-
silencing. (A) Immunoblot analysis for FKBP52 on lysates from co-transfected HEK293 cells demonstrated 
suppression of the FKBP52 protein. TRPV5 expression was not altered by the FKBP52 protein suppression. (B) 
45Ca2+ uptake was measured in HEK293 cells as shown in Figure 3A. Cells co-transfected with the siFKBP52 and 
TRPV5 showed an increased 45Ca2+ influx compared to siLuc/TRPV5-transfected cells. The closed bars represent 
cells transfected with siFKBP52, while the open bars are used for the siRNA control, siLuc. Values are expressed 
as means ± SEM. (n = 4). *P < 0.01 significantly different from the respectively mock-transfected cells. #P < 0.02 
significantly different from siLuc TRPV5-transfected cells.
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relation of currents remained unchanged (Figure 4A), whereas a significant reduction in 
macroscopic currents was observed (Figure 4B). Application of a hyperpolarizing voltage step 
to -100 mV from a holding potential of +70 mV showed a decreased Ca2+ peak current, whereas 
no significant differences were observed on the Ca2+-dependent inactivation (a hallmark of the 
channel) (Figure 4C,D).  
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Inactivation of TRPV5 Ca2+ currents at negative membrane potentials was assessed by 
comparing the time of 10% inactivation in cells co-expressing TRPV5 and FKBP52. Time of 
10% inactivation was not significantly different for Ca2+ currents in cells co-expressing FKBP52 
and TRPV5 compared to cells expressing TRPV5 only (32 ± 12 milliseconds, n = 20 versus 
38 ± 5 milliseconds, n = 15, respectively, P > 0.05). 
 
 
Figure 4. Inhibition of TRPV5 activity by FKBP52 over-expression. HEK293 cells were co-transfected with 
TRPV5 and FKBP52, or/and empty vector, and were analyzed by patch-clamp. (A) Current-voltage relations 
measured from 450 milliseconds voltage ramps in nominally DVF solution in HEK293 cells over-expressing either 
TRPV5 and empty vector or TRPV5 in combination with FKBP52. (B) Average current densities at -80 mV in 
nominally DVF solution for cells co-expressing either TRPV5 and empty vector or TRPV5 in combination with 
FKBP52. Cells co-transfected with TRPV5 and FKBP52 displayed significantly decreased Na+ currents at -80 mV 
(1997 ± 260 pA/pF versus 2882 ± 325 pA/pF (n = 20)). (P < 0.001 versus TRPV5 control currents). (C) Inward 
Ca2+ currents measured with 10 mM extracellular Ca2+ during a 3 seconds step to -100 mV from a holding 
potential of +70 mV. (D) Average peak current density during a voltage step to -100 mV in 10 mM Ca2+. Cells co-
transfected with TRPV5 and FKBP52 displayed significantly decreased Ca2+ peak current 160 ± 22 versus 
250 ± 25 pA/pF (n = 20). *P < 0.005, versus TRPV5 control currents. 
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Role of the FKBP52 PPIase activity in TRPV5-mediated Ca2+ influx 
The enzymatic activity of FKBP52 was abolished by double mutation of two highly conserved 
amino acidic residues (FD67DV mutant) as described previously (21). The FD67DV mutant and 
wild-type FKBP52 were co-transfected in HEK293 cells with TRPV5 and functionally analyzed 
using the 45Ca2+ uptake assay. The FD67DV mutant reverted the inhibitory effect of FKBP52 on 
TRPV5-mediated Ca2+ influx (Figure 5A). Immunoblot analysis of the cell lysates demonstrated 
that both FKBP52 wild-type and the mutant FD67DV are equally expressed and do not interfere 
with the TRPV5 expression (Figure 5B). 
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Effect of FK506 on TRPV5 activity  
The immunosuppressant FK506, known to bind and inhibit FKBP52 enzymatic activity, was 
assessed for its effect on TRPV5-mediated Ca2+ influx. First, the dose-dependent relationship of 
FK506 was determined in HEK293 cells demonstrating that overnight incubation with high 
Figure 5. FKBP52 inhibitory effect on 45Ca2+ influx through TRPV5 depends on the PPIase activity of 
FKBP52. (A) HEK293 cells were co-transfected with TRPV5 and the empty vector (TRPV5), or the FKBP52 
construct (FKBP52/TRPV5) or the catalytic inactive FKBP52 mutant (FD67DV/TRPV5). The inhibitory effect of 
FKBP52 on TRPV5-mediated 45Ca2+ influx was abolished by FD67DV. Data are expressed as means ± SEM. 
(n = 5). *P < 0.01 significantly different from mock-transfected cells. #P < 0.02 significantly different from TRPV5-
transfected cells. (B) Immunoblot analysis for FKBP52 was performed on the lysates of HEK293 cells co-
transfected with TRPV5 and the empty vector (TRPV5), or the FKBP52 construct (FKBP52/TRPV5) or the 
catalytic inactive FKBP52 mutant (FD67DV/TRPV5) that were applied in the functional assay in (A). The results 
demonstrated equal expression of wild-type and mutated FKBP52 and immunostaining for TRPV5 showed equal 
expression of the channel. 
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concentrations (in the range of 10 nM to 100 μM) diminishes the cell viability (Figure 6A). Then, 
HEK293 cells transiently transfected with TRPV5 were incubated overnight with 10 nM of FK506 
and tested for their 45Ca2+ uptake. Incubation with FK506 resulted in significantly increased 
45Ca2+ influx in TRPV5-transfected cells (Figure 6B). To further substantiate this effect, FK506 
action was evaluated in kidney primary cultures. The primary cultures of rabbit CNT/CCD cells 
form confluent monolayers that exhibit many characteristics of the original polarized epithelia, 
including a PTH- and vitamin D-stimulated transepithelial Ca2+ transport (20). Overnight 
incubation of 10 nM FK506 significantly stimulated transcellular Ca2+ transport in these primary 
kidney cells (Figure 6C).  
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Measurements of the transepithelial resistance across the cell monolayer showed that higher 
concentrations (1 μM and 100 μM) of FK506 disturbed the integrity of the confluent cell 
monolayer. 
 
 
Figure 6. FK506 stimulatory effect on Ca2+ influx of TRPV5-expressing HEK293 and primary CNT/CCD 
cells. (A) HEK293 cells were incubated overnight with FK506 at a concentration between 0 to 100 μM. The effect 
of FK506 on cell viability was counted by the trypan-blue exclusion assay. (B) TRPV5-transfected HEK293 cells 
were incubated overnight with 0 or 10 nM FK506. 45Ca2+ uptake measurements showed a stimulatory effect of 
FK506 on 45Ca2+ influx. (C) TRPV5-expressing monolayers of rabbit CNT/CCD primary cell cultures were 
incubated overnight with FK506 at a concentration of 0 to 100 μM. 10 nM of FK506 showed increased Ca2+ 
transport upon FK506 treatment whereas higher concentrations disturbed the cell monolayer resulting in reduced 
Ca2+ transport. Data are expressed as means ± SEM. (n = 4). *P < 0.01 versus control cells. 
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Regulation of FKBP52 in kidney 
To estimate the putative effect of FK506 on FKBP52 transcription, renal mRNA expression was 
determined by quantitative real time PCR in rats treated with FK506 (1 mg/day) or vehicle for 
seven days. The results demonstrated that FK506 has no significant effect on FKBP52 mRNA 
expression compared to control (0.32 ± 0.03 versus 0.28 ± 0.02 copies FKBP52/HPRT). In 
addition, the FKBP52 protein expression was measured in renal total lysates from TRPV5-/- 
mice. Immunoblot analysis for FKBP52 showed a 63 ± 11% decrease in TRPV5-/- mice 
compared to their wild-type littermates (Figure 7). 
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Figure 7. Regulation of FKBP52 expression. (A) Immunoblotting of FKBP52 in total kidney homogenates of 
TRPV5-/- and wild-type littermates. 10 μg of total protein was loaded per lane and each lane represents the renal 
homogenate from an individual mouse. (B) The intensity of the immunopositive bands were quantified by 
densitometry. FKBP52 expression is depicted as a percent ratio to wild-type mice. Data are expressed as means 
± SEM. *P < 0.05 versus wild-type mice. 
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DISCUSSION 
The present study demonstrated that FKBP52 binds and co-localizes with the epithelial Ca2+ 
channel TRPV5 in the distal part of the nephron. FKBP52 reduced TRPV5 activity as indicated 
by the functional analysis using FKBP52 siRNA and co-expression studies in HEK293 cells. 
This inhibitory action was reverted by abrogation of the PPIase activity in FKBP52, as well as by 
administration of the FKBP52 blocker, FK506. Our findings suggest that the immunophilin 
FKBP52 is a TRPV5 auxiliary protein regulating channel activity. 
FKBP52 transcription was strongly stimulated by two majors regulators of the Ca2+ homeostasis: 
vitamin D3 and dietary Ca2+ (22), in line with the regulation observed for TRPV5 (23). We 
showed here that renal FKBP52 expression is diminished in TRPV5-/- mice further supporting a 
functional coupling between both proteins. 
Indeed, knockdown of the FKBP52 protein expression by siRNA gene silencing, as well as 
inhibition of FKBP52 enzymatic activity by binding to FK506, increased Ca2+ influx through 
TRPV5. In addition, expression of the FKBP52 protein reduced TRPV5-mediated Ca2+ and Na+ 
currents, suggesting that FKBP52 decreases the number of functional channels at the plasma 
membrane. In this regulatory process, it seems that the enzymatic activity of FKBP52 plays a 
critical role, since inactivation of FKBP52 PPIase activity abolished its effect on TRPV5 activity. 
FKBP52 ability to modify its substrates by catalyzing the cis-trans isomerization of proline 
residues is often a rate-limiting step in protein folding (24). Moreover, it is possible that FKBP52 
operates through multiple targets to regulate the function of the channel, considering that it 
contains putative ATP, GTP and calmodulin binding sites (25,26). 
Consistent with our findings on the FKBP52 inhibitory role in TRPV5 Ca2+ influx, is a previous 
study that identified the FKBP52 Drosophila melanogaster homologue, FKBP59, as a 
physiological regulator of TRPL channel activity (7). FKBP59 interacts directly with the highly 
conserved TRPL sequence 701LPPPFNVLP709 and inhibits Ca2+ influx. In Drosophila 
melanogaster (7) as well as in mammals (8) the proline residue of the first LP-motif, located next 
to mouth of the channel pore, plays a crucial role in this association. Conspicuously, TRPV5 
contains such an LP motif next to the pore region at the amino acidic position 551-552, where 
the FKBP52 binding site is located. The FK506 drug has been shown to mimic the LP-dipeptide 
(27) and to disrupt the FKBP52 interaction with TRPCs (8). However, FK506 did not interrupt 
the FKBP52-TRPV5 association suggesting an alternative mechanism. This would mean that 
FK506 binds TRPV5 and modulates its activity without displacing the association of FKBP52, 
similar to the mechanism previously described for the regulation of the Drosophila melanogaster 
homologues FKBP59 and TRPL (7). The physiological relevance of the latter hypothesis needs 
further confirmation since it is based on in vitro experiments.  
FKBP52 is expressed along the apical region of DCT and CNT tubules together with TRPV5. In 
addition, FKBP52 is also localized in the cytosol. This finding together with the stimulatory effect 
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of FK506 drug on Ca2+ influx observed in primary CNT/CCD renal cells further substantiated the 
physiological relevance of FKBP52 in active transepithelial Ca2+ transport. Our results imply that 
while high concentrations of FK506 are toxic for the cells, submicromolar concentrations (10 
nM) stimulate transcellular Ca2+ transport. This dose-dependent effect could explain the 
nephrotoxicity observed in patients treated with the immunosuppressive drug FK506 (28,29). 
On the other hand, it has been previously demonstrated that the hypercalciuric effect of FK506 
is mediated through the decreased expression of calbindin-D28K (30) and TRPV5 (17). Contrary 
to the reduction in TRPV5 expression upon FK506 administration, we showed that FKBP52 
expression is not altered under the same conditions. To this regard, the reduction of the 
TRPV5/FKBP52 ratio is reminiscent of transient expression in HEK293 cells where an excess of 
FKBP52 inhibits TRPV5-mediated Ca2+ influx. Certainly, given the complexity of the in vivo 
situation, the FK506-induced hypercalciuria awaits further investigation particularly concerning 
the putative role of other FKBP proteins.  
In conclusion, FKBP52 participates in active transepithelial Ca2+ transport along the distal part of 
the nephron by reducing TRPV5 activity. This inhibitory effect on TRPV5 is mediated by the 
enzymatic PPIase activity of FKBP52 and is reverted by FK506 administration. 
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ABSTRACT 
The epithelial Ca2+ channels TRPV5 and TRPV6 constitute the apical Ca2+ entry pathway in the 
process of active Ca2+ (re)absorption. By yeast-two-hybrid and GST pull-down analysis we 
identified RGS2 as a novel TRPV6-associated protein. RGS proteins determine the inactivation 
kinetics of heterotrimeric G protein-coupled receptor (GPCR) signaling by regulating the GTP-
ase activity of Gα subunits. Here we demonstrate that TRPV6 interacts with the N-terminal 
domain of RGS2 in a Ca2+-independent fashion and that over-expression of RGS2 reduces the 
Na+ and Ca2+ current of TRPV6 but not those of TRPV5-transfected HEK293 cells. In contrast, 
over-expression of the deletion mutant ΔN-RGS2, lacking the N-terminal domain of RGS2, in 
TRPV6-expressing HEK293 cells did not show this inhibition. Furthermore, cell surface 
biotinylation indicated that the inhibitory effect of RGS2 on TRPV6 activity is not mediated by 
differences in trafficking or retrieval of TRPV6 from the plasma membrane. This effect probably 
results from the direct interaction between RGS2 and TRPV6, affecting the gating properties of 
the channel. Finally, the scaffolding protein spinophilin (SPL), shown to recruit RGS2 and 
regulate GPCR-signaling via Gα, did not affect RGS2 binding and electrophysiological properties 
of TRPV6, indicating a GPCR-independent mechanism of TRPV6 regulation by RGS2.  
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INTRODUCTION 
The Transient Receptor Potential (TRP) superfamily includes more than 30 different proteins, all 
of which are considered to form subunits of cation channels (1-5). Based on sequence 
homology, the TRP family can be divided in seven main subfamilies: the TRPC (‘Canonical’) 
family, the TRPV (‘Vanilloid’) family, the TRPM (‘Melastatin’) family, the TRPP (‘Polycystin’) 
family, the TRPML (‘Mucolipin’) family, the TRPA (‘Ankyrin’) family, and the TRPN (‘NOMPC’) 
family. TRPV6 is the most Ca2+ selective ion channel in the TRP superfamily with a Ca2+ 
selectivity of more than 100 times over monovalent cations (6,7).  
Recently, the electrophysiological properties of TRPV6 have been studied extensively. When 
measured in heterologous expression systems, TRPV6 displays characteristic inward rectifying 
currents carried by Ca2+ or monovalent cations when Ca2+ is omitted from the extracellular 
solution. These inward currents are blocked by Mg2+ in a voltage-dependent manner (8), that is 
removed upon neutralization of a single negatively charged amino acid residue - D541 - within 
the pore region. The pore diameter of TRPV6 was recently estimated at 5.4 Å by cystein 
scanning experiments (9). Together with its closest relative, TRPV5, TRPV6 shares a common 
feature that is the Ca2+-dependent inactivation of the currents. 
TRPV6 is predominantly expressed in placenta, pancreas, small intestine, and colon (6,10-12). 
In these tissues TRPV6 plays a major role in Ca2+ transport (reviewed in (13,14). 
To date, screening and domain-mapping of the carboxyl-terminus of TRPV6 has revealed 
proteins associating with TRPV6 and subsequently the regulatory functions of these interacting 
proteins have been studied; e.g. Rab11a, NHERF4, S100A10 (15-17). In contrast, little is known 
about the molecular mechanisms involved in regulation of the channel via its intracellular N-
terminal domain. At present, six ankyrin repeats have been predicted in this region (18). Ankyrin 
repeats have been shown to act as a scaffold in molecular recognition to mediate protein-
protein interactions (19). These, or other regions in the N-terminal domain of TRPV6, may bind 
regulatory proteins interacting in pathways that mediate the Ca2+-transporting activity of the 
channel.  
The aim of this study was to identify regulatory proteins that interact with the N-terminal domain 
of TRPV6. To this end, we identified RGS2 as a novel binding partner of TRPV6 by yeast-two-
hybrid screening. RGS2 is a member of the RGS family of proteins that are able to terminate 
signaling of heterotrimeric G protein-coupled receptors (GPCRs) by enhancing the GTP-ase 
activity of active Gα subunits (20). To date, over 20 different RGS proteins have been identified, 
and their effector functions extend beyond negative regulation of GPCR signaling. RGS proteins 
can act as effector antagonists, binding to either the effector protein or the Gα subunit to prevent 
an operative physical interaction. They have also been shown to interact with a wide variety of 
auxiliary proteins, such as CaM, spinophilin (SPL) and 14-3-3 protein, which can influence their 
subcellular localization, stability and function (21). In this respect, the finding of RGS2 as a 
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protein interacting with TRPV6 may lead to altered channel activity by disturbances in protein 
trafficking or a direct effect at the cell surface. The putative role of RGS2 in active Ca2+ 
absorption was established by a comprehensive approach including pull-down assays, 
electrophysiological analysis and cell-surface expression of RGS2 interacting with TRPV6.  
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EXPERIMENTAL PROCEDURES 
Constructs and cRNA synthesis 
The TRPV6, TRPV6 N-tail, and TRPV5 constructs were generated in pGEX 6p-2 and 
pCINeo/IRES-GFP vectors as described previously (22). The coding sequence of wild-type 
RGS2 protein was amplified from total mouse kidney cDNA material using primers with a HA tag 
included  and cloned into the PT7Ts vector as BglII – SpeI fragment, and subsequently into the 
pCINeo/IRES-GFP vector as an NheI – XhoI fragment. RGS2 and ΔN-RGS2 (deletion of the N-
terminal domain of RGS2: amino acids 1-82) were subcloned from the PT7Ts vector without the 
HA-tag to the pGEX 6p-2 (Amersham Biosciences, Piscataway, NJ, USA) vector using forward 
and reverse primers containing BamH I and XhoI restriction sites respectively. pT7Ts constructs 
were linearized, and cRNA was synthesized in vitro as described previously (16). In 
pCINeo/IRES-GFP, ΔN-RGS2 was obtained by in vitro mutagenesis of wild-type RGS2. All 
constructs were verified by sequence analysis. Rat-SPL (in pCMV-myc) and human-RGS2 (in 
pGex-KG) constructs were described previously (23). 
 
Yeast-two-hybrid system 
Yeast-two-hybrid experiments were performed as described previously (16). In short, the N-tail 
of mouse TRPV6 was cloned in the pAS-1 yeast cloning and expression vector. Using this 
vector, the yeast strain Y153 was transformed to Trp prototrophy. Subsequently, yeast was 
transformed with a mouse kidney cDNA library (Clontech, Palo Alto, CA, USA) present in the 
pACT2 vector, containing a leucine selection marker. Yeast cells were plated on Trp-Leu-His 
selective medium containing 25 mM 3-aminotriazole. Positive colonies were assayed for β-
galactosidase activity. Subsequently, yeast DNA of positive colonies was isolated and prey 
plasmids were rescued by electroporation into KC8-cells. Results were confirmed using purified 
library plasmids and a negative control was performed by replacing the pAS-1 containing the N-
tail of mouse TRPV6 with the pAS-1 containing the N-tail of rat γ-subunit of the epithelial Na+ 
channel (ENaC). 
 
Reverse Transcriptase (RT)-PCR analysis 
Total RNA was isolated from different mouse tissues using TRIzol and subjected to reverse 
transcription as described (24). For RGS2 RT-PCR, the oligonucleotide primer sequences were 
as follows: forward primer with BglII restriction site 5’-
GAAGATCTGCCACCATGCAAAGTGCCAGTTCCTG-3’ and reverse with SpeI restriction site 
5’-GGACTAGTTCATGTAGCATGGGGCTCCG-3’; β-actin forward 5'-
ACGATTTCCCTCTCAGCTGTG-3', reverse 5'-GTATGCCTCTGGTCGTACCAC-3'. For SPL the 
following primers were used: forward primer 5’-CTTAGGAACACCAAAGGCC-3’, and reverse 
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primer 5’-GTAGTCCTTGATGAGACGC-3’. PCR fragments were analyzed by electrophoresis on 
1% (w/v) agarose. 
 
Pull-down assays 
RGS2 pGex-KG and HA-RGS2, HA-ΔN-RGS2 and empty pGex 6p-2 constructs were 
transformed in Escherichia coli BL21 and glutathione S-transferase (GST) fusion proteins were 
expressed and purified according to the manufacturer's protocol (Amersham Biosciences, 
Piscataway, NJ, USA). [35S]Methionine-labeled TRPV6 N-tail was prepared using a reticulocyte 
lysate system (Promega, Madison, WI, USA) and analyzed for pull-down with GST, GST-HA-
RGS2 or GST-HA-ΔN-RGS2 fusion proteins immobilized on glutathione-Sepharose 4B beads 
(Amersham Biosciences, Piscataway, NJ) as described previously (16). After extensive 
washing, bound proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), and visualized by Coomassie staining and autoradiography. For 
pull-down with hRGS2; TRPV6/mock, SPL/mock, and TRPV6/SPL were transiently transfected 
in human embryonic kidney 293 (HEK293) cells and after 72 hours extracts from lyzed cells 
were adjusted to equal input concentrations and analyzed for pull-down with GST or GST-
hRGS2 fusion proteins immobilized on gluthatione-Sepharose 4B beads. The beads were 
washed extensively and pulled proteins were analyzed by SDS-PAGE and immunoblotting. 
 
Electrophysiology and solutions 
The full-length cDNAs encoding TRPV5, TRPV6, RGS2, and ΔN-RGS2 were transiently 
transfected in HEK293 cells and patch-clamp experiments were performed in the tight-seal 
whole-cell configuration at room temperature using an EPC-9 patch-clamp amplifier controlled 
by the Pulse software (HEKA Elektronik, Lambrecht, Germany), as described previously (25). 
Cells were held at +20 mV, and voltage ramps of 450 milliseconds, ranging from -100 to +100 
mV, were applied every 5 seconds. Cell capacitance and access resistance were monitored 
continuously using the automatic capacitance compensation of the Pulse software. Na+ current 
densities were obtained by dividing the current amplitude measured at -80 mV during the ramp 
protocols by the cell capacitance. Ca2+-dependent inactivation was studied using a 3 seconds 
voltage step to -100 mV from a holding potential of +70 mV. From this step protocol, Ca2+ peak 
values were extracted by dividing the current at -100 mV by the cell capacitance. The standard 
extracellular solution (Krebs) contained: 150 mM NaCl, 6 mM CsCl, 1 mM MgCl2, 10 mM 
HEPES/NaOH, and 10 mM glucose, pH 7.4. The concentration of Ca2+ ranged between 1 and 
10 mM. Divalent free (DVF) solutions did not contain added divalent cations, whereas trace 
amounts of divalent cations were removed with 100 µM EDTA. The standard internal (pipette) 
solution contained: 20 mM CsCl, 100 mM Cs-aspartate, 1 mM MgCl2, 4 mM Na2ATP, 10 mM 
BAPTA, 10 mM HEPES/CsOH, pH 7.2. Cells were kept in a nominal Ca2+-free medium to 
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prevent Ca2+ overload and exposed for a maximum of 5 minutes to a Krebs solution containing 
1.5 mM Ca2+ before sealing the patch pipette to the cell. The analysis and display of patch-
clamp data were performed using Igor Pro software (WaveMetrics, Lake Oswego, USA).  
 
Biotinylation 
TRPV6, HA-RGS2 and empty pCINeo/IRES-GFP constructs were transfected transiently in 
HEK293 cells and subjected to cell surface biotinylation as described previously (26). 
Biotinylated proteins were eluted with SDS-PAGE loading buffer, separated on 10% (w/v) SDS-
PAGE gel, and analyzed by immunoblotting with rabbit antiserum against TRPV6 (1:2000) (11). 
 
Statistical Analysis 
In all experiments, the data are expressed as mean ± SEM. Overall statistical significance was 
determined by analysis of variance. In case of significance (P < 0.05), individual groups were 
compared using a Student’s t test. 
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RESULTS 
Identification of RGS2 as a TRPV6-associated protein 
To identify proteins that interact with TRPV6, the N-terminal tail of TRPV6 was used to screen a 
library of mouse kidney cDNA by the yeast-two-hybrid technique. RGS2 was identified as a 
positive clone and belongs to the R4 subfamily of Regulator of G-protein Signaling proteins (27). 
To confirm the interaction, the full-length cDNA sequence of RGS2 was re-analyzed in a yeast-
two-hybrid with the N-tail of TRPV6 as bait. The γ-subunit of the epithelial Na+ channel (γENaC) 
was used as a negative control. TRPV6 and RGS2 displayed a strong interaction whereas 
TRPV6 and γENaC did not interact (data not shown). 
 
The RGS2 gene is ubiquitously expressed 
The expression of RGS2 in different mouse tissues was analyzed by RT-PCR. RGS2 was 
detected ubiquitously (Figure 1, upper panel). All tissues expressed β-actin that was used as a 
positive control to confirm the integrity of the cDNAs (Figure 1, lower panel). As negative 
controls, the primer sets for RGS2 and β-actin were screened in the absence of cDNA (depicted 
as H2O samples in Figure 1). 
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TRPV6 interacts with the N-terminal domain of RGS2 
The interaction between TRPV6 and the binding domain of RGS2 was further established using 
GST pull-down assays. To this end, RGS2 and ΔN-RGS2 were expressed as GST fusion 
proteins immobilized on gluthatione sepharose 4B beads. Subsequently, these fusion proteins 
were tested for their interaction with in vitro translated [35S]methionine-labeled N-tail of TRPV6 
in the presence or absence of 1 mM Ca2+. As shown in Figure 2, the N-tail of TRPV6 
associated with GST-fused RGS2 in a Ca2+-independent fashion whereas no binding between 
the N-tail of TRPV6 and GST-fused ΔN-RGS2 or GST alone was observed, neither in the 
presence nor absence of Ca2+. 
Figure 1. Tissue distribution of RGS2. RNA was extracted from different mouse tissues and RGS2 expression 
was determined by RT-PCR. The RGS2 specific band was amplified from all the indicated tissues (upper panel). 
As a control, β-actin was amplified to ensure the integrity of the cDNAs (lower panel). 
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RGS2 inhibits specifically TRPV6 activity 
To study the functional effect of RGS2 binding to TRPV6 the electrophysiological properties of 
the TRPV6 channel were investigated in the presence of RGS2. Steeply inward rectifying 
currents carried by Na+ could be measured in HEK293 cells co-expressing TRPV6 and empty 
vector (mock) and in cells expressing both TRPV6 and RGS2 (Figure 3A,B). The current 
carried by Na+ was significantly reduced in cells expressing both TRPV6 and RGS2 
(Figure 3B,C,  n = 15 cells, P < 0.001).  
Figure 2. Interaction of TRPV6 and RGS2. [35S]Methionine labeled TRPV6 N-tail was incubated with GST, 
GST/RGS2 or GST/ΔN-RGS2 immobilized on glutathione-sepharose 4B beads, either in the presence (1 mM 
Ca2+) or absence (10 mM EGTA) of Ca2+. TRPV6 N-tail interacted with RGS2 whereas no binding with GST/ΔN-
RGS2 or GST alone was observed. 
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Likewise, RGS2 co-expression significantly reduced the Ca2+ current in response to a 
hyperpolarizing voltage step in TRPV6-expressing cells (Figure 3D,E, n = 15 cells, P < 0.001), 
while the Ca2+-dependent inactivation of the currents remained unchanged. In addition, the 
inhibitory effect of RGS2 on TRPV6-mediated Na+ and Ca2+ currents was studied for its closest 
relative, TRPV5, during identical experimental conditions. In contrast to TRPV6, RGS2 had no 
significant effect on Na+ and Ca2+ currents recorded from TRPV5-expressing HEK293 cells 
(Figure 4).  
Figure 3. Inhibition of TRPV6-induced Na+ and Ca2+ currents by RGS2. HEK293 cells were transiently 
transfected with TRPV6/mock (CTRL) or TRPV6/RGS2 and subsequently analyzed by immunoblotting (A) and by 
whole-cell patch-clamp. (B) Current-voltage (I-V) relations measured from ramp protocol in nominally DVF 
solution from CTRL (solid trace) or TRPV6/RGS2-transfected cells (dotted trace). The I-V curve shows inward 
rectification typical for TRPV6 (solid trace), which is not changed by co-expressing RGS2 (dotted trace). (C) 
Average Na+ current density at -80 mV in nominally DVF solution was 384 ± 133 pA/pF for CTRL cells compared 
to 65 ± 8 pA/pF for TRPV6/RGS2 co-expressing cells (n = 15 cells for each condition). (D) Averaged Ca2+ 
currents measured with 10 mM Ca2+ in the extracellular solution using the step protocol in CTRL cells (solid trace) 
and TRPV6/RGS2 co-expressing cells (dotted trace). (E) Average density of the Ca2+ peak current measured as 
in (D) was 228 ± 35 pA/pF for CTRL compared to 56 ± 8 pA/pF for cells co-transfected with TRPV6 and RGS2 
(n = 15 cells for each condition). * indicates significant difference (P < 0.001). 
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TRPV6 activity is inhibited by the N-terminal domain of RGS2 
To test the physiological significance of the N-terminal domain of RGS2 on TRPV6 activity, the 
electrophysiological properties of TRPV6-mediated currents in HEK293 cells co-expressing 
either RGS2 or ΔN-RGS2 were determined. Inward rectifying currents carried by Na+ could be 
measured in HEK293 cells co-transfected with TRPV6 and ΔN-RGS2 or RGS2, or with TRPV6 
and mock (Figure 5A,B). The Na+ currents were significantly reduced in cells co-expressing 
TRPV6 with RGS2 whereas cells co-expressing ΔN-RGS2 and TRPV6 did not show this 
reduction (Figure 5B,C, n = 10 cells, P < 0.001). Likewise, RGS2 significantly reduced the Ca2+ 
current in response to a hyperpolarizing voltage step in TRPV6-expressing cells (Figure 5D,E, 
Figure 4. Activity of TRPV5 is not affected by co-expressing RGS2. HEK293 cells were transiently 
transfected with TRPV5/mock (CTRL) or TRPV5/RGS2 and analyzed using immunoblotting (A) and by whole-cell 
patch-clamp. (B) I-V relations measured from ramp protocol in nominally DVF solution in CTRL (solid trace) or 
TRPV5/RGS2-transfected cells (dotted trace). (C) Average Na+ current density at -80 mV in nominally DVF 
solution was 495 ± 130 pA/pF for CTRL cells compared to 600 ± 100 pA/pF for TRPV5/RGS2 co-expressing cells 
(n = 15 cells for each condition). (D) Averaged Ca2+ currents measured with 10 mM Ca2+ in the extracellular 
solution using the step protocol in CTRL cells (solid trace) and TRPV5/RGS2-expressing cells (dotted trace). (E) 
Average density of the Ca2+ peak current measured as in (D), was 210 ± 50 pA/pF for CTRL compared to 
201 ± 35 pA/pF for cells co-transfected with TRPV5 and RGS2 (n = 15 cells for each condition). 
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n = 10 cells, P < 0.001) whereas co-expression of ΔN-RGS2 with TRPV6 had no effect on the 
TRPV6-mediated current amplitude. 
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RGS2 does not affect TRPV6 abundance at the plasma membrane 
To investigate whether RGS2 influences trafficking of TRPV6, cell surface expression of TRPV6 
in HEK293 cells co-expressing RGS2 and TRPV6 was examined using Sulfo-NHS-LC-LC-
Biotin. TRPV6 was detected in total cell lysates of TRPV6-expressing cells as well as in the 
biotinylated plasma membrane fractions of TRPV6 and TRPV6/RGS2 co-expressing cells 
Figure 5. Inhibition of TRPV6-mediated Na+ and Ca2+ currents by RGS2, but not ΔN-RGS2. HEK293 cells 
were transiently transfected with TRPV6/mock (CTRL) or TRPV6 and RGS2 or ΔN-RGS2 and analyzed using 
immunoblotting (A) and by whole-cell patch-clamp. (B) I-V relations measured from ramp protocol in nominally 
DVF solution from CTRL (solid trace), TRPV6/RGS2-transfected cells (dotted trace) and TRPV6/ΔN-RGS2-
transefected cells (dashed trace). (C) Average Na+ current density at -80 mV in nominally DVF solution was 
268 ± 40 pA/pF for CTRL, 30 ± 5 pA/pF for cells transfected with TRPV6 and RGS2 and 280 ± 45 pA/pF for 
TRPV6/ΔN-RGS2-transfected cells (n = 10 cells for each condition). (D) Averaged Ca2+ currents measured with 
10 mM Ca2+ in the extracellular solution using the step protocol in CTRL cells (solid trace), TRPV6/RGS2-
expressing cells (dotted trace) and TRPV6/ΔN-RGS2 co-expressing cells (dashed trace). (E) Average density of 
the Ca2+ peak current measured as in (D), was 200 ± 50 pA/pF for CTRL, 55 ± 10 pA/pF for TRPV6/RGS2 co-
expressing cells and 196 ± 55 pA/pF for TRPV6/ΔN-RGS2 co-expressing cells (n = 10 cells for each condition). 
* indicates significant difference (P < 0.001). 
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(Figure 6). TRPV6 expression in the biotinylated membrane fraction was not significantly 
altered by co-expression of RGS2. 
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TRPV6 is independently regulated from the scaffolding protein SPL 
The effect of SPL on the interaction of RGS2 with TRPV6 was investigated by GST pull-down 
assay. Total cell lysates of HEK293 cells transiently transfected with TRPV6, SPL, or TRPV6 
and SPL, were prepared and equal amounts of protein were analyzed for the interaction with 
RGS2. As indicated in Figure 7, TRPV6 associated with RGS2 both in the presence or absence 
of SPL.  
 
Figure 6. Cell-surface expression of TRPV6. HEK293 cells were transfected with TRPV6 ± RGS2. The 
extracellular parts of the proteins were biotinylated, precipitated with neutravidin beads, and immunoblotted for 
TRPV6. Samples of the lysed cells (“total cell lysates”, left panel) were immunoblotted in parallel to visualize the 
amount of expressed proteins. Both TRPV6 alone and TRPV6 with RGS2-transfected cells showed cell surface 
expression, whereas mock-transfected cells did not (“plasma membrane”, right panel). 
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Next, the electrophysiological properties of TRPV6-mediated currents were examined by whole 
cell patch-clamp in HEK293 cells co-expressing TRPV6 and SPL or TRPV6 and mock. Co-
expression of SPL and TRPV6 had no significant effect either on Na+ or Ca2+ currents (n = 12 
cells for each condition) as depicted in Figure 8. 
Figure 7. Effect of SPL on the interaction of RGS2 and TRPV6. Extracts from HEK293 cells transfected with 
TRPV6 and SPL were used for pull-down assay with GST or GST fused to RGS2. Pulled proteins were analyzed 
for TRPV6 (top panel) and SPL (lower panel) expression by immunoblotting. 
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Figure 8. Activity of TRPV6 is not affected by SPL. HEK293 cells were transiently transfected with 
TRPV6/mock (CTRL) or TRPV6/SPL and analyzed by immunoblotting and by whole-cell patch clamp. Average 
Na+ current density measured at -80 mV from the ramp protocol was 344 ± 70 pA/pF for CTRL and 335 ± 80 
pA/pF for TRPV6/SPL co-expressing cells and average density of the Ca2+ peak current measured from the step 
protocol was 204 ± 35 pA/pF for CTRL and 195 ± 40 pA/pF for TRPV6/SPL co-expressing cells (n = 12 cells for 
each condition). 
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DISCUSSION 
The present study demonstrates a novel regulatory function of RGS2 by direct inhibition of 
TRPV6 channel activity at the plasma membrane. This conclusion is based on the following 
experimental data. First, interaction of RGS2 with TRPV6 specifically inhibits both Na+ and Ca2+ 
currents through TRPV6 whereas no effect on TRPV5 activity was observed. Second, deletion 
of the N-terminal domain of RGS2 disrupts the binding with TRPV6 and restores the original 
electrophysiological properties of the channel. Third, RGS2 expression does not interfere with 
TRPV6 trafficking from and towards the plasma membrane (to mediate its inhibitory effect on 
channel activity). Fourth, the multi-domain scaffolding protein SPL does not affect binding and 
electrophysiological properties of TRPV6 in the presence of RGS2. Therefore, our data indicate 
that TRPV6 activity is regulated by RGS2 without the involvement of GPCR signaling. 
We showed that the N-terminal tail of RGS2 is essential for the interaction with and the activity 
of TRPV6. The N-terminal domain has already been described to be an important regulatory site 
for RGS2. Together with the  “RGS-box” domain, it is necessary for its effector protein 
interactions, e.g. GPCRs and/or auxiliary proteins such as SPL  (23,28,29). In addition, the 
membrane targeting sequence has also been predicted in this domain (30,31). 
Patch-clamp analysis of HEK293 cells transfected with TRPV6 or TRPV5 revealed that 
specifically TRPV6 activity is inhibited by co-expression of RGS2. Interestingly, an analogous 
inhibitory mechanism has only been found for CaM and TRPV6 (32). Since both Na+ and Ca2+ 
currents through TRPV6 were inhibited by RGS2, and thus affecting not specifically the Ca2+ 
conductance of the channel, we expected a disturbed TRPV6 trafficking towards the cell 
surface. In contrast, cell surface biotinylation in TRPV6-expressing HEK293 cells demonstrated 
that RGS2 does not affect channel expression in the biotinylated fractions. Therefore, the 
inhibitory effect of RGS2 is presumably mediated directly at the plasma membrane. 
RGS2 needs to be recruited towards the cell surface in order to affect the gating properties of 
TRPV6. Roy and co-workers (33) showed that G proteins recruit RGS proteins towards the 
plasma membrane. In their study, the abundance of RGS2 and RGS4 proteins at the plasma 
membrane was enhanced when the number of G proteins was increased or when they 
interacted with their GPCR. Also SPL has been shown to be involved in RGS protein 
recruitment (23). Investigating the role of SPL provided us with additional evidence for a direct 
effect of RGS2 on TRPV6 activity. Wang and co-workers (23) showed that SPL is a scavenger 
of RGS2 which forms a SPL-RGS2 protein complex that regulates Ca2+ signaling by binding the 
third intracellular domain of GPCRs. In their study, the binding of RGS2 with the α-adrenergic 
receptor (AR) was investigated by GST pull-down analysis. The interaction between RGS2 and 
the AR was significantly increased in the presence of SPL. Furthermore, they observed that the 
inhibitory effect of RGS2 on Ca2+-activated Cl- currents in parotid duct cells was increased in the 
presence of SPL. For this reason, we anticipated that SPL could increase the inhibitory effect of 
 118
endogenously present RGS2 on TRPV6 activity in HEK293 cells when acting via a Gαq-coupled 
GPCR. RGS2 expression was confirmed in HEK293 cells by RT-PCR (data not shown). First, it 
was demonstrated that SPL does not change TRPV6 expression (Figure 7, top panel). 
Second, TRPV6-mediated Na+ and Ca2+ currents were not affected by SPL as well (Figure 8). 
Therefore, we conclude that the inhibitory effect of RGS2 on TRPV6 activity is independently 
regulated of a GPCR, but is rather mediated by direct interaction of RGS2 and TRPV6.  
In conclusion, we have identified RGS2 as a novel regulatory protein specifically inhibiting the 
activity of the epithelial Ca2+ channel TRPV6. Our findings may provide insight in the direct 
regulation of different TRP channels by interacted proteins at the plasma membrane. 
 
ACKNOWLEDGEMENTS 
We thank Dr. K.M. Druey (Molecular Signal Transduction Section, Laboratory of Allergic 
Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
Bethesda, Maryland 20892) for kindly providing the RGS2 antibody and J.A. Janssen for 
excellent technical assistance. This work was supported by the Dutch Organization of Scientific 
Research (NWO-ALW 814.02.001 and Zon-MW 016.006.001). 
 119
REFERENCES 
1. Birnbaumer, L., Yildirim, E., and Abramowitz, J. Cell Calcium. 33: 419-432, 2003 
2. Clapham, D. E. Nature. 426: 517-524, 2003 
3. Montell, C. Cell Calcium. 33: 409-417, 2003 
4. Putney, J. W., Jr. Cell Calcium. 34: 339-344, 2003 
5. Montell, C., Birnbaumer, L., and Flockerzi, V. Cell. 108: 595-598, 2002 
6. Hoenderop, J. G., Vennekens, R., Muller, D., et al. J Physiol. 537: 747-761, 2001 
7. Pedersen, S. F., Owsianik, G., and Nilius, B. Cell Calcium. 38: 233-252, 2005 
8. Voets, T., Janssens, A., Prenen, J., Droogmans, G., and Nilius, B. J Gen Physiol. 121: 
245-260, 2003 
9. Voets, T., Janssens, A., Droogmans, G., and Nilius, B. J Biol Chem. 279: 15223-15230, 
2004 
10. Peng, J. B., Chen, X. Z., Berger, U. V., et al. J Biol Chem. 274: 22739-22746, 1999 
11. Nijenhuis, T., Hoenderop, J. G., van der Kemp, A. W., and Bindels, R. J. J Am Soc 
Nephrol. 14: 2731-2740, 2003 
12. Wissenbach, U., Niemeyer, B. A., Fixemer, T., et al. J Biol Chem. 276: 19461-19468, 
2001 
13. den Dekker, E., Hoenderop, J. G., Nilius, B., and Bindels, R. J. Cell Calcium. 33: 497-
507, 2003 
14. Hoenderop, J. G., Nilius, B., and Bindels, R. J. Physiol Rev. 85: 373-422, 2005 
15. van de Graaf, S. F., Chang, Q., Mensenkamp, A. R., Hoenderop, J. G., and Bindels, R. 
J. Mol Cell Biol. 26: 303-312, 2006 
16. Van de Graaf, S. F., Hoenderop, J. G., Gkika, D., et al. EMBO J. 22: 1478-1487, 2003 
17. van de Graaf, S. F., Hoenderop, J. G., van der Kemp, A. W., Gisler, S. M., and Bindels, 
R. J. Pflugers Arch. 452: 407-417, 2006 
18. Erler, I., Hirnet, D., Wissenbach, U., Flockerzi, V., and Niemeyer, B. A. J Biol Chem. 
279: 34456-34463, 2004 
19. Mosavi, L. K., Cammett, T. J., Desrosiers, D. C., and Peng, Z. Y. Protein Sci. 13: 1435-
1448, 2004 
20. De Vries, L., Zheng, B., Fischer, T., Elenko, E., and Farquhar, M. G. Annu Rev 
Pharmacol Toxicol. 40: 235-271, 2000 
21. Abramow-Newerly, M., Roy, A. A., Nunn, C., and Chidiac, P. Cell Signal. 18: 579-591, 
2006 
22. Nilius, B., Prenen, J., Hoenderop, J. G., et al. J Biol Chem. 277: 30852-30858, 2002 
23. Wang, X., Zeng, W., Soyombo, A. A., et al. Nat Cell Biol. 7: 405-411, 2005 
24. Van Abel, M., Hoenderop, J. G., Dardenne, O., et al. J Am Soc Nephrol. 13: 2102-2109, 
2002 
25. Vennekens, R., Hoenderop, J. G., Prenen, J., et al. J Biol Chem. 275: 3963-3969, 2000 
26. Chang, Q., Hoefs, S., van der Kemp, A. W., Topala, C. N., Bindels, R. J., and 
Hoenderop, J. G. Science. 310: 490-493, 2005 
27. Ross, E. M., and Wilkie, T. M. Annu Rev Biochem. 69: 795-827, 2000 
28. Bernstein, L. S., Ramineni, S., Hague, C., et al. J Biol Chem. 279: 21248-21256, 2004 
29. Hague, C., Bernstein, L. S., Ramineni, S., Chen, Z., Minneman, K. P., and Hepler, J. R. 
J Biol Chem. 280: 27289-27295, 2005 
30. Heximer, S. P., Lim, H., Bernard, J. L., and Blumer, K. J. J Biol Chem. 276: 14195-
14203, 2001 
31. Kehrl, J. H., and Sinnarajah, S. Int J Biochem Cell Biol. 34: 432-438, 2002 
32. Lambers, T. T., Weidema, A. F., Nilius, B., Hoenderop, J. G., and Bindels, R. J. J Biol 
Chem. 279: 28855-28861, 2004 
33. Roy, A. A., Lemberg, K. E., and Chidiac, P. Mol Pharmacol. 64: 587-593, 2003 
 
 
 
 120
 
Chapter 6 
 
 
 
 
Molecular determinants of permeation through the cation channel 
TRPM6 
 
 
 
 
 
 
 
 
 
 
Catalin N. Topala1, Wouter Tiel Groenestege1, Stéphanie Thebault1, Dennis van den 
Berg1, Bernd Nilius2, Joost G. Hoenderop1 and René J. Bindels1 
 
 
 
 
1Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud 
University Nijmegen Medical Centre, The Netherlands, 2Department of Physiology, 
Campus Gasthuisberg, Catholic University Leuven, Belgium 
 
 
 
 
 
 
Cell Calcium. 41: 513-523, 2007 
 122
 123
ABSTRACT 
TRPM6 and its closest relative TRPM7 are members of the Transient Receptor Potential 
Melastatin (TRPM) subfamily of cation channels and are known to be Mg2+ permeable. By 
aligning the sequence of the putative TRPM6 pore with the pore sequences of the other 
subfamily members, we located in the loop between the 5th and the 6th transmembrane domain, 
a stretch of amino acids residues, 1028GEIDVC1033, as the potential selectivity filter. Two 
negatively charged residues, E1024 (conserved in TRPM6, TRPM7, TRPM1 and TRPM3) and 
D1031 (conserved along the entire TRPM subfamily), were identified as important determinants of 
cation permeation through TRPM6, because neutralization of both residues into an alanine 
resulted in non-functional channels. Neutralization of E1029 (conserved in TRPM6, TRPM7, 
TRPM4 and TRPM5) resulted in channels with increased conductance for Ba2+ and Zn2+, 
decreased ruthenium red sensitivity and larger pore diameter compared to wild-type TRPM6. 
Changing the residue I1030 into methionine, resulted in channels with lower conductance for Ni2+, 
decreased sensitivity to ruthenium red block and reduced pore diameter. Thus, these data 
demonstrate that amino acid residues E1024, I1030 and D1031 are important for channel function 
and that subtle amino acid variation in the pore region accounts for TRPM6 permeation 
properties. 
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INTRODUCTION 
Beside being the most abundant intracellular cation after K+, Mg2+ is an important cofactor for 
many biological processes, such as protein synthesis, nucleic acid stability and neuromuscular 
excitability (1,2). Mg2+ homeostasis involves the kidney as the primary regulatory site, the 
intestine as the absorption place, while the bone is the storage location (3). Transcellular Mg2+ 
transport in renal and intestinal epithelia is of vital importance for overall Mg2+ homeostasis. 
There is both a passive (paracellular) and an active (transcellular) mechanism for Mg2+ 
(re)absorption in renal and intestine epithelia (2). However, the molecular mechanism of 
transcellular Mg2+ transport is not fully understood. Recently, investigations in consanguineous 
families suffering from hypomagnesemia with secondary hypocalcemia (HSH) have identified 
mutations in the gene encoding the Transient Receptor Potential Melastatin 6 (TRPM6) protein 
as the cause of the disease (4,5). It was demonstrated that TRPM6 functions as a molecular 
determinant of transcellular Mg2+ transport in renal and intestinal epithelia (6). 
TRPM6 shares with its closest relative TRPM7 approximately 50% sequence homology at the 
amino acid level (6). Whereas TRPM7 appears to be ubiquitously expressed, TRPM6 
expression is restricted to kidney and intestine (6), where it plays an important role in Mg2+ 
(re)absorption (6). Consistent with a role in Mg2+ homeostasis, we demonstrated recently that 
dietary Mg2+ restriction upregulates TRPM6 expression in mice kidney, while a Mg2+-enriched 
diet increases TRPM6 expression in colon (7). These diets did not affect TRPM7 expression 
levels in kidney and colon. Atypically for other ion channels, TRPM6 and TRPM7 contain a 
serine/threonine protein kinase domain at the C-terminus resembling that of elongation factor 2 
(eEF-2) kinase and other α-kinases. The kinase function in channel regulation remains elusive 
(4,8-12). 
Recently, we have functionally characterized TRPM6 using electrophysiological analysis (6). 
This protein forms constitutively active divalent selective cation channels, with a higher affinity 
for Mg2+ than for Ca2+ at physiological membrane potentials and divalent concentrations. 
TRPM6 becomes permeable to monovalent cations when all divalent cations are omitted from 
the extracellular solution. Despite this initial characterization of TRPM6, the molecular 
determinants of its Mg2+ permeability remain unknown. Moreover, in a recent paper, Li et al 
described in detail the functional differences in divalent ion permeability between homomeric 
TRPM6, homomeric TRPM7 and heteromeric TRPM6/TRPM7 channel complexes 
demonstrating unequivocally that TRPM6 can form by itself functional channels without TRPM7 
co-expression (13). The study also demonstrated that TRPM6 displays single channel 
conductance that is 2- and 1.5-fold bigger than TRPM7 and TRPM6/TRPM7 complexes. 
To date there is limited knowledge about the structures of TRP channels pores and even less is 
known about TRPM channels pores. In a recent study Owsianik et al summarized the current 
knowledge about permeation and selectivity of TRP channels (14). They propose and describe 
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a general approach as a toolkit for characterizing the permeation and selectivity of ion channels. 
The aim of the present study was to identify the amino acid stretch responsible for Mg2+ 
permeation of TRPM6. To this end, a combined approach consisting in site-directed 
mutagenesis and electrophysiological measurements was used to investigate the role of amino 
acid residues from the putative selectivity filter in the permeation properties of TRPM6. Our data 
indicate that a short amino acid stretch of the pore region, 1028GEIDVC1033, determines the 
TRPM6 conductance properties and its sensitivity to the channel pore blocker, the hexavalent 
cation ruthenium red. 
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EXPERIMENTAL PROCEDURES 
Molecular biology 
The full-length open reading frame from N-terminally HA-tagged human (h)TRPM6 was cloned 
as a BclI - BspEI fragment in the pCINeo/IRES-GFP vector (6). This bicistronic expression 
vector, pCINeo/IRES-GFP/HA-hTRPM6, was used to co-express hTRPM6 and enhanced GFP 
in Human Embryonic Kidney cells (HEK293). Mutagenesis of the amino acids E1024, E1029, I1030, 
D1031, V1032 and of the TRPM6-TRPM4 and TRPM6-TRPV6 chimeric constructs was performed 
using QuickChangeTM site-directed mutagenesis (Stratagene, La Jolla, USA). The sequence of 
each mutant was verified by sequence analysis of the corresponding cDNA. 
 
Cell culture and transfection 
HEK293 cells were grown in Dulbecco's modified Eagle's medium (Bio Whittaker-Europe, 
Verviers, Belgium) containing 10% (v/v) fetal calf serum, 2 mM L-glutamine and 10 μg/ml 
ciproxin at 37°C in a humidity-controlled incubator with 5% (v/v) CO2. The cells were transiently 
transfected with the respective constructs using Lipofectamine 2000 (Invitrogen-Life 
Technologies, Breda, The Netherlands), as described previously (15), and electrophysiological 
recordings were performed 16 to 36 hours post-transfection. Transfected cells were identified by 
their green fluorescence when illuminated at 480 nm. Non-transfected (GFP-negative) cells from 
the same batch were used as controls. 
 
Electrophysiology 
Patch-clamp experiments were performed in the tight-seal whole-cell configuration at room 
temperature (20-25°C) using an EPC-9 patch-clamp amplifier computer controlled by Pulse 
software (HEKA Electronik, Lambrecht, Germany). Patch pipettes had resistances between 2 
and 4 MΩ after filling with the standard intracellular solution. Cells were held at 0 mV, and 
voltage ramps of 450 ms ranging from -100 to +100 mV were applied every 2 s. Cell 
capacitance and access resistance were continuously monitored using the automatic 
capacitance compensation of the Pulse software package. Extracting the current amplitudes at 
+80 and -80 mV from individual ramp current records assessed the temporal development of 
membrane currents. Current densities were obtained by normalizing the current amplitude to the 
cell membrane capacitance. 
 
Solutions 
The standard pipette solution contained (in mM): 150 NaCl, 10 EDTA, and 10 HEPES (pH 7.2 
adjusted with NaOH). The extracellular solution contained (in mM): 150 NaCl and 10 HEPES 
(pH 7.4 adjusted with NaOH), supplemented with either 1 mM CaCl2 (to assess the time-course 
for development of currents), 10 mM EDTA (divalent-free solutions, DVF), or the same 
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concentration of divalent cations (for the permeation profile determinations). The relative 
permeabilities (PX/PNa) of mono-, di-, tri-, and tetramethyl ammonium substituents and of N-
methyl-D-glucamine (NMDG) were measured using solutions in which all Na+ was substituted by 
the respective cations and calculated from the biionic reversal potentials (16). All potentials were 
corrected for possible liquid junction potentials, which were calculated according to Barry (17). In 
these permeation experiments, the standard pipette solution was used as intracellular solution. 
For the ammonium derivates, the following compounds diameters were used (in nm): 0.36, 0.46, 
0.52, 0.58, and 0.68 for monomethylammonium (MA+), dimethylammonium (DMA+), 
trimethylammonium (TriMA+), tetramethylammonium (TetMA+), and for NMDG+ respectively. To 
fit the points from the graph plotting permeability ratios of the different organic cations (Χ) 
versus their estimated diameters, the excluded volume considering friction of the permeating ion 
Equation 1 (18) was used: 
/aa/d)k(/PP NaX 21−=  
where a is the organic cation diameter, k is a constant factor and d the minimal pore diameter. 
The ammonium derivates were purchased from Sigma. 
 
Statistical Analysis 
Data analysis and graphs were prepared using IgorPro software (WaveMetrics, Lake Oswego, 
USA). Data are expressed as mean ± SEM. Overall statistical significance was determined by 
analysis of variance. In case of significance (P < 0.05), individual groups were compared using 
Student's t test. 
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RESULTS 
Sequence analysis of the putative pore-forming region of TRPM6 
Figure 1 shows a sequence alignment of the putative pore region of the TRPM subfamily. The 
structure of the loop between the 5th and the 6th transmembrane domains (TM5 and TM6) was 
modeled based on the K+ channel KcsA crystal structure (19). In this region, TRPM6 shares the 
highest sequence homology with TRPM7, also known to conduct Mg2+ when heterologously 
expressed in HEK293 cells (8,9,20). TRPM6 and TRPM7 contain two glutamate residues, E1024 
and E1029 (highlighted yellow in Figure 1).  
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The E1024 is conserved in TRPM1 and TRPM3. In addition, TRPM6 shares an aspartate residue 
D1031 (highlighted red in Figure 1) with all the other members of the TRPM subfamily. To assess 
the contribution of these amino acid residues in the permeation properties of TRPM6, these 
residues were neutralized by alanine substitution (mutants E1024A, E1029A, and D1031A). To 
delineate the role of the conserved aspartate residue (D1031), adjacent amino acids were 
mutated. I1030 was substituted by a methionine in order to mimic the pore properties of the 
monovalent selective channel TRPM4 (mutant I1030M), and the V1032 was substituted by an 
alanine (mutant V1032A). The positions for the amino acid residues mutated for this study are 
marked with asterisks in Figure 1. 
 
Functional characterization of TRPM6 pore mutants 
To determine which amino acids in the pore region account for the permeation properties of 
TRPM6, the activation kinetics of wild-type channels were compared with those of the mutant 
proteins. The currents recorded from TRPM6-transfected cells reached a plateau level of 
295 ± 40 pA/pF (n = 30 cells) within 100-200 s, while non-transfected (NT) cells (n = 10 cells) 
displayed only background current, probably endogenous TRPM7 (75 ± 27 pA/pF) that is 
activated over a longer period, as depicted in Figure 2A. When expressed in HEK293 cells, the 
Figure 1. The putative pore-forming region of TRPM6. Alignment of the putative pore sequences of the TRPM 
subfamily on the rows, which represent the amino acid sequences from the respective human TRPM subfamily 
channels. The GenBank accession numbers are: NP_002411, AAY22174, NP_066003, NP_060106, NP_055370, 
NP_060132, NP_060142, and NP_076985 starting from TRPM1 to TRPM8. The highly conserved hydrophobic 
residues are highlighted in grey, the conserved aspartate is shown in red, and the conserved residues with polar 
or charged groups are shown in yellow (adapted from (24,35)). Asterisks denote the amino acid residues mutated 
in this study. 
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TRPM6 pore mutants showed three different phenotypes: E1029A displayed a time-course of 
activation and a current amplitude similar to wild-type TRPM6 (n = 10 cells) (Figure 2B), I1030M 
and V1032A showed activation kinetics similar with TRPM6, while their current amplitudes were 
significantly reduced (178 ± 40 and 150 ± 45 pA/pF respectively versus 295 ± 40 pA/pF, 
P < 0.05, n = 10 cells for each mutant), as depicted in Figure 2C and D, and E1024A and D1031A 
showed no current (n = 5 cells) (Figure 2E). Mutations in the pore region of TRPM6 did not 
change the current-voltage properties of the currents as summarized in Figure 2F. 
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Interestingly, when co-expressed with wild-type TRPM6 in a 1:1 cDNA ratio, D1031A showed a 
dominant negative effect since the currents recorded from these cells (n = 8 cells) were identical 
in the time-course of development, current-voltage relation and amplitude with the currents from 
NT cells as shown in Figure 3. The dominant negative effect of D1031A suggests that assembly 
with wild-type TRPM6 is not disturbed. Channel complexes containing wild-type and mutant 
Figure 2. Functional expression of wild-type TRPM6 and pore mutant proteins. (A) Average time-course of 
inward (at -80 mV) and outward currents (at +80 mV) development from cells expressing wild-type TRPM6 (♦), 
and non-transfected cells (NT ▲). (B-E) Average time course of inward and outward currents development from 
cells expressing the mutant E1029A (B), I1030M (C), V1032A (D), E1024A () and D1031A ({) (E); the dotted line 
indicates the averaged time course for wild-type TRPM6. (F) Current-voltage relations from cells transfected with 
either TRPM6, or mutant proteins as indicated, obtained under experimental conditions as in other panels, 
measured 200 s after whole-cell establishment.
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proteins could be retained at the endoplasmic reticulum or reach the plasma membrane 
showing defective pore architecture.  
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Likewise, expression of D1031A alone could have the same outcome as the co-expression with 
wild-type TRPM6. Despite repetitive attempts, the low abundance of TRPM6 proteins at the 
plasma membrane did not allow us to determine whether these proteins are expressed at the 
cell surface. 
 
Conductance profile of TRPM6 pore mutants 
To establish the conductance properties of TRPM6, we determined the permeation profile of the 
wild-type channel and the functional pore mutants. The permeation rank order of divalent 
cations compared to Ca2+ was assessed by the ratio of inward current at -80 mV, when Ca2+ 
ions are equimolar substituted by other divalent cations. When normalized to the inward current 
amplitude in the presence of 10 mM Ca2+, the following conductance profile for TRPM6 was 
obtained: Ba2+ (1.66) > Ni2+ (1.16) > Mg2+ (1.08) > Zn2+ (1.01) ≥ Ca2+ (1.00) (n = 5-8 cells) 
(Figure 4A). The permeation rank order obtained for the mutant E1029A was: Ba2+ (2.34) > Zn2+ 
Figure 3. Effect of co-expression of wild-type TRPM6 and the pore mutant D1031A. (A) Average time course 
of inward and outward currents development from cells expressing wild-type TRPM6 (dotted line) or TRPM6 with 
the pore mutant D1031A. (B) Current-voltage relations from HEK293 cells transfected with either wild-type TRPM6, 
or TRPM6 with the pore mutant D1031A, measured 200 s after whole-cell establishment. (C) Histogram 
summarizing the currents amplitudes measured 200s after whole-cell establishment at +80 mV from NT cells, 
cells transfected with wild-type TRPM6 and cells transfected with TRPM6 together with the pore mutant D1031A, 
asterisk denotes P < 0.05 versus wild-type TRPM6. 
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(1.29) > Ni2+ (1.14) > Mg2+ (1.08) > Ca2+ (1.00) (Figure 4B). The E1029A displayed an increased 
conductance to Ba2+ and Zn2+ compared to TRPM6. For the permeation rank order of the 
mutant I1030M, the following values were obtained: Ba2+ (1.74) > Mg2+ (1.01) ≥ Ca2+ (1.00) ≥ Zn2+ 
(0.99) > Ni2+ (0.92), (n = 5 cells) (Figure 4C). The I1030M mutant had a lower conductance for 
Ni2+ compared to TRPM6. These data are summarized in Figure 4D. 
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To further characterize the TRPM6 pore permeability, its permeation profile was compared with 
the homologous TRPM7 channel as previously described by Monteilh-Zoller et al (20). When 
normalized to the inward current amplitude in 10 mM Ca2+, the following relative values were 
obtained for TRPM7: Ba2+ (4.62) > Ni2+ (3.69) > Zn2+ (2.11) > Mg2+ (1.24) > Ca2+ (1.00) (n = 8 
cells). This comparison, summarized in Figure 4E, revealed that TRPM6 and TRPM7 display 
different permeation rank orders in the way that TRPM6 has a higher conductance for Mg2+ than 
TRPM7.  
Figure 4. Divalent permeation through wild-type TRPM6 and pore mutant proteins. (A-C) Magnified views of 
the inward currents recorded with extracellular solutions containing 10 mM of the indicated divalent cations, from 
HEK293 cells expressing TRPM6 (A), E1029A (B), and I1030M (C). (D) Histogram summarizing relative permeation 
rank order determined from the ratio of inward current for the indicated divalent cation, for TRPM6 (black bars) 
and pore mutants E1029A (white bars) and I1030M (grey bars), (asterisks represent P < 0.05 versus wild-type 
TRPM6). (E) Histogram summarizing the relative permeation profile for TRPM6 (black columns) and TRPM7 
(white columns) determined from the ratio of inward current amplitude in the presence of the indicated divalent 
cation, and the inward current amplitude with Ca2+ containing extracellular solution.
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Next, the effect of micromolar concentrations of divalent cations (Ca2+ and Mg2+) present in the 
extracellular solutions on inward monovalent (Na+) current was investigated. As shown in 
Figure 5A,B both Mg2+ and Ca2+ inhibited the TRPM6 current in the micromolar range. The 
concentration for half-maximal TRPM6 current inhibition (IC50) was calculated from the dose-
response curve for Mg2+ (n = 5 cells for each point) (Figure 5C) and Ca2+ (n = 5 cells for each 
point) (Figure 5D) and yielded values of 0.9 and 3.5 μM with Hill coefficients of 0.8 and 0.83 
respectively.  
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These values were in concordance with the ones from our previous paper (6). For the pore 
mutants, the IC50 for Mg2+ sensitivity was (in μM): 1.1, 1.0, and 0.8, for E1029A, I1030M and V1032A, 
respectively (Figure 5E), while the IC50 for Ca2+ sensitivity for the pore mutants was (in μM): 
3.4, 3.6 and 3.4 for E1029A, I1030M and V1032A, respectively (Figure 5F). No significant differences 
were observed between the pore mutants and wild-type TRPM6. 
 
Figure 5. Mg2+ and Ca2+ inhibit TRPM6-mediated inward monovalent currents. (A and B) Current-voltage 
relations obtained from HEK293 cells expressing TRPM6 in divalent-free solution (DVF) and in the presence of 
0.1 and 1 μM Mg2+, or 1 and 5 μM Ca2+. (C) Dose-response curve for the inhibition of inward monovalent current 
at -80 mV by Mg2+. (D) Dose-response curve for the inhibition of inward monovalent current at -80 mV by Ca2+. (E 
and F) Dose-response curves for the inhibition of inward monovalent current by Mg2+ (E) and Ca2+ (F) for the pore 
mutant proteins, E1029A (●), I1030M (■) and V1032A (▼). 
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Effect of pore mutations on TRPM6 ruthenium red sensitivity 
As previously demonstrated, TRPM6 can be blocked by the hexavalent cation ruthenium red 
(RR) in a voltage-dependent manner (6). As depicted in Figure 6 A-D, RR blocked specifically 
the inward monovalent currents carried by wild-type TRPM6 or the pore mutants. To determine 
which amino acid residues in the TRPM6 pore are involved in the inhibitory effect of RR, a dose-
response curve was established for RR block of the inward TRPM6 and pore-mutant’s 
monovalent currents (n = 5 cells for each point) (Figure 6E). The following IC50 for RR 
sensitivity were obtained (in µM): 15.3 for E1029A with the Hill coefficient of 0.92, 11.9 for I1030M 
with Hill coefficient of 0.77 and 4.8 for V1032A with a Hill coefficient of 0.84 compared to 5.3 for 
TRPM6 with a Hill coefficient of 0.90. E1029A and I1030M mutants showed a significantly 
(P < 0.05) reduced sensitivity to RR compared to wild-type channel.  
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Figure 6. The inhibitory effect of ruthenium red (RR) on TRPM6 pore mutants. (A-D) Current-voltage 
relations of monovalent currents in absence (solid lines), or in the presence of RR either at 5 µM RR (dotted lines) 
or 10 µM RR (dashed lines) obtained from cells expressing wild-type TRPM6 (A), and the pore mutants E1029A 
(B), I1031M (C) and V1032A (D). (E) Dose-response curves for the inhibition of the TRPM6-mediated inward 
monovalent current by RR (♦) and the pore mutant proteins: E1029A (●), I1030M (■) and V1032A (▼). 
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Measurement of the pore diameter of TRPM6 
To estimate the TRPM6 pore diameter, the permeability ratios of currents carried by organic 
monovalent cations of increasing size relative to Na+ current were measured. When Na+ was 
used as the sole charge carrier, the current reverted close to 0 mV and had a slightly inward-
rectifying shape (Figure 7A). All Na+ ions from the extracellular solution were substituted by 
methyl-ammonium or its di-, tri- and tetra methyl derivatives (MA+, DMA+, TriMA+, TetMA+), or by 
the larger organic cation N-methyl-D-glucamine (NMDG+). All the tested cations were able to 
permeate wild-type TRPM6, E1029A and I1030M channels (Figure 7A-C). The permeability ratios 
relative to Na+ (PX/PNa) were calculated from the biionic reversal potentials (16): 0.827 ± 0.004, 
0.483 ± 0.007, 0.360 ± 0.015, 0.262 ± 0.016, and 0.230 ± 0.015 for MA+, DMA+, TriMA+, 
TetMA+, and NMDG+ respectively.  
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Figure 7D depicts the permeability ratios of the different cations versus their estimated diameter 
for TRPM6, E1029A and I1030M (n = 5 cells for each point). Data points were fitted using Eq. 1 
(see Experimental procedures section for more details) resulting in significant differences 
(P < 0.05) in pore diameters of 1.15, 1.25 and 1.05 nm for TRPM6, E1029A and I1030M, 
respectively. 
To further delineate the selectivity filter of TRPM6, two chimeras were prepared in which the 
identified selectivity filters of TRPM4 or TRPV6 were inserted. To this respect an amino acid 
stretch from the TRPM6 pore 1028GEIDVC1033 was replaced by the sequence 981EDMDVA986 to 
Figure 7. Measurements of the TRPM6 pore diameter. (A-C) Extracts of current-voltage relations obtained 
during voltage ramps in divalent-free (DVF) solutions containing Na+, methylammonium (MA+), 
dimethylammonium (DMA+), trimethylammonium (TriMA+), tetramethylammonium (TetMA+), or N-methyl-D-
glucamine (NMDG+) as the sole extracellular cation, from cells expressing TRPM6 (A), E1029A (B) and I1030M (C). 
(D) The relative permeabilities (PX/PNa) of the different organic cations plotted as a function of the cation diameter 
for TRPM6 (♦) and pore mutants: E1029A (●) and I1030M (■). Data points were fitted according to Equation 1 (see 
Experimental procedures section for more details). 
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construct the TRPM6-TRPM4 selectivity filter chimera and by the sequence 539TIIDGP544 to 
create the TRPM6-TRPV6 chimera. Both constructs resulted in non-functional channels when 
expressed in HEK293 cells (data not shown). 
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DISCUSSION 
The Mg2+-selective cation channel TRPM6 represents the first molecular key player of 
transcellular Mg2+ (re)absorption in renal and intestinal epithelia. Mutations in TRPM6 described 
for HSH patients imply that TRPM6 indeed plays a crucial role as the gatekeeper of Mg2+ 
(re)absorption. The present study indicates that a short amino acid stretch of the pore region, 
1028GEIDVC1033, determines the TRPM6 permeability properties and its sensitivity to the channel 
pore blocker, RR. Our conclusions are based on the following experimental observations. First, 
the mutant E1029A shows different permeation properties compared to wild-type TRPM6. 
Second, the estimated pore diameter of TRPM6 increases when E1029 is neutralized into an 
alanine and decreases when I1030 is changed into a methionine. Third, the sensitivity of TRPM6 
to RR block depends on the E1029 and I1030 residues in the pore forming region of the channel. 
 
TRPM6 pore localization 
Mutations that affect basic pore properties have been mainly described for the TRPV (vanilloid) 
subfamily, namely TRPV1, TRPV4, TRPV5 and TRPV6 (21-23), while the only characterized 
member of TRPM subfamily is TRPM4 (24). For TRPV5 and TRPV6, it has been shown that 
neutralization of an aspartate residue, D542 in TRPV5, which corresponds to D541 in TRPV6, 
abolishes the Ca2+ permeation, Ca2+-dependent current decay and block by extracellular Mg2+, 
whereas permeation of monovalent cations remains basically intact (25).  
Although the molecular determinants of TRPM6 Mg2+ selectivity were not fully revealed with this 
study, we obtained essential evidences that the region between the residues 1028GEIDVC1033 
forms a part of the TRPM6 pore based on the fact that neutralizing the negatively charged 
residues in this region resulted in channels with different characteristics. Moreover, replacing the 
putative selectivity filter of TRPM6 with the previously identified pores of both TRPV6 and 
TRPM4 resulted in non-functional channels (data not shown). Similarly to TRPM4, neutralizing 
the negatively charged amino acid residues in this area has dramatic consequences on TRPM6 
functionality. As demonstrated for TRPM4 (24), when mutating D1030 into alanine, which is 
conserved throughout the entire TRPM subfamily, we obtained non-functional channels. This 
non-functional phenotype could be explained by a crucial role of D1030 for the integrity of TRPM6 
pore. In contrast to TRPM4, at positions 1028 and 1036, TRPM6 contains non-charged residues 
while TRPM4 possesses glutamates at these positions and therefore, the delineation of the 
TRPM6 selectivity filter sequence appears different. However, we showed by alteration of the 
pore diameter due to mutation of E1029 and I1030 that the region from 1029 to 1031 determines 
the narrowest area of the channel pore. 
Traditionally, the minimal pore size of an ion channel can be estimated by the largest permeant 
ion that carries a measurable current (16,18). Recently, using this approach, the pore diameter 
of TRPV6 was estimated (26). Surprisingly, TRPM6-associated inward currents could be 
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measured with all organic cations including NMDG+ whereas for TRPV6, DMA+ was the largest 
cation that could permeate the channel pore (26). The remarkable inward current measured with 
NMDG+ as the sole charge carrier could be blocked in the presence of RR (data not shown), 
proving clearly that NMDG+ is able to permeate TRPM6 pore. NMDG+ permeation has been 
already described for TRPV1 and purinergic receptors P2X (27,28). For estimation of the pore 
diameter of TRPM6, fitting of the relative permeation versus the cation diameter had to be 
extrapolated because we did not find any organic cation that does not permeate through 
TRPM6. Interestingly, the estimated diameter of the TRPM6 pore (1.15 nm) is significantly 
larger compared to other channels like TRPV6 (0.54 nm), voltage-gated Ca2+ channels and 
estimations for Ca2+ release activated currents (0.38 nm in Jurkat cells and 0.32-0.55 nm in rat 
basophilic leukemia cells (29-31). However, further studies are required to debate if molecular 
sieving is the main mechanism underlying the selectivity of Mg2+ channels.  
Recently, the selectivity filter of TRPM4 was revealed by Nilius et al. (24). They demonstrated 
that the pore properties of TRPM4 are determined by a subset of amino acid residues, in 
contrast to members of the TRPV subfamily in which a single amino acid residue accounts for 
the permeability properties of the pore. Our results support their observations and prove that 
members of the TRPM subfamily have a more complex pore structure compared to their close 
relatives of the TRPV subfamily. 
 
TRPM6 pore properties 
To investigate the key determinants of TRPM6 pore properties, two main directions were 
followed: first, the negatively charged residues of the putative pore region were neutralized, and 
second, the role of the conserved D1031 and other amino acid residues in its close vicinity were 
investigated. Mutation of the three negatively charged residues in the putative TRPM6 
selectivity filter (E1024, E1029 and D1031) or in the conserved pore helix (E1012, E1016, data not 
shown) had important functional consequences since neutralization of these residues resulted in 
non-functional channels, except for E1029. These data suggest that E1012, E1016, E1024 and D1031 
play an important role in determining the pore properties of the channel. Neutralization of E1029 
did not alter the current amplitude, but significantly reduced the sensitivity to RR, and Zn2+ and 
Ba2+ conductance. Most likely, negative charge at the inner mouth of the channel pore provides 
a binding site for positively charged cations, inducing open channel block (32). These data are 
in line with the fact that the pore diameter of this mutant is increased. We suggest that E1029 
plays an important role in the TRPM6 pore architecture and takes part in the RR binding site of 
TRPM6. Second, alteration of the amino acid residues in close vicinity of the conserved D1031 
had relevant consequences as the mutation of I1030 and V1032 resulted in functional channels, but 
with different characteristics compared to wild-type TRPM6. Mutation of I1030 resulted in a 
channel with a smaller pore size. For this latter mutant additional properties have been affected: 
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I1030M is less permeable to Ni2+, but displays the same conductance for Zn2+ and Ca2+ with wild-
type TRPM6 and is more sensitive to RR. Despite the fact that Ni2+ has a smaller diameter than 
Ca2+ and Zn2+ and that I1030M forms channels with a reduced pore diameter, the altered 
conductance could be explained by differences in ion’s hydration energy with water molecules 
and by structural changes in the selectivity filter encompassing the permeation of ions (33). 
Next, the V1032A mutant showed no change in RR block and pore diameter, but had decreased 
current amplitudes indicating that the molecular determinants of the TRPM6 gating parameters 
may lay up-stream in the TRPM6 sequence. None of these mutations (E1029, I1030, V1032) affected 
the Ca2+ and Mg2+ sensitivity which is in line with the hypothesis that pore mutations are not 
expected to influence Ca2+ binding to the activation site(s) (34). 
We and other groups (6,13) are able to record TRPM6-associated currents in HEK293 cells 
without co-expressing TRPM7, whereas Gudermann and co-workers suggested that TRPM6 
requires co-expression with TRPM7 to form functional channels at the plasma membrane (11). 
Moreover, Li et al. could demonstrate functional differences at the divalent ions permeation and 
single channel conductance between homomeric TRPM6 and TRPM7 and heteromeric 
TRPM6/TRPM7 channels (13). These apparent contradictions could be reconciled by the fact 
that we can detect low TRPM7-like endogenous currents in non-transfected HEK293 cells.  
In conclusion, the molecular determinants of Mg2+ selectivity and permeation of TRPM6 appear 
to be determined by changes in a stretch of amino acid residues from the pore region, 
1028GEIDVC1033, rather than by a single residue as demonstrated for the Ca2+ selective TRPV5 
and TRPV6 channels. Subsequent studies like crystallographic assays will be needed to 
investigate in more detail the pore structure of TRPM6. 
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INTRODUCTION 
Many physiological functions rely on the precise maintenance of body Ca2+ and Mg2+ balance, 
which are tightly regulated by the concerted actions of intestinal absorption, renal reabsorption, 
and exchange with bone. The kidney plays a central role in the homeostasis of divalent ions. 
Ca2+ and Mg2+ reabsorption occurs mainly in the proximal tubules and the thick ascending limb 
(TAL) of Henle's loop via a passive paracellular pathway (Figure 1A). At the level of the distal 
convoluted tubule (DCT) and the connecting tubule (CNT), Ca2+ and Mg2+ are reabsorbed via an 
active transcellular route (Figure 1A). In these kidney segments, reabsorption of divalents is 
regulated in a Ca2+ and Mg2+-specific manner and it determines the final excretion in the urine.  
 
 
By studying several mice models for Ca2+-related disorders, the epithelial Ca2+ channels, 
TRPV5 and TRPV6 have been demonstrated to act as physiological gatekeepers of active Ca2+ 
transport (1-4). Therefore, a tight regulation of TRPV5 and TRPV6 is of particular importance 
since it determines the amount of Ca2+ excreted and consequently affects Ca2+ homeostasis. In 
this respect, the hormonal regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 has 
been extensively studied. It was demonstrated that activation of transcription/translation of 
TRPV5 and TRPV6 by the parathyroid hormone (PTH), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 
dietary Ca2+ and 17β-estradiol (2,6-9) increased active Ca2+ reabsorption (Figure 1B). However, 
Figure 1. Cellular regulation of epithelial Ca2+ channels, the gatekeepers of renal Ca2+ reabsorption. (A) 
Overview of the Ca2+ reabsorption process along the nephron consisting of the proximal tubule (PT), the thick 
ascending limb of Henle’s loop (TAL) and the distal convoluted tubule (DCT). The reabsorbed proportions from 
the total filtered amount of Ca2+ at the glomeruli are indicated in percentages. (B) Cartoon depicting: the long-term 
transcriptional/translational effect of hormones (PTH, 1,25(OH)2D3, dietary Ca2+, 17β-estradiol); intracellular 
factors affection the biophysical properties of the channel (pH, [Ca2+]i); the effect of accessory proteins indirectly 
affecting the trafficking of the channels to the plasma membrane (S100A10/annexin2, Rab11a, NHERF2, 
FKBP52) or directly affecting channel gating at the plasma membrane (Ca2+ binding proteins, RGS2); the effect of 
new calciotropic factors from the pro-urine acting directly (klotho) or via GPCR (tissue kallikrein) to control the 
plasma membrane abundance of the channels. 
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dietary Ca2+ and 17β-estradiol (2,6-9) increased active Ca2+ reabsorption (Figure 1B). However, 
the regulation of these ion channels is also governed via accessory proteins that control their 
activity (10), beside long-term effect of hormones affecting the transcription/translation of these 
proteins (Figure 1B). We identified a number of auxiliary proteins as critical components 
modulating the activity of epithelial Ca2+ channels (10). The characterization of these accessory 
proteins provided insights in important molecular pathways modulating Ca2+ transport. This 
thesis describes the identification and characterization of auxiliary proteins regulating TRPV5 
and/or TRPV6. Tissue kallikrein (TK) (chapter 2) and the extracellular Ca2+-sensing receptor 
(CaSR) (chapter 3) were selected based on previous knowledge of their involvement in Ca2+ 
homeostasis. FK506 binding protein (FKBP) was selected by a microarray assay (chapter 4), 
while RGS2 (chapter 5) was identified by yeast-two-hybrid screening for proteins binding the 
amino-terminal region of TRPV6. Moreover, the identification of the epithelial Mg2+ channel 
TRPM6 as the gatekeeper of active Mg2+ reabsorption provided new insights in our 
understanding of renal Mg2+ wasting. In chapter 6 of this thesis, the molecular determinants of 
cation permeation through TRPM6 are described together with the implications of channel 
function for overall Mg2+ homeostasis. 
 
Extracellular factors control the epithelial Ca2+ channels 
The studies included in this thesis proved the existence of calciotropic factors present in the pro-
urine (Figure 2) that control the activity of TRPV5, the gatekeeper of active renal Ca2+ 
reabsorption. Firstly, the anti-aging hormone klotho regulates TRPV5 activity via a novel 
mechanism modifying its glycosylation status, thereby entrapping the channel at the cell 
surface. Secondly, functional characterization of TK-/- mice revealed that these animals exhibit a 
pronounced hypercalciuria, analogous to the Ca2+ leak observed in TRPV5-/- mice. The study 
described in chapter 2 demonstrated that TK stimulates active Ca2+ reabsorption via the 
bradykinin (BK) receptor type 2 pathway involving protein kinase C (PKC)-dependent activation 
of TRPV5. In addition, the study included in chapter 3 implies that extracellular CaSR activation 
leads to increased TRPV5 activity. Furthermore, the extracellular pH appears to act as a 
dynamic switch controlling cell surface expression of TRPV5. In the following pages, the 
mechanisms for controlling TRPV5 activity by these novel calciotropic factors will be discussed.  
 
Klotho enhances TRPV5 activity 
In 1997, Kuro-o et al. (11) described a transgenic mice line with a single genomic insertion of a 
transgene, phenotypically resembling several age-related disorders. The affected gene was 
named klotho, after the Greek goddess who spins the thread of life. Besides a shortening of 
their lifespan, these infertile mice exhibit several characteristics frequently associated with 
human premature aging syndromes including arteriosclerosis, osteoporosis, skin atrophy and 
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ectopic calcification (14). Interestingly, overexpression of klotho in mice resulted in a significant 
extension of lifespan and suppression of aging related symptoms (12). Allelic variations of the 
klotho gene are related to life expectancy and coronary artery disease in humans (13-15). The 
klotho gene encodes a single-pass transmembrane protein with an amino terminal signal 
sequence, a putative extracellular domain with two internal repeats and a short intracellular 
domain at the carboxyl-terminus. Klotho is predominantly expressed in DCT/CNT of the kidney 
(16), and to a lesser extent in the choroid plexus of the brain (11), and the parathyroid glands 
(17). After cleavage, the amino-terminal domain of klotho is secreted into the urine, blood and 
cerebrospinal fluid (16,18). This secreted form exhibits β-glucuronidase activity (19). 
Ample observations connect klotho to an important role in Ca2+ homeostasis. Klotho deficient 
mice (klotho-/-) show a mild hypercalcemia (11) associated with high levels of 1,25(OH)2D3 
caused by increased activity of renal 25-hydroxyvitamin D-1α-hydroxylase (1α-OHase), which is 
the rate-limiting enzyme in 1,25(OH)2D3 synthesis (20). Dietary suppression of 1,25(OH)2D3 
levels reverted most of the klotho-/- mouse phenotype (no arteriosclerosis, osteoporosis and 
ectopic calcification), beside a prolongation of their life expectancy (24). Conversely, 
administration of 1,25(OH)2D3 induced klotho expression in the kidney (21). Klotho-/- mice exhibit 
bone abnormalities, including osteoporosis, and have ~20% lower bone mineral density 
compared to wild-type littermates (11). In humans, several single-nucleotide polymorphisms in 
klotho gene have been associated with low mineral bone density in postmenopausal women 
(22,23). Recently, it was established that klotho is involved in the regulation of TRPV5 activity 
(19). First, microarray studies revealed that klotho expression is decreased in TRPV5 knockout 
(TRPV5-/-) mice. Second, treatment of TRPV5-expressing human embryonic kidney (HEK293) 
cells with preconditioned culture medium from klotho-expressing cells strongly enhanced 
TRPV5-mediated Ca2+ currents. Third, cell surface protein labeling experiments demonstrated a 
significant raise in plasma membrane expression of TRPV5 after overnight klotho treatment 
(Figure 2). These effects could be mimicked by β-glucuronidase indicating that the enzymatic 
activity of klotho is responsible for enhanced TRPV5 activity (Figure 2). Finally, deletion of the 
conserved N-glycosylation site of TRPV5 (N358Q) abolished the klotho-mediated activation of 
TRPV5, proving that klotho affects the extracellular glycosylation status of the channel.  
Of interest, the molecular shift in protein size (~10-15 kDa) after glycosylation of TRPV5 
suggests a complex N-glycan structure consisting of at least one hundred sugar residues 
attached at position N358. Consequent to the cleavage of the N-glycan, the epithelial Ca2+ 
channels could be anchored at the plasma membrane. This effect may involve another plasma 
membrane protein(s) that could sense the glycosylation status of the channels and stabilize 
them at the cell surface. Another possible mechanism to increase plasma localization of these 
channels is to change the recycling rate of the proteins to the plasma membrane. This could be 
achieved by reducing protein degradation of the channels and stimulate their recycling towards 
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the plasma membrane. However, the actual molecular mechanism that determines the 
increased plasma membrane abundance of TRPV5 caused by klotho treatment remains to be 
discovered. 
ADP
ADP
ADP
 
 
In line with these observations, other studies demonstrated that the activity of ion channels 
could be controlled via modifications of their glycosylation status. It was shown that N-
glycosylation of TRPV4, a close relative of TRPV5, at position N651 influences channel 
expression at the plasma membrane (24). The glycosylation-defective mutant (N651Q) of 
TRPV4 displayed an increased cell surface abundance as demonstrated by expression and 
biotinylation experiments. In addition to TRP channels, the activity of voltage-gated potassium 
channels is also changed by the N-linked glycosylation status which determines the stability of 
the channel at the cell surface (25). Moreover, it was described that modifications in the N-
linked glycans of voltage-gated sodium channel subunits affect the gating of these channels 
(21). 
Interestingly, a recent study (26) postulated that klotho could influence Ca2+ reabsorption by an 
alternative mechanism. In the choroid plexus, klotho increases the plasma membrane 
Figure 2. Regulation of renal Ca2+ reabsorption by new calciotropic factors. Scheme depicting an epithelial 
cell from the distal convoluted tubule (DCT) showing the molecular effects of klotho, tissue kallikrein and 
extracellular pH on TRPV5 channel activity. Ca2+ enters the cell from the pro-urine via TRPV5 and is sequestered 
by Ca2+-binding protein (CaBP28K). Next, bound Ca2+ diffuses to the basolateral site of the cell where it is extruded 
into the blood compartment via NCX1 and/or PMCA1b. Klotho exerts its effect by hydrolysis of the N-glycosylated 
TRPV5 channel, thereby stabilizing the channel complex at the apical plasma membrane. This will enable 
prolonged transcellular Ca2+ transport across the epithelium. Tissue kallikrein activates the bradykinin receptor 2 
(B2R) resulting in protein kinase C (PKC) dependent phosphorylation of TRPV5 at the plasma membrane. Urinary 
pH controls trafficking of TRPV5 channels to and from the plasma membrane. 
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localization of Na+,K+-adenosine triphosphatase (Na+,K+-ATPase). This effect of klotho might 
also occur in the kidney, where the Na+ gradient created by increased Na+,K+-ATPase plasma 
membrane levels stimulates passive Ca2+ reabsorption. In conclusion, klotho can directly 
increase the renal Ca2+ entry pathway capacity (more TRPV5 channels in the plasma 
membrane) or indirectly stimulate passive renal Ca2+ reabsorption via increased transepithelial 
driving force (by affecting Na+,K+-ATPase localization), for an efficient and integrated control of 
Ca2+ balance (27). 
The implications of these klotho-related studies are potentially far-reaching given the diversity 
and ubiquitous presence of ion channel glycosylation and add new dimensions to the potential 
mechanisms of channel regulation (28). 
 
Tissue kallikrein stimulates Ca2+ reabsorption 
TK is the main kinin-forming enzyme in mammals (29) and is produced in the kidney (30), where 
it co-localizes with TRPV5 (3,31). Beside being one of the major proteins that is synthesized in 
the nephron and secreted into the tubular fluid, TK displays serine protease activity and 
converts kininogen to kinin, which then acts through kinin receptors such as the BK receptor 
type 2 (B2R) (32). Remarkably, TK can also directly activate the B2R independently of BK 
release by protease cleavage of the amino-terminal domain of B2R (33). Previous studies 
indicate that the kallikrein-kinin system plays an important role in blood pressure regulation, salt 
sensitivity, water balance and electrolyte excretion (34). Furthermore, it was demonstrated that 
TK knockout (TK-/-) mice show a marked hypercalciuria as an effect of impaired renal tubular 
Ca2+ reabsorption (31), a feature similar to the phenotype of TRPV5-/- mice (5). The striking 
increase in Ca2+ excretion exhibited by TK-/- mice is not accompanied by changes in Ca2+, PTH 
and 1,25-(OH)2D3 blood concentrations. 
The molecular mechanisms by which TK influences renal Ca2+ reabsorption are described in 
chapter 3 (35). TK significantly enhanced transcellular Ca2+ transport in primary cultures from 
rabbit CNT/cortical collecting duct (CCD) cells. This stimulation could be mimicked by 
application of BK and was prevented by a B2R antagonist demonstrating the involvement of the 
B2R in the stimulatory effect of TK (Figure 2). An increase in TRPV5-mediated currents was 
observed after TK treatment, explaining the enhanced Ca2+ transport. The role of phospholipase 
C (PLC) in TK-dependent increase of TRPV5 activity was investigated using PLC inhibitors. 
Inhibition of PLC prevented the stimulatory effect of TK. In accordance with previous 
observations, application of a cell permeable analog of diacylglycerol (DAG), oleyl-acetyl-
glycerol (OAG), which activates PKC, also increased TRPV5 activity, suggesting the 
involvement of the PLC/DAG/PKC pathway (Figure 2). Detailed sequence analysis of TRPV5 
indicated that the channel contains six putative PKC phosphorylation sites. From these sites, 
only inactivation of serines at positions 299 and 654 into alanine rendered TRPV5 completely 
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insensitive to TK. Additionally, cell surface protein labeling experiments revealed that TK 
treatment significantly enhances expression of TRPV5 at the plasma membrane. Contrary, TK 
did not affect the cell surface abundance of the PKC phosphorylation-defective TRPV5 mutants 
S299A and S654A. Importantly, TK treatment did not affect TRPV5 closest homolog, TRPV6, 
since the serine at position 654 is not conserved in TRPV6. Therefore, it appears that both 
serine residues are critical for stimulation by TK. Pulse-chase assays demonstrated a slow 
internalization rate of TRPV5 from the plasma membrane after TK treatment pointing to a 
delayed retrieval of the channel complexes from the plasma membrane as possible mechanism. 
Interestingly, it was shown that a member of the Shaker family of potassium channels, the 
voltage-gated potassium channel Kv1.3, is regulated by changes in its phosphorylation status 
(36). Pulse-chase experiments showed an increased half-life residence time of the 
phosphorylated form of these channels at the cell surface. 
Our study demonstrated a significant role of TK as a new calciotropic factor in the pro-urine. 
Beside its well described functions in the regulation of water-Na+ balance and consequently in 
controlling blood pressure, TK secreted in the pro-urine is also involved in local regulation of 
active Ca2+ reabsorption. This effect may be important in the spatial-temporal regulation of body 
Ca2+ homeostasis, since it can lead to precise and rapid changes in the cell surface localization 
of the epithelial Ca2+ channel TRPV5, the gatekeeper of active renal Ca2+ transport. The 
autocrine and/or paracrine stimulation of TRPV5-mediated renal Ca2+ reabsorption by TK 
represents a new mechanism efficiently controlling Ca2+ excretion. 
 
Activation of the Ca2+-sensing receptor stimulates TRPV5 activity 
Until the cloning of the extracellular CaSR, it was unclear how the body can sense the 
extracellular Ca2+ concentration. The molecular cloning of CaSR, functioning as G protein-
coupled receptor (GPCR) in bovine parathyroid gland, proved that extracellular Ca2+ serves as 
extracellular first “messenger” in addition to its well-recognized functions as intracellular second 
messenger (38). Consequent to its molecular cloning, many subsequent studies addressed the 
function of CaSR in Ca2+ homeostasis. In chief cells from the parathyroid glands, CaSR senses 
elevated blood Ca2+ concentration and signals via Gαi and Gαq to regulate multiple second 
messengers. The result of CaSR activation and subsequent intracellular signaling is a reduction 
in PTH secretion from the parathyroid glands. Lower circulating PTH levels reduce renal Ca2+ 
reabsorption resulting in lower blood Ca2+ concentration. Beside its localization in the 
parathyroid glands, CaSR is expressed also in other tissues such as bone, intestine and kidney, 
all being important players in maintaining body Ca2+ balance. In the kidney, CaSR is present at 
the luminal side of the proximal and DCT and basal lateral membranes of the thick ascending 
limb (41).  
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In TAL, CaSR functions to regulate Ca2+ excretion and in the distal tubules, controls 
vasopressin mediated water flux. Although CaSR is co-expressed with TRPV5 at the apical 
membrane of the cells from DCT and CNT, the functional correlation between these two 
important proteins for Ca2+ homeostasis was until now poorly investigated. The study in 
chapter 4 describes for the first time a functional link between CaSR and TRPV5 (Figure 1B). 
Consequent to CaSR stimulation, the down-stream signaling pathway is activated and TRPV5 
activity is enhanced. The effect of CaSR stimulation with neomycin is specific for TRPV5 since 
the activity of its closest relative, TRPV6, was unaffected subsequent to CaSR activation. The 
molecular mechanism involved in this effect is dependent of the PLC/PKC signaling cascade. 
Using inactivating point mutations of the six putative PKC phosphorylation sites in TRPV5, we 
demonstrated that only two residues, S299 and S654 account for the increased channel activity 
consequent to CaSR stimulation. Furthermore, a pharmacological approach was used to down-
regulate the PMA sensitive isoforms of PKC, demonstrating the one of these proteins is involved 
in the signaling pathway that connects CaSR activation to TRPV5 enhanced activity. The results 
are in concordance with our previous work, in which the same signaling cascade leads to 
increased TRPV5 activity upon activation of another GPCR, the B2R, by TK (36). Our study 
provided answers to the question concerning the role of CaSR in renal DCT/CNT. It is 
interesting that CaSR in DCT/CNT has an opposing effect on Ca2+ reabsorption compared to its 
function in the parathyroid glands or the apical segments of the nephron. Moreover, in a 
previous study (37) it was postulated that activation of CaSR expressed at the basolateral 
membrane of Madin-Darby canine kidney (MDCK) cells inhibits Ca2+ transport by inhibiting 
PMCA. However, our results show that, activation of the CaSR presumably expressed at the 
apical membrane of DCT/CNT cells, increase TRPV5-mediated Ca2+ entry. These apparently 
contradicting findings could be conciliated by considering the expression site of the CaSR in 
these studies. Increased blood Ca2+ concentrations could activate the CaSR expressed at the 
basolateral membranes determining reduction in Ca2+ reabsorption. Alternatively, increased 
Ca2+ concentrations in the pro-urine activate CaSR expressed at the apical membranes, which 
in turn stimulate Ca2+ reabsorption. A balance of these two processes allows a precise control of 
urinary Ca2+ excretion.  
Since there is a clear correlation between high Ca2+ levels in the urine and kidney stones 
formation, the body employs precise mechanisms to sense variations of Ca2+ levels in the pro-
urine. In addition, increased Ca2+ concentration in the pro-urine is a sign for hypercalciuria 
besides being a sign of increased water reabsorption, and therefore, the organism is able to 
trigger compensatory mechanisms. Therefore, the expression of CaSR at the apical membrane 
of epithelial cells from DCT/CNT and its potential functional role unveiled in this study may 
represent a new pathway of a local feedback mechanism to rapidly control urinary Ca2+ 
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excretion. These results provide new clues in our understanding of the regulation of renal Ca2+ 
reabsorption. 
 
Pro-urine pH dynamically controls TRPV5 activity 
Acid-base homeostasis is known to affect renal handling of Ca2+ (38). In the past, the clinical 
effect of chronic metabolic acidosis and metabolic alkalosis on Ca2+ reabsorption in the distal 
part of the nephron was intensively investigated. Urinary Ca2+ excretion increases during 
metabolic and respiratory acidosis (39). This is attributed to direct effects of acidosis on active 
Ca2+ reabsorption in the distal part of the nephron. Conversely, metabolic alkalosis in, for 
example, the milk-alkali syndrome, volume contraction, or treatment of nephrolithiasis by 
bicarbonate supplementation enhances Ca2+ reabsorption (43). The effects of chronic acidosis 
and alkalosis on Ca2+ reabsorption could be explained by variations in expression levels of the 
key proteins for this process such as TRPV5 and the calbindin-D28K (43). Beside the effects of 
chronic alterations in acid-base homeostasis on TRPV5 expression, pH changes could directly 
influence TRPV5 activity. In this aspect, it was shown that acidification of the apical medium 
inhibits transcellular Ca2+ transport in primary cultures of rabbit CNT/CCD cells (40). Moreover, it 
was demonstrated that acidification of the extracellular medium reduces TRPV5-mediated 
currents, affecting the current kinetics, Mg2+ blockage as well as the Ca2+ affinity (41). Recently, 
there were indications that mutation of the glutamate at position 522 into glutamine (E522Q) in 
TRPV5, decreases inhibition of the channel by extracellular protons (42), suggesting that this 
amino acid residue controls conformational changes of the pore helix caused by extracellular 
acidification (43). However, a novel molecular mechanism was proposed (44) to explain the 
direct effects of pH on TRPV5 activity by showing that extracellular pH regulates the plasma 
membrane recruitment of TRPV5 (Figure 2). Despite this apparent controversy, all observations 
show an important physiological role of extracellular pH in determining TRPV5 activity. 
Extracellular pH controls the TRPV5 activity at two levels: determines the levels of TRPV5 
expression at the plasma membrane, and gates the channels at the cell surface. Extracellular 
acidification rapidly reduced, whereas alkalinization increased TRPV5-mediated currents. Total 
internal reflection fluorescence (TIRF) microscopy experiments revealed that alkalinization of 
the extracellular media determines the rapid recruitment of TRPV5-containing vesicles towards 
the plasma membrane, whereas acidification controls the retrieval of the same vesicles. 
Lambers and colleagues demonstrated that the effect of extracellular pH is specific for TRPV5 
channels trafficking, since the movements of TRPM7-containing vesicles were unaffected by pH 
changes. However, extracellular pH affects directly the gating of other channels beside TRPV5, 
e.g. TRPM7 (45). Therefore, it is tempting to speculate that, in physiological conditions, 
extracellular pH controls TRPV5 activity mainly by affecting the trafficking of the channels 
towards the plasma membrane. Cell surface protein labeling assays further substantiated this 
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finding showing that increased extracellular pH triggers an increase in plasma membrane 
abundance of TRPV5 channels. This effect was additionally confirmed using 
methanethiosulfonate derivate (MTSET), a compound that irreversibly binds to a cysteine 
residue within the TRPV5 sequence inactivating the channels present in the plasma membrane 
(46). The functional recovery in TRPV5 activity after chemical inactivation with MTSET is 
enhanced by an alkaline pH. Altogether, these experiments provided evidence that changes in 
pH regulate TRPV5 activity by controlling its trafficking towards the cell surface. Although it was 
clearly demonstrated that extracellular pH controls the plasma membrane recruitment of 
TRPV5, the molecular machinery underlying this process needs to be clarified. It is still unclear 
how extracellular pH is sensed by the intracellular vesicles containing TRPV5. Variations in 
extracellular pH may affect the intracellular pH (40), which is shown to control the movement of 
intracellular trafficking vesicles to and from the plasma membrane. However, another potential 
mechanism is the existence of a plasma membrane proton sensor that translates extracellular 
pH changes into intracellular signals, leading to recruitment of TRPV5 containing vesicles 
towards the plasma membrane. Unraveling the molecular mechanisms by which pH affects 
TRPV5 activity increase our knowledge about the regulation renal Ca2+ reabsorption, and 
contribute to the concept of the pH-dependent regulation of other ion transport proteins.  
 
Regulation of epithelial Ca2+ channels by accessory proteins 
A number of regulatory proteins have recently been described that modify the biophysical, 
pharmacological, and expression properties of ion channels and transporters by direct protein-
protein interactions. These newly identified associated proteins have facilitated the elucidation 
of important molecular pathways modulating ion transport. Similarly, identification of the 
molecular players that associate with TRPV5 and TRPV6 could be pivotal in our understanding 
of the regulation of these channels. 
 
The immunophilin FKBP52 inhibits TRPV5 activity 
FKBP was one of the genes determined by microarray assay to be regulated by dietary Ca2+ 
supplementation of 1α-OHase deficient mice (47). FKBP52 is a widely expressed cytosolic 
enzyme that belongs to the FKBP subfamily of immunophilin proteins (48-50). FKBP proteins 
are characterized by their peptidyl-prolyl cis-trans isomerase (PPIase) activity, as well as by 
their strong affinity to immunosuppressive drug FK506 (49). The PPIase has a chaperoning 
activity that often constitutes a rate-limiting step in protein folding and can be inhibited by FK506 
(49). The immunosuppressive drug FK506 cause as common side-effect hypercalciuria. 
Chapter 2 describes the co-localization of FKBP52 with TRPV5 in the DCT and CNT of the 
kidney and its putative role in regulating TRPV5 activity. To investigate the role of FKBP52 in 
TRPV5 regulation a small-interference (si)RNA approach was developed. Knocking-down 
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FKBP52 gene expression resulted in enhanced TRPV5-mediated Ca2+ influx suggesting an 
inhibitory role for FKBP52 on TRPV5 activity (Figure 1B). Consistent with our findings on the 
inhibitory effect of FKBP52 on TRPV5 activity, is a previous study that identified the FKBP52 
Drosophila melanogaster homologue, FKBP59, as physiological regulator of TRPL channel 
activity (51). FKBP59 interacts directly with the highly conserved TRPL sequence 
701LPPPFNVLP709 and inhibits Ca2+ influx. In Drosophila melanogaster (51) as well as in 
mammals (52) the proline residue of the first LP-motif, located next to mouth of the channel 
pore, plays a crucial role in this association. Conspicuously, TRPV5 contains such a LP motif 
next to the pore region at the amino acidic position 551-552, where the FKBP52 binding site is 
located. The FK506 drug has been shown to mimic the LP-dipeptide (53) and to disrupt the 
FKBP52 interaction with TRPCs (52). However, FK506 did not interrupt the FKBP52-TRPV5 
association suggesting an alternative mechanism. This means that FK506 binds TRPV5 and 
modulates its activity without displacing the association of FKBP52, similar to the mechanism 
previously described for the regulation of the Drosophila melanogaster homologues FKBP59 
and TRPL (51). The physiological relevance of the latter hypothesis needs further confirmation 
since it is based on in vitro experiments. 
In addition, we demonstrated that ablation of FKBP52 PPIase activity either by FK506 
administration or by mutation of the FKBP52 catalytic site resulted in the inhibition of TRPV5 
channel. We hypothesized that FKBP52 affects TRPV5 activity by affecting trafficking of the 
channels to the cell surface (Figure 1B). FKBP52 co-localizes with microtubules of the 
cytoskeleton and binds to cytoplasmic dynein (54,55), a motor protein responsible for the 
movement of vesicles along microtubules. Association of dynein to FKBP52 depends on the 
PPIase domain and defines the trafficking of steroid receptors to the cell nucleus (55,56). 
Similarly, FKBP52 could participate in the TRPV5 trafficking towards the plasma membrane 
through its PPIase activity by binding to microtubules of the cytoskeleton. In concordance with 
our hypothesis, a recent report demonstrated association of TRPV1 channels to the 
microtubules of the cytoskeleton, while TRPV1 activation resulted in the depolymerization of 
microtubules affecting the transmission of pain sensation (57). Functional studies with FK506 in 
primary cultures of DCT/CNT epithelial cells substantiated the physiological relevance of the co-
localization of FKBP52 with TRPV5 in kidney. Submicromolar concentrations (10 nM) of FK506 
stimulate active Ca2+ reabsorption in these cells while higher concentrations have a toxic effect. 
This dose dependent effect could explain the nephrotoxicity observed in patients treated with 
this immunosuppressive drug FK506 (58,59). FK506-induced nephrotoxicity includes 
intratubular calcification and tubular basophilia in rats (61). In addition, long-term treatment (28 
days) of rats with FK506 resulted in increased bone turnover with net bone resorption (62). 
Since TRPV5 is essential in bone turnover (60), FK506 could enhance osteoclastic bone 
resorption by increasing TRPV5-mediated active Ca2+ transport. On the other hand, it has been 
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previously demonstrated that FK506 administration results in hypercalciuria (61). However, the 
doses and the duration of treatments cannot be compared between the experiments performed 
in rats and the primary cultures of DCT/CNT epithelial cells. The proposed molecular 
mechanism for the FK506-induced hypercalciuria is that FK506 down-regulates calbindin-D28K 
and TRPV5 expression. Altogether, given the complexity of the in vivo situation, the FK506-
induced hypercalciuria awaits further investigation regarding the specificity of FK506 effect and, 
in particular, concerning the role of other FKBP’s.  
 
RGS2 inhibits the epithelial Ca2+ channel TRPV6 
RGS2 was identified as a novel binding partner of TRPV6 by a yeast two-hybrid screening for 
proteins that interact with the amino terminus of TRPV6. RGS2 is a member of the RGS family 
of proteins that terminate signaling of heterotrimeric GPCR, by enhancing the GTPase activity of 
active Gα subunits (62). To date, over twenty different RGS proteins have been identified, and 
their effector functions extend beyond negative regulation of GPCR signaling. RGS proteins can 
act as effector antagonists, binding to either the effector protein or the Gα subunit to prevent an 
operative physical interaction. It has also been demonstrated that RGS proteins can interact 
with a wide variety of auxiliary proteins, such as calmodulin, spinophilin (SPL) and the 14-3-3 
protein, which can influence the subcellular localization, stability and function of RGS proteins 
(63). Chapter 5 describes the interaction of the amino terminal domain of RGS2 with the amino 
terminus of TRPV6 in a Ca2+-independent fashion, and the putative role of RGS2 in modulating 
TRPV6 functioning. To investigate the role of RGS2 in TRPV6 regulation, a combined approach 
including biochemical and functional assays was applied. Co-expression of TRPV6 with RGS2 
determined an inhibition in both Ca2+ and Na+ TRPV6-mediated currents. Interestingly, the 
currents through TRPV5, the closest homologue of TRPV6, were not affected by RGS2 co-
expression, demonstrating the specificity of the RGS effect on TRPV6. The physiological 
relevance of RGS2 binding to TRPV6 via its amino terminus was determined using a RGS2 
mutant lacking the amino-terminal domain (delta-N RGS2). Co-expression of the delta-N RGS2 
mutant with TRPV6 did not affect the current. To support our findings, the amino-terminal 
domain RGS2 has already been described as an important regulatory site for this protein. 
Together with the “RGS-box” domain, it is necessary for interactions with RGS2 effector 
proteins, GPCRs, and/or auxiliary proteins such as SPL. Since we showed that RGS2 does not 
affect the plasma membrane abundance of TRPV6 by biotinylation experiments, the inhibitory 
effect of RGS2 on TRPV6-mediated currents is mediated directly at the plasma membrane 
(Figure 1B). Therefore, RGS2 needs to be recruited to the cell surface to affect the gating 
properties of TRPV6. In this aspect, it has been previously demonstrated that G-proteins recruit 
RGS proteins to the plasma membrane (64). However, the actual mechanism to explain the 
RGS2 inhibition of TRPV6 channels, still remains to be investigated. It is tempting to speculate 
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that RGS2 protein, upon binding to TRPV6, can determine conformational changes affecting the 
pore structure and altering the regular functioning of the channel. Future experiments, such as 
cysteine substitution of the amino acid residues in the TRPV6 pore, are needed to clarify this 
aspect. On the other hand, RGS2 may affect TRPV6 activity by closing either by blocking the 
channels at the plasma membrane. Given that TRPV6 forms constitutively active channels, 
measuring the single channel activity of TRPV6, may be the method of choice to study the 
actual mechanism of RGS2 inhibition on TRPV6 activity. 
In addition, SPL has been shown to be involved in RGS protein recruitment to the plasma 
membrane (65). The inhibitory effect of RGS2 on TRPV6 activity is independently regulated of a 
GPCR and is mediated by a direct interaction between RGS2 and TRPV6. These findings 
suggest that the activity of TRP channels may be directly controlled by interacting proteins at 
the plasma membrane. 
 
TRPM6 channel, the gatekeeper of active Mg2+ transport 
TRPM6 together with its closest relative, TRPM7, are the only channels from the TRPM family 
known to be permeable for Mg2+. Unlike other members of the TRP family, TRPM6 and TRPM7 
contain α-kinase domains in their carboxyl-terminal tails (66). The identification of TRPM6 
(67,68) as the gene mutated in patients suffering from hypomagnesemia with secondary 
hypocalcemia (HSH) represents the first case in which a human disorder has been attributed to 
a channel kinase. Correlated to its role in Mg2+ homeostasis, TRPM6 protein is specifically 
localized along the apical membrane of the renal DCT, colon and the brush-border membrane 
of the small intestine, epithelia particularly associated with active Mg2+ (re)absorption (66). 
When heterologously expressed, TRPM6 induces an Mg2+ and Ca2+ permeable cation channel 
with a 5-fold higher affinity for Mg2+ than for Ca2+, tightly regulated by intracellular Mg2+ levels. 
Despite the initial functional characterization of TRPM6, the molecular determinants of its Mg2+ 
permeability remained unknown. To date, limited understanding exists concerning the structure 
of TRP channels pores and lesser is known about TRPM pores. The study in chapter 6 
describes the role of amino acid residues from the putative selectivity filter of TRPM6 in the 
permeation properties of the channel. A short amino acid stretch from the pore region, 
1028GEIDVC1033 (Figure 3A), determines the conductivity properties of the channel and the 
channel sensitivity to the channel pore blocker, the hexavalent cation ruthenium red. The 
structure of the loop between the fifth and the sixth transmembrane domains was modeled 
based on the crystal structure of the K+ channel KcsA (69) (Figure 3). In this region, TRPM6 
shares two conserved amino acid residues, E1024 and E1029, with its closest homologue 
TRPM7. All members of the TRPM subfamily contain a conserved aspartate residue (D1031 in 
TRPM6), that could be and important structural component of their selectivity filters. Point 
mutations in the TRPM6 putative selectivity filter resulted in three different phenotypes: E1029A 
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with current amplitudes similar to wild-type TRPM6 channel, I1030M and V1032A with reduced 
current amplitudes, while the mutants E1024A and D1031A showed no measurable currents 
(Figure 3A). This non-functional phenotype of D1031A could be explained by a crucial role of 
this residue in maintaining the integrity of the TRPM6 pore, as demonstrated for TRPM4 (70) or 
could be explained by the endoplasmic reticulum retaining of these mutant proteins. The 
ultimate prove to solve this dilemma will come from investigations of cell surface expression of 
these proteins.  
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Recently, a study by Li and colleagues (71) implied that the stretch of amino acid residues from 
the position 1024 to 1029 are key determinants of the TRPM6 permeation properties. Moreover, 
this study showed that the negatively charged residues at positions E1024 and E1029 are 
involved in the pH sensitivity of TRPM6. These results, apparently contradicting our findings, 
could be reconciled by the hypothesis that the residues before the position E1024 are part of a 
putative α-helix actually sustaining the selectivity filter of the channel. Disrupting this α-helix 
structure may destabilize the channel pore leading to the formation of non-functional channels. 
It appears that the pore structure of TRPM channels is more complex than the pore structures of 
other TRP channels. In this respect, Oberwinkler and colleagues recently identified several 
TRPM3 spliced variants, TRPM3α1-5 (72). While the TRPM3α-2 displayed high permeability to 
Ca2+ and Mg2+, TRPM3α-1, which includes an additional stretch of 12 amino acids following the 
conserved aspartate, a residue equivalent to D1031 in TRPM6, exhibited a more than 10-fold 
Figure 3. Modeling of the selectivity filter of the epithelial Mg2+ channel TRPM6 based on the pore 
structure of the KcsA channel. (A) Sequence alignment of putative pore regions of TRPM6 and its closest 
relative TRPM7. (B) The amino acid residues lining the pore of TRPM6 channel are depicted in frontal as in 
lateral view. Localization of the key determinants of TRPM6 permeability is indicated by arrows. The 3-D modeling 
of the TRPM6 pore region was performed using Swiss Model software (5) using the pore structure of KcsA as 
template. 
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lower permeability for divalent cations (72). This can be explained by a possible re-arrangement 
of the pore structure caused by this stretch of additional twelve residues. 
The increased estimated size of the TRPM6 pore diameter when E1029 is mutated and the 
decreased when I1030 is neutralized, demonstrated that the region from 1029 to 1031 
determines the narrowest area of the channel pore (Figure 3). E1029A showed an increased 
pore diameter, reduced ruthenium red sensitivity and conductance to Zn2+ and Ba2+ compared 
to wild-type TRPM6. Most likely, the negative charges at the inner mouth of the pore provide a 
binding site for positively charged cations, inducing open channel block (73). Our findings 
constitute the first evidence that permeation properties of Mg2+ permeable channels are 
determined by a stretch of amino acid residues (Figure 3), rather than single amino acid 
residues as for the Ca2+-selective TRPV5 and TRPV6 channels (74,75). 
 
Conclusions and future perspectives  
Active Ca2+ reabsorption in the kidney represents a key process in Ca2+ homeostasis. Since 
TRPV5 is the rate-limiting step in Ca2+ entry, tight control of its activity enables us to adjust Ca2+ 
reabsorption to varying Ca2+ demands of the body. The experimental data summarized in the 
first two studies from this thesis indicate the existence of novel calciotropic factors that act from 
the pro-urine to regulate active Ca2+ reabsorption. The control of cell surface expression of the 
TRPV5 channel by its N-linked glycosylation status, its PKC-dependent phosphorylation and by 
extracellular pH describes new ways for an efficient control of the body Ca2+ balance. Moreover, 
as described in the studies included in this thesis, associated proteins control from the 
intracellular compartment the activity of the epithelial Ca2+ channels. In conclusion, the function 
of the epithelial Ca2+ channels is controlled intracellular by accessory proteins and extracellular 
by novel calciotropic factors. The major challenges in the future are to completely understand 
how these mechanisms that functionally regulate the epithelial Ca2+ channels are integrated in 
the complex machinery involved in maintaining body Ca2+ balance. As discussed in the last 
study from this thesis, unraveling the molecular determinants of permeation through TRPM6 
pore opens new lines in our understanding of general permeation characteristics of ion 
channels and particularly, Mg2+ permeation. Future challenges lay ahead in correlating the 
molecular mechanisms controlling the epithelial Ca2+ and Mg2+ channels activity with their 
integrated role in wide physiological context. 
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SUMMARY 
Introduction 
Ion channels are specialized proteins that span the plasma membrane of living cells allowing 
ion fluxes through this essentially impermeable barrier. Most ion channels show selectivity in 
that their pores are more permeable to some ions than to others. Based on their selective 
permeability, ion channels can be subdivided in: Na+ selective channels, K+ selective channels, 
Ca2+ selective channels, Cl- selective channels, and non-selective channels that do not 
discriminate between their permeants. The development of the patch-clamp technique enabled 
the researcher for the first time to monitor in real-time the activity of ion channels in the plasma 
membrane. The TRP (Transient Receptor Potential) family consists of ion channels with 
structural similarities. TRP proteins are widely expressed in organisms and contribute to diverse 
functions and processes ranging from thermal, tactile or taste sense to transepithelial Ca2+ and 
Mg2+ transport. The epithelial Ca2+ channels TRPV5 and TRPV6 represent two highly 
homologous members of the TRP family that are mainly expressed in Ca2+-transporting 
epithelia. TRPV5 plays the role of gatekeeper for renal Ca2+ reabsorption while TRPV6 forms 
the main Ca2+ influx pathway in the small intestine. The epithelial Mg2+ channel TRPM6 
constitutes the Mg2+ entry gate for transepithelial Mg2+ transport. TRPM6 shares with its closest 
homologue, TRPM7, beside their exceptional Mg2+ permeability, the presence of an atypical α-
kinase in the carboxyl-terminal domain. A tight regulation of the epithelial Ca2+ and Mg2+ 
channels is of particular physiological importance for maintaining the body balance of these 
divalent ions. Therefore, the living organisms are equipped with an efficient feedback 
homeostatic system capable of maintaining the extracellular concentrations of these ions 
between narrow limits. The regulation of the epithelial Ca2+ and Mg2+ channels occurs at 
different levels and involves: (i) the long-term transcriptional and translational effects of 
hormones, (ii) the biophysical properties of the channels, and the effect of regulatory proteins 
acting (iii) on the trafficking of the channels to the plasma membrane or (iv) directly on its 
plasma membrane stabilization and activity. In recent years the electrophysiological properties 
of these ion channels were studied extensively, but particular aspects of the integration and 
control of their activity in a physiological context still remain to be studied. Therefore, the 
general goal of this thesis was to get further insight into the physiological and molecular 
regulation of epithelial Ca2+ and Mg2+ channels in order to ultimately understand the 
transcellular transport of these divalent cations. 
 
Tissue kallikrein stimulates TRPV5 activity 
Since it was recently demonstrated that mice lacking the serine protease tissue kallikrein (TK) 
exhibit robust hypercalciuria comparable to the Ca2+ leak in TRPV5-/- mice, we delineated the 
molecular mechanisms connecting these two proteins. TK is excreted into urine in the CNT of 
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the kidney where it overlaps TRPV5 expression. First, using animal models, we demonstrated 
that TK expression correlates with the amount of Ca2+ excreted. Furthermore, using ex vivo 
assays it was demonstrated that TK enhances transepithelial Ca2+ transport. The stimulatory 
effect of TK was mimicked by bradykinin (BK) and could be reversed by application of an 
antagonist for the BK receptor type 2 (B2R). Using TRPV5 transiently transfected cells, it was 
shown that TK application stimulates TRPV5 activity. Then, the down-stream pathway 
consequent to B2R activation was investigated. Using a phospholipase C (PLC) inhibitor and a 
cell permeable analog of diacylglycerol (DAG) it was demonstrated that TK activates the 
PLC/DAG pathway. The DAG analog increased the TRPV5 activity via protein kinase C (PKC) 
phosphorylation of the channel since inactivation of the PKC phosphorylation sites S299 and 
S654 in TRPV5 prevented TK effect. Cell surface labeling with biotin revealed that TK enhances 
the amount of TRPV5 channels at the plasma membrane by delaying its retrieval. Summarizing, 
TK stimulates Ca2+ reabsorption in the kidney via the BK activated PLC/DAG/PKC pathway and 
induces subsequently stabilization of the TRPV5 channels at the plasma membrane. 
 
Ca2+-sensing receptor activation increases TRPV5 activity 
Although the involvement of the Ca2+ sensing receptor (CaSR) in Ca2+ homeostasis was 
comprehensively studied in the recent years, its role in the DCT and CNT of the kidney, where 
TRPV5 channels are expressed, remained elusive. Using combined functional and biochemical 
assays, we demonstrated that CaSR activation results in increased TRPV5 activity. CaSR can 
be activated, beside Ca2+, by antibiotics and amino acids. We used neomycin and L-
phenylalanine to specifically activate CaSR overexpressed in HEK293 cells. Activation of CaSR, 
co-expressed with TRPV5, determines an increase in TRPV5 activity via the PKC 
phosphorylation of the channel. Inactivation of the putative PKC phosphorylation sites at 
positions S299 and S654 in TRPV5 prevented the effect of CaSR activation, proving that these 
two amino acid residues are essential for the effect. Interestingly, the activity of TRPV5 closest 
homologue, TRPV6, was not affected upon CaSR activation. Cell surface protein labeling 
revealed that CaSR activation leads to increased plasma membrane localization of TRPV5 
channels. In conclusion, we postulate a role for the CaSR in the apical compartment of the 
DCTs and CNTs in the kidney, where the CaSR is co-expressed together with TRPV5. 
 
FKBP52 inhibits TRPV5 activity 
FKBP52 is a ubiquitously expressed cytosolic enzyme characterized by the ability to catalyze 
the cis-trans isomerization of cis-peptidyl-propyl bonds, and by its strong binding to the 
immunosuppressive drug FK506. This protein was identified in a microarray screening for genes 
regulated by dietary Ca2+ supplementation of 1α-OHase deficient mice. Our study demonstrated 
that FKBP52 specifically interact and co-localize with TRPV5 in the distal part of the nephron. 
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Moreover, by functional assays, we demonstrated that FKBP52 decreases TRPV5-mediated 
Ca2+ influx. On the other hand, gene silencing of FKBP52 or administration of a FKBP52 blocker 
enhanced TRPV5 activity. The catalytic activity of FKBP52 is critical for this effect on TRPV5, 
since inactivation of its peptidyl-propyl cis-trans isomerase domain by mutagenesis prevented 
the effect. Furthermore, we demonstrated that submicromolar concentrations of FK506 
stimulate Ca2+ transport, while higher concentrations are toxic for the cells. This dose-response 
effect could explain the nephrotoxicity observed in patients treated with FK506. Certainly, given 
the complexity of the in vivo situation, the role of FK506 in hypercalciuria needs further 
investigations particularly concerning the putative role of other FKBP proteins. 
 
RGS2 inhibits TRPV6 activity 
RGS2 is a member of the RGS family of proteins that are able to terminate the signaling of 
heterotrimeric G-protein-coupled receptors (GPCR). This novel binding partner of TRPV6 was 
identified by yeast-two hybrid screening for regulatory proteins that interact with the amino-
terminal domain of TRPV6. Using comprehensive biochemical assays, as the yeast-two hybrid 
screening and pulldown analysis, we confirmed that RGS2 interacts with TRPV6 in a Ca2+-
independent fashion. Functional assays demonstrated that RGS2 reduces both Na+ and Ca2+ 
TRPV6-mediated currents. The amino-terminal tail of RGS2 protein is critical for this effect, 
since deletion of this domain by mutagenesis prevented the reduction in TRPV6 currents. 
Interestingly, the currents of TRPV5, the closest relative of TRPV6, were not affected by RGS2. 
Furthermore, cell surface biotinylation indicated that the inhibitory effect of RGS2 on TRPV6 is 
not mediated by differences in trafficking or retrieval of TRPV6 to and from the plasma 
membrane. This effect is possibly accounted from the direct interaction between RGS2 and 
TRPV6, affecting the gating properties of the channel. Finally, we showed that spinophilin, a 
scaffolding protein known to recruit RGS2, does not affect the interaction between RGS2 and 
TRPV6, indicating a GPCR-independent mechanism of TRPV6 regulation by RGS2. 
 
Molecular determinants of TRPM6 permeation properties 
TRPM6 and its closest homologue TRPM7 are members of the TRPM subfamily of cation 
channels and are known to be Mg2+ permeable. TRPM6 shares ~50% sequence homology at 
the amino acid level with its closest relative TRPM7, and atypically for other ion channels, both 
channels contain a serine/threonine protein kinase domain in their carboxyl-termini. Despite the 
initial functional characterization of TRPM6, the molecular determinants of its Mg2+ permeability 
remained unknown. Using a sequence alignment of the putative TRPM6 pore with pore 
sequences of the other subfamily members, we located in the loop between the fifth and the 
sixth transmembrane domain, a stretch of six amino acid residues as the potential selectivity 
filter. By point mutations resulting in neutralization of the negatively charged residues, we found 
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two amino acid residues as important determinants of cation permeation through TRPM6. 
Neutralization of the glutamate at position 1029 and of the isoleucine at position 1030 resulted 
in channels with modified pore diameter and decreased ruthenium red block compared to wild-
type TRPM6 channels. These findings suggest that the region between 1029 and 1031 
determines the narrowest area of the TRPM6 channel pore. Our results demonstrate that subtle 
amino acid variation in the pore region accounts for TRPM6 permeation properties. Certainly, 
given the lack of crystallography data, subsequent studies are needed to investigate the actual 
three-dimensional structure of the TRPM6 pore in more detail. 
 
Conclusion and future perspectives 
The aim of this thesis was to get more insight into the physiological and molecular regulation of 
epithelial Ca2+ and Mg2+ channels. Indeed, the first five chapters of this thesis describe the 
molecular regulation of the epithelial Ca2+ channels, TRPV5 and TRPV6, by accessory proteins. 
TK increased TRPV5 activity by affecting the PKC-dependent phosphorylation of TRPV5. 
Possibly, TK operates through a hormonal receptor, activating the PLC/DAG/PKC pathway that 
ultimately results in accumulation of TRPV5 channels at the plasma membrane by a decrease in 
their retrieval. CaSR activation increased TRPV5 activity, an effect initiated also from the 
extracellular compartment. FKBP52 inhibited the TRPV5 activity via its peptidyl-propyl cis-trans 
isomerase activity. RGS2 modulated TRPV6 activity affecting the channel gating by direct 
interaction at the plasma membrane. Finally, the study on TRPM6 permeation properties 
brought new light on the structure and function of amino acid residues from the pores of Mg2+-
permeable ion channels. Consequently, the functional characterization of accessory proteins 
controlling the function of epithelial Ca2+ channels provided molecular insight into the regulatory 
mechanisms of ion channels activity. Further investigations, on the physiological relevance of 
the role of accessory proteins in regulating the epithelial Ca2+ channels, may reveal the 
existence of new proteins networks and could elucidate the mechanisms of precise regulation 
and integration of Ca2+ homeostasis to the body’s varying demands. 
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SAMENVATTING 
Inleiding 
Ionkanalen zijn gespecialiseerde eiwitten in de plasmamembraan van levende cellen. Ze zorgen 
voor een ionenflux over de plasmamembraan die zelf in essentie impermeabel is voor ionen. De 
meeste ionkanalen vertonen selectiviteit, oftewel hun poriën zijn meer permeabel voor bepaalde 
ionen dan voor anderen. Op basis van hun selectieve permeabiliteit kunnen ionkanalen 
onderverdeeld worden in: Na+ selectieve kanalen, K+ selectieve kanalen, Ca2+ selectieve 
kanalen, Cl- selectieve kanalen en non-selectieve kanalen die geen onderscheid maken tussen 
het soort ion. De ontwikkeling van de patch-clamp techniek maakte het voor het eerst mogelijk 
om de activiteit van ionkanalen aanwezig in de plasmamembraan rechtstreeks waar te nemen. 
De Transient Receptor Potential (TRP) familie van ionkanalen bestaat uit kanalen met 
structurele overeenkomsten. Deze TRP eiwitten komen tot expressie in verscheidene 
organismen en ze spelen een rol bij diverse functies en processen, van temperatuur-, gevoels- 
of tastzintuigen tot transepitheliaal Ca2+ en Mg2+ transport. Twee homologe leden van de TRPV 
subfamilie, TRPV5 en TRPV6, zijn Ca2+ kanalen die voornamelijk tot expressie komen in Ca2+-
transporterende epitheelcellen. TRPV5 vervult de rol van poortwachter voor de Ca2+ resorptie in 
de nier, terwijl TRPV6 betrokken is bij de Ca2+ opname in de dunne darm. Het epitheliale Mg2+ 
kanaal TRPM6 vormt de Mg2+ toegangspoort bij transepitheliaal Mg2+ transport. TRPM6 heeft, 
net als zijn homoloog TRPM7, een uitzonderlijke Mg2+ permeabiliteit. Uniek voor deze kanalen 
is dat ze een α-kinase bevatten in het carboxyl terminus domein. Regulatie van de epitheliale 
Ca2+ en Mg2+ kanalen is van belang voor de ionenbalans in het lichaam. Daarom bevatten 
levende organismen een efficiënt feedback homeostase systeem dat de extracellulaire 
ionconcentraties begrenst. Er zijn diverse niveaus waarop de epitheliale Ca2+ en Mg2+ kanalen 
worden gereguleerd: via (i) de transcriptionele en translationele effecten van hormonen, (ii) de 
biofysische eigenschappen van kanalen, en door het effect van regulatoire eiwitten op (iii) het 
transport van de kanalen naar de plasmamembraan of (iv) direct op de stabiliteit en activiteit 
van de kanalen in de membraan. In de laatste jaren zijn de elektrofysiologische eigenschappen 
van deze ionkanalen intensief bestudeerd, waarbij echter bepaalde aspecten van de integratie 
en regulatie van kanaalactiviteit in een fysiologische context verder onderzoek vereisen. Dit 
proefschrift tracht meer inzicht te verschaffen in de fysiologische en moleculaire regulatie van 
epitheliale Ca2+ en Mg2+ kanalen om uiteindelijk het transcellulaire transport van deze divalente 
kationen beter te begrijpen. 
 
Kallikreine stimuleert de TRPV5 activiteit 
Recent is aangetoond dat muizen zonder de serineprotease kallikreine (TK) een hypercalciurie 
vertonen, vergelijkbaar met het Ca2+ lek in TRPV5-/- muizen. Deze studie beschrijft de 
moleculaire mechanismen die deze eiwitten verbinden. TK wordt uitgescheiden in de urine door 
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de verbindingsbuis van de nier, daar waar ook TRPV5 tot expressie komt. Door middel van een 
diermodel is aangetoond dat TK expressie correleert met de hoeveelheid Ca2+ die 
uitgescheiden wordt. Verder laten ex vivo studies zien dat TK transepithelial Ca2+ transport 
stimuleert. Het stimulerende effect van TK kan worden nagebootst door bradykinine (BK) en 
geblokkeerd worden door een antagonist van de BK receptor type 2 (B2R). Door gebruik te 
maken van TRPV5-getransfecteerde cellen is aangetoond dat toevoeging van TK de activiteit 
van TRPV5 stimuleert. Vervolgens is de navolgende route van B2R activering onderzocht. Het 
gebruik van een fosfolipase C (PLC) remmer en een celpermeabele analoog van diacylglycerol 
(DAG) heeft aangetoond dat TK de PLC/DAG route activeert. De DAG analoog verhoogt 
TRPV5 activiteit via proteïne kinase C (PKC) afhankelijke fosforylatie van het kanaal. Inactivatie 
van de PKC fosforylatieplaatsen S299 en S654 in TRPV5 verhinderde het TK effect. Door 
eiwitten op de plasmamembraan te labelen met biotine is aangetoond dat TK het aantal TRPV5 
kanalen in de plasmamembraan verhoogt door de terugname van het kanaal uit de membraan 
te vertragen. Samengevat blijkt dat TK de Ca2+ resorptie in de nier stimuleert via de BK 
geactiveerde PLC/DAG/PKC route en vervolgens de TRPV5 kanalen op de plasmamembraan 
stabiliseert. 
 
Activering van de calcium sensing receptor stimuleert de TRPV5 activiteit 
Hoewel de betrokkenheid van de Ca2+ sensing receptor (CaSR) in de Ca2+ homeostase 
intensief bestudeerd is in de afgelopen jaren, is er nog veel onbekend rondom haar rol in de 
distale en verbindingsbuizen van de nier, waar TRPV5 tot expressie komt. Door het gebruik van 
gecombineerde functionele en biochemische studies is aangetoond dat activering van de CaSR 
resulteert in een verhoogde TRPV5 activiteit. De CaSR kan naast activatie door Ca2+ ook 
geactiveerd worden door bepaalde typen antibiotica en aminozuren. In een overexpressie 
celmodel is gebruik gemaakt van neomycine en L-fenylalanine om specifiek de CaSR te 
activeren. Co-expressie van TRPV5 en de CaSR, waarbij de CaSR geactiveerd wordt, leidt tot 
een verhoogde TRPV5 activiteit via PKC fosforylatie van het kanaal. Inactivatie van de 
mogelijke PKC fosforylatieplaatsen S299 en S654 in TRPV5 verhinderde het effect van CaSR 
activatie op het kanaal, dat aantoont dat deze twee aminozuren essentieel zijn voor het effect. 
Daarnaast bleek de activiteit van de TRPV5 homoloog, TRPV6, niet beïnvloed te worden door 
CaSR activatie. Het labelen van de plasmamembraan eiwitten toonde aan dat CaSR activatie 
leidt tot een verhoogd aantal TRPV5 kanalen in de plasmamembraan. Deze studie beschrijft 
voor het eerst een mogelijke rol van de CaSR aan de apicale zijde van de distale en 
verbindingsbuizen in de nier, waar de CaSR samen met TRPV5 tot expressie komt. 
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FKBP52 remt TRPV5 activiteit 
FKBP52 is een cytosolisch enzym met een breed expressiepatroon. Het kan de cis-trans 
isomerisatie van cis-peptidyl-propyl verbinding katalyseren en het bindt aan de 
immunosuppressieve drug FK506. FKBP52 is geïdentificeerd door middel van een microarray 
screening naar genen die gereguleerd worden door Ca2+-diëten in 1α-OHase knock-out muizen. 
Deze studie laat zien dat FKBP52 een specifieke interactie aangaat met TRPV5 en dat er 
sprake is van co-lokalisatie met TRPV5 in het distale deel van het nefron. Bovendien is door 
middel van functionele analyse aangetoond dat FKBP52 de TRPV5-afhankelijke Ca2+ influx 
remt. Verder blijkt remming van FKBP52 gentranslatie, of door toevoeging van een FKBP52 
remmer, de TRPV5 activiteit te stimuleren. De katalytische activiteit van FKBP52 is essentieel 
voor het effect op TRPV5, want inactivatie van het peptidyl-propyl cis-trans isomerase domein 
door mutagenese kon het effect voorkomen. Verder is aangetoond dat submicromolaire 
concentraties van FK506 Ca2+ transport kan stimuleren, terwijl hogere concentraties toxisch zijn 
voor de cellen. Dit dosisafhankelijke effect kan de nefrotoxiciteit verklaren die voorkomt in 
patiënten die behandeld worden met FK506. Gezien de complexiteit in de in vivo situatie zal de 
rol van FK506 bij hypercalciurie verder onderzocht moeten worden, vooral de mogelijke rol van 
andere FKBP eiwitten. 
 
RGS2 remt de TRPV6 activiteit 
RGS2 is een lid van de RGS familie met eiwitten die de signalering van heterotrimere G-eiwit 
gekoppelde receptoren (GPCR) kunnen beëindigen. Deze nieuwe bindingspartner van TRPV6 
is geïdentificeerd door middel van een yeast-two hybrid screening voor regulatoire eiwitten die 
binden aan het amino-terminale domein van TRPV6. Door het gebruik van biochemische 
assays zoals de yeast-two hybrid screening en een pulldown analyse is de Ca2+-onafhankelijke 
interactie tussen RGS2 en TRPV6 bevestigd. Functionele studies toonden aan dat RGS2 de 
Na+ en Ca2+ stromen van TRPV6 kan remmen. Deletie van het amino-terminale domein van 
RGS2 door mutagenese kon de verminderde TRPV6 stromen verhinderen, waaruit blijkt dat dit 
domein essentieel is voor het effect op TRPV6. Daarnaast worden de stromen van TRPV5, die 
verwant is aan TRPV6, niet beïnvloed door RGS2. Labelen van eiwitten op de 
plasmamembraan met biotine heeft aangetoond dat het remmende effect van RGS2 op TRPV6 
niet tot stand komt door veranderingen in transport van TRPV6 naar en uit de 
plasmamembraan. Het effect is mogelijk het resultaat van de directe interactie tussen RGS2 en 
TRPV6, dat de open status van het kanaal beïnvloed. Tot slot is er aangetoond dat spinophilin, 
een ankereiwit dat RGS2 rekruteert, niet de interactie tussen RGS2 en TRPV6 beïnvloedt. Dit 
duidt op een GPCR-onafhankelijk mechanisme van TRPV6 regulatie door RGS2. 
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Moleculaire bepaling en eigenschappen van TRPM6 permeabiliteit 
TRPM6 en haar homoloog TRPM7 zijn leden van de TRPM subfamilie van kationkanalen en 
zijn permeabel voor Mg2+. TRPM6 heeft op het niveau van aminozuurvolgorde een ~50% 
homologie met TRPM7. De kanalen zijn uniek in het feit dat ze een serine/threonine proteïne 
kinase domein bevatten in de carboxy terminus. Ondanks de eerdere functionele 
karakterisering van TRPM6 is er nog veel onbekend over de moleculaire aspecten van de Mg2+ 
permeabiliteit. Door middel van sequentie vergelijking van de mogelijke TRPM6 porie met de 
porie sequenties van andere familieleden werd er tussen het vijfde en zesde transmembraan 
domein een regio gevonden van zes aminozuren die kan dienen als mogelijke selectiviteitsfilter. 
Door hier puntmutaties aan te brengen, die de negatief geladen residuen neutraliseren, zijn 
twee aminozuren gevonden die belangrijk zijn voor de doorgang van kationen in TRPM6. 
Neutralisatie van het glutaminezuur op positie 1029 en/of de isoleucine op positie 1030 
resulteerde in kanalen met een veranderde poriediameter en een verlaagde remming van 
ruthenium rood vergeleken met normale TRPM6 kanalen. Deze bevindingen suggereren dat de 
regio tussen 1029 en 1031 het meest nauwe gedeelte van de porie in het kanaal bepaalt. De 
resultaten laten zien dat subtiele aminozuurveranderingen in de porie regio eigenschappen van 
de TRPM6 doorlaatbaarheid kan veranderen. Zeker vanwege het ontbreken van kristalstructuur 
gegevens zijn verder studies noodzakelijk om de driedimensionale structuur van de TRPM6 
porie te onderzoeken. 
 
Conclusie en vooruitzichten 
Dit proefschrift tracht meer inzicht te verschaffen in de fysiologische en moleculaire regulatie 
van epitheliale Ca2+ en Mg2+ kanalen. De eerste vijf hoofdstukken van het proefschrift 
beschrijven de moleculaire regulatie van de epitheliale Ca2+ kanalen TRPV5 en TRPV6 door 
geassocieerde eiwitten. TK verhoogt TRPV5 activiteit vanuit het extracellulaire compartiment, 
via een tot nu toe onbekende route om de activiteit van de ionkanalen te reguleren. TK activeert 
een hormonale receptor, dat zorgt voor activatie van de PLC/DAG/PKC route. Dit leidt 
uiteindelijk tot accumulatie van TRPV5 kanalen in de plasmamembraan door een verminderde 
terugname. Activering van de CaSR verhoogt de TRPV5 activiteit, een effect dat tevens vanuit 
het extracellulaire compartiment wordt geïnitieerd. FKBP52 remt de TRPV5 activiteit via 
peptidyl-propyl cis-trans isomerase activiteit. RGS2 moduleert de TRPV6 activiteit door de 
kanaal permeabiliteit te beïnvloeden via directe interactie aan de plasmamembraan. Daarnaast 
levert de studie naar de eigenschappen van TRPM6 iondoorlaatbaarheid nieuwe bevindingen in 
de structuur en functie van aminozuren in de porie van Mg2+-permeabele ionkanalen. De 
functionele karakterisatie van geassocieerde eiwitten die epitheliale Ca2+ kanalen reguleren 
geeft moleculair inzicht in de regulatiemechanismen van kanaalactiviteit. Verder onderzoek naar 
de fysiologische relevantie van de rol van deze eiwitten in de regulatie mechanismen zou het 
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bestaan van nieuwe eiwitnetwerken kunnen ontrafelen. Verder zou het de mechanismen achter 
de specifieke regulatie en intergratie van de Ca2+ balans in het lichaam kunnen verhelderen. 
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REZUMAT 
Introducere 
Canalele ionice sunt proteine specializate integrate în membrana citoplasmatică a celulelor şi 
permit fluxul ionic prin această barieră impermeabilă. Majoritatea canalelor ionice prezintă 
selectivitate ionică, în faptul că porul lor este mai permeabil pentru anumiţi ioni decât pentru alţii. 
În funcţie de selectivitatea lor, canalele ionice pot fi împărţite în: canale selective pentru Na+, 
canale selective pentru K+, canale selective pentru Ca2+, canale selective pentru Cl-, şi canale 
neselective care nu deosebesc ionii permeanţi. Dezvoltarea tehnicii de patch-clamp a permis 
pentru prima dată monitorizarea în timp real a activităţii canalelor ionice din membrana 
citoplasmatică. Familia TRP de canale ionice este compusă din canale cu similarităţi structurale. 
Proteinele din această familie sunt exprimate în diverse ţesuturi din organism şi contribuie la 
diverse funcţii şi procese pornind de la senzaţii termice, tactile sau gustative până la transportul 
transepitelial al ionilor de Ca2+ şi de Mg2+. Canalele epiteliale de Ca2+, TRPV5 şi TRPV6, 
reprezintă doi membri ai familiei TRP foarte asemănători din punct de vedere al secvenţei de 
aminoacizi şi sunt exprimate în principal în epiteliile unde are loc transportul activ de Ca2+. 
TRPV5 are rolul de controlor al reabsorbţiei renale de Ca2+, în timp ce TRPV6 formează 
principala cale de absorbţie a Ca2+ în intestinul subţire. Canalul epitelial de Mg2+ constituie calea 
de intrare a Mg2+ în celule, în procesul de transport transepitelial al Mg2+. Pe lângă excepţionala 
permeabilitate pentru Mg2+, TRPM6 are în comun cu cel mai apropiat omolog al său, TRPM7, 
prezenţa unei α-kinaze atipice în domeniul carboxyl terminal. Un strâns control al canalelor 
epiteliale de Ca2+ şi de Mg2+ are o importanţă fiziologică deosebită pentru menţinerea balanţei 
organismului pentru aceşti ioni divalenţi. De aceea, organismele sunt dotate cu un sistem 
homeostatic de feedback capabil să menţină în limite restrânse concentraţia extracelulară a 
acestor ioni. Controlul canalelor epiteliale de Ca2+ şi de Mg2+ are loc la diferite niveluri: (i) la 
nivel transcripţional şi translaţional pe termen lung al diferiţilor hormoni, (ii) la nivelul 
proprietăţilor biofizice ale canalelor determinate şi de efectul proteinelor reglatoare care 
acţionează (iii) asupra translocaţiei canalelor spre membrana citoplasmatică sau (iv) direct 
asupra activităţii canalelor din membrana citoplasmatică. În ultimii ani, proprietăţile 
electrofiziologice ale acestor canale ionice au fost studiate pe larg, dar anumite aspecte ale 
integrării şi controlului activităţii lor într-un context fiziologic mai larg au rămas încă să fie 
investigate. De aceea, scopul general al acestei teze este să clarifice aspectele reglării la nivel 
fiziologic şi molecular a canalelor epiteliale de Ca2+ şi de Mg2+ pentru o mai bună înţelegere a 
transportului transepitelial al acestor cationi divalenţi. 
 
Kalikreina stimulează activitatea canalului ionic TRPV5 
Deoarece recent a fost demonstrat faptul că şoarecii lipsiţi de kalikreină (TK) dezvoltă o extremă 
hipercalciurie comparabilă cu scurgerile de Ca2+ ale şoarecilor fără TRPV5, am încercat să 
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descriem mecanismele moleculare care corelează aceste două proteine. TK este excretată în 
urină din segmentul tubular colector unde este exprimat şi TRPV5. Folosind modele animale, 
am demonstrat că nivelul de exprimare al TK este corelat cu cantitatea de Ca2+ excretată. Apoi, 
folosind experimente ex vivo am demonstrat că TK stimulează transportul transepitelial de Ca2+. 
Acest efect a fost iniţiat şi de bradikinină (BK) şi a putut fi blocat prin aplicarea unui antagonist 
al receptorului pentru bradikinină subtipul 2 (B2R). Folosind celule transfectate temporar cu 
TRPV5 am arătat că TK stimulează activitatea canalului TRPV5. Apoi, a fost studiată cascada 
enzimatică care este activată după stimularea B2R. Folosind un inhibitor al fosfolipazei C (PLC) 
şi un analog permeabil al diacilglicerolului (DAG) am demonstrat că TK activează cascada 
PLC/DAG. Analogul DAG măreşte activitatea canalului TRPV5 prin fosforilarea canalului de 
către protein kinaza C (PKC), deoarece inactivarea situsurilor de fosforilare de către PKC din 
TRPV5 a împiedicat acest efect. Prin etichetarea proteinelor din membrana citoplasmatica cu 
biotină, am demonstrat că TK măreşte numărul de canale TRPV5 din membrana citoplasmatică 
prin încetinirea reciclării lor. În concluzie, TK stimulează reabsorbţia renală a Ca2+ prin activarea 
cascadei PLC/DAG/PKC de către BK şi induce stabilizarea canalelor TRPV5 în membrana 
citoplasmatică. 
 
Activarea receptorul pentru calciu determină creşterea activităţii canalului TRPV5 
Deşi implicarea receptorului pentru Ca2+ (CaSR) în homeostazia Ca2+ a fost studiată pe larg, 
rolul său în DCT şi CDT din rinichi, locul de maximă exprimare a canalului TRPV5, a rămas 
până acum necunoscut. Folosind experimente funcţionale şi biochimice, am demonstrat că 
stimularea CaSR determină o activitate crescută a canalului TRPV5. CaSR poate fi activat prin 
aplicarea de antibiotice şi anumiţi aminoacizi. Am folosit neomicina şi L-fenil-alanina pentru a 
activa CaSR în celule care exprimă acest receptor. Când este exprimat împreună cu TRPV5, 
activarea CaSR duce la o creştere în activitatea canalului TRPV5 prin intermediul fosforilării 
canalului de către PKC. Inactivarea în TRPV5 a posibilelor situsuri de fosforilare de către PKC, 
poziţiile S299 şi S654, a stopat efectul activării CaSR, demonstrând că aceşti doi aminoacizi 
sunt esenţiali pentru acest efect. În mod surprinzător, activitatea celui mai apropiat omolog al 
canalului TRPV5, TRPV6, nu a fost influenţată de activarea CaSR. Prin etichetarea proteinelor 
din membrana citoplasmatică cu biotină am demonstrat că după activarea CaSR creşte 
cantitatea de canale TRPV5 din membrana citoplasmatică. În concluzie, am demonstrat pentru 
primă oară un posibil rol al CaSR din compartimentul apical al DCT şi CNT din rinichi, acolo 
unde CaSR este exprimat împreună cu TRPV5. 
 
FKBP52 inhibă activitatea canalului TRPV5 
FKBP52 este o proteină citosolică exprimată în întreg organismul. Această proteină este 
caracterizată prin activitatea să enzimatică de cis-trans izomerază a legăturilor cis-peptidil-
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isopropil şi prin afinitatea sa puternică faţă de compusul imunosupresiv FK506. Această 
proteină a fost identificată printr-un test pentru genele care sunt reglate prin suplimentarea cu 
Ca2+ a dietei şoarecilor lipsiţi de enzima 1αOHază. Studiul nostru a demonstrat că FKBP52 
interacţionează specific şi este co-exprimat împreună cu TRPV5 în partea distală a nefronului. 
Mai mult, prin experimente funcţionale, am demonstrat că FKBP52 inactivează influxul de Ca2+ 
mediat de către TRPV5. Pe de altă parte, inactivarea genei care codifică pentru FKBP52 sau 
administrarea unui blocant al FKBP52 au determinat o creştere a activităţii canalului TRPV5. 
Activitatea catalitică a FKBP52 este esenţială pentru acest efect, deoarece inactivarea centrului 
catalitic activ al proteinei prin mutageneză a împiedicat efectul acesteia asupra canalului 
TRPV5. Apoi, am demonstrat că FK506 în concentraţii submicromolare stimulează transportul 
de Ca2+, pe când în concentraţii mai mari FK506 manifestă un efect toxic asupra celulelor. 
Această caracteristică dependentă de doză ar putea explica efectul nefrotoxic observat la 
pacienţii trataţi cu FK506. Totuşi, ţinând cont de complexitatea situaţiei in vivo, rolul FK506 în 
hipercalciurie trebuie investigat în viitor, mai ales legat de rolul potenţial al altor FKBP proteine 
în acest proces. 
 
RGS2 inhibă activitatea canalului TRPV6 
RGS2 este membră a familiei RGS, proteine capabile să întrerupă cascada de semnalizare a 
receptorilor cuplaţi cu proteinele G (GPCR). Acest nou partener al canalului TRPV6 a fost 
identificat printr-un studiu asupra proteinelor regulatoare care pot interacţiona cu domeniul 
amino-terminal al TRPV6. Folosind experimente biochimice, am confirmat interacţiunea RGS2 
cu domeniul amino-terminal al TRPV6 într-o manieră independenta de Ca2+. Analize funcţionale 
au demonstrat că RGS2 reduce curenţii de Na+ şi de Ca2+ mediaţi de TRPV6. Domeniul amino-
terminal al RGS2 este vital pentru acest efect deoarece un mutant al RGS2 lipsit de acest 
domeniu nu a mai putut reduce curenţii prin TRPV6. Surprinzător, curenţii prin TRPV5, cel mai 
apropiat omolog al canalului TRPV6, nu au fost afectaţi de RGS2. Apoi, etichetarea proteinelor 
din membrana citoplasmatică cu biotină a demonstrat că efectul RGS2 asupra canalului TRPV6 
nu este determinat de diferenţe în traficul canalului către şi de la membrana citoplasmatică. 
Este posibil ca acest efect să fie mediat prin interacţiunea directă dintre RGS2 şi TRPV6, care 
afectează proprietăţile de deschidere-închidere a canalului. În final, am demonstrat că 
spinofilina, o proteină a scheletului celular cunoscută a media recrutarea RGS2 către 
membrana citoplasmatică, nu afectează interacţiunea RGS2 cu TRPV6. Acest fapt indică un 
mecanism independent de GPCR al reglării canalului TRPV6 de către RGS2. 
 
Determinanţi moleculari ai permebilităţii canalului TRPM6 
TRPM6 şi cel mai apropiat omolog al său, TRPM7, sunt membri ai subfamiliei TRPM de canale 
ionice şi sunt printre puţinele canale ionice permeabile pentru Mg2+. TRPM6 are ~50% din 
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secvenţa de aminoacizi în comun cu TRPM7 şi ambele canale conţin o unitate enzimatică în 
domeniul carboxil terminal. Deşi recent a fost caracterizat funcţional, determinanţii moleculari ai 
permeabilităţii canalul TRPM6 au rămas necunoscuţi până în prezent. Folosind un aliniament al 
porului probabil al canalului TRPM6 cu porii altor canale din aceeaşi subfamilie, am localizat în 
bucla dintre segmentele transmembranare 5 şi 6 o scurtă secvenţă de aminoacizi care poate 
funcţiona ca filtru de selectivitate. Folosind mutaţii singulare ale aminoacizilor încărcaţi cu 
sarcină negativă din această regiune am descoperit doi aminoacizi ca fiind determinanţi 
importanţi ai permeabilităţii canalului TRPM6 pentru cationi divalenţi. Neutralizarea glutamatului 
de la poziţia 1029 şi a izoleucinei de la poziţia 1030 a avut ca rezultat formarea unor canale cu 
diametru al porului diferit şi cu sensibilitate la blocare cu ruthenium red scăzută în comparaţie 
cu canalele TRPM6. Aceste descoperiri sugerează faptul că regiunea cuprinsă între poziţiile 
1029 şi 1031 formează cea mai îngustă parte a porului canalului TRPM6. Rezultatele noastre 
susţin ipoteza conform căreia variaţii subtile ale aminoacizilor din regiunea porului determină 
permeabilitatea canalului TRPM6. Totuşi, ţinând cont de lipsa unor date concrete de 
cristalografie, studii viitoare sunt necesare pentru a clarifica în detaliu structura tridimensională 
a porului canalului TRPM6. 
 
Concluzii şi perspective 
Scopul acestei teze a fost să aducă noi detalii în reglarea fiziologica şi moleculară a canalelor 
epiteliale de Ca2+ şi de Mg2+. Primele cinci capitole ale tezei descriu reglarea la nivel molecular 
a canelelor epiteliale de Ca2+, TRPV5 şi TRPV6, de către proteine accesorii. TK creşte 
activitatea canalului TRPV5, acţionând din compartimentul extracelular, un nou mod de a 
controla activitatea canalelor ionice. TK acţionează prin intermediul unui receptor pentru 
hormonul BK, activând cascada enzimatică PLC/DAG/PKC, care în final duce la acumularea 
canalelor TRPV5 în membrana citoplasmatică. Stimularea CaSR determină o creştere a 
activităţii canalului TRPV5, efect iniţiat de asemenea din compartimentul extracelular. FKBP52 
inhibă activitatea canalului TRPV5 prin intermediul activităţii enzimatice de peptidil-propil cis-
trans izomerază. RGS2 modulează activitatea canalului TRPV6 modificând proprietăţile de 
deschidere-închidere ale canalului prin interacţiunea directă cu TRPV6 în membrana 
citoplasmatică. În final, studiul despre proprietăţile de permeabilitate ale canalului TRPM6 
aruncă o noua lumină asupra structurii şi funcţiei aminoacizilor din porurile canalelor permeabile 
pentru Mg2+. În consecinţă, caracterizarea funcţională a proteinelor reglatoare ale activităţii 
canalelor epiteliale de Ca2+ aduce noi cunoştinţe despre mecanismele pentru controlul activităţii 
canalelor ionice. Studii viitoare, despre însemnătatea fiziologică a acestor proteine accesorii în 
reglarea canalelor epiteliale de Ca2+, vor putea demonstra existenţa unor noi reţele de proteine 
şi vor ajuta la clarificarea mecanismelor de reglare şi integrare specifică şi precisă a 
homeostaziei Ca2+ la nevoile variate ale organismului. 
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List of abbreviations 
 
1,25(OH)2D3 1,25-dihydroxy-vitamin D3  
[Ca2+]i intracellular Ca2+ concentration 
1α-OHase 25-hydroxyvitamin D3-1α-hydroxylase 
2-APB 2-aminoethoxydiphenyl borate 
ADP adenosine diphosphate 
ANOVA analysis of variance 
ATP adenosine 5'-triphosphate 
B2R bradykinin 2 receptor 
BAPTA 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
BK bradykinin 
bp base pairs 
BSA bovine serum albumin 
BSPRY B-box and SPRY-domain containing protein 
CaM calmodulin 
CaBP Ca2+-binding protein 
cAMP cyclic adenosine monophosphate 
CaSR Ca2+-sensing receptor 
CCD cortical collecting duct 
cDNA complementary deoxyribonucleic acid 
cGMP cyclic guanosine monophosphate 
CNT connecting tubules 
CTRL control 
DAG diacylglycerol 
DCT distal convoluted tubules 
DMA dimethylammonium 
DMEM Dulbecco modified Eagle's minimal essential medium 
DRG dorsal root ganglion 
DTT dithiothreitol 
DVF divalent free 
ECaC epithelial Ca2+ channel 
EDTA ethylene diamine tetra acetic acid 
eEF-2 elongation factor 2 
EGTA ethylene glycol-bis(b-aminoethyl ether)-N,N,N',N'-tetra acetic acid 
ENaC epithelial Na+ channel 
ER endoplasmic reticulum  
FACS fluorescence-activated cell sorting 
FKBP52 FK506-binding protein 52 
GFP green fluorescent protein 
GPCR G protein-coupled receptor 
GST glutathione S-transferase 
GTP guanosine triphophate 
HEK 293 human embryonic kidney 293 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
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HSH hypomagnesemia with secondary hypocalcemia 
i single channel current 
I whole cell current  
IC50 half maximal inhibitory concentration 
IP3 inositol triphoshpate  
I-V current-voltage 
L-Phe L-phenylalanine 
MA monomethylammonium 
MDCK Madin-Darby Canine Kidney 
mRNA messenger ribonucleic acid 
MTSET [2-(trimethylammonium)-ethyl]-methanethiosulfonate 
NCX1 Na+-Ca2+-exchanger 1 
NHE Na+-H+ exchanger 
NHERF4 NHE regulating factor 4  
NKCC2 Na+,K+,2Cl--co-transporter subtype 2 
NMDG N-methyl-D-glucamine 
OAG 1-oleoyl-acetyl-sn-glycerol  
P2X purinergic receptors 
PAGE polyacrylamide electrophoresis gel 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDZ PS095/DLG/Z0-1 
PIP2 phosphatidylinositol-4,5-biphosphate 
PKA protein kinase A 
PKC  protein kinase C 
PLC phospholipase C 
PMA phorbol 12-myristate 13-acetate 
PMCA1b Ca2+-ATPase 1b 
Po open probability  
PPIase peptidyl-propyl cis-trans isomerase 
PTH parathyroid hormone 
Px permeability for cation x 
RGS2 regulator of G protein signaling 2 
ROC receptor operated channel 
ROMK renal outer medullary K+ channel 
RR ruthenium red 
SCAM substituted cysteine accessibility method 
SDS sodium dodecyl sulphate 
SEM standard error of the mean 
siRNA small interference ribonucleic acid 
SMOC second messenger operated channel 
SNARE soluble N-ethylmaleimide-sensitive-factor attachment  
SPL spinophilin 
TAL thick ascending limbs of the Henle’s loop 
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TBS tris buffered saline 
TCA trichloroacetic acid 
TetMA tetramethylammonium 
TIRF Total Internal Reflection Fluorescence 
TG trigeminal ganglion 
TK tissue kallikrein 
TK-/-  TK knockout 
TM transmembrane domain 
TriMA trimethylammonium 
Tris tris(hydroxyl-methyl)aminomethane 
TRP transient receptor potential  
TRPA anchorin-repeat containing TRP  
TRPC TRP canonical  
TRPL TRP like 
TRPM TRP melastatin  
TRPML mucolipins TRP 
TRPP TRP polycistyns 
TRPV TRP vanilloid 
TRPV5-/-  TRPV5 knockout  
VOC voltage operated channel 
WNK4 “with no lysine” kinase 4 
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